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Abstract 
 
Monocarboxylate transporters (MCTs) are responsible for the bi-directional diffusion of 
monocarboxylic acids, such as lactate, pyruvate, β-hydroxybutyrate and acetate, across 
cellular membrane. As a result, they play essential roles in cellular metabolism and 
various biological processes. In this thesis, we first reported an update on the new 
developments and advances of MCTs families in the past decade, with an emphasis on 
their functional roles and regulation mechanisms. Then, we studied MCT1 and its 
regulation by protein kinase A (PKA), the canonical Wnt/β-catenin and Notch signaling 
pathways in an immortalized rat brain endothelial (RBE4) cell line. Our results showed 
that cAMP-dependent PKA activation caused dephosphorylation and subsequent 
internalization of MCT1 from plasma membrane into early endosomes. Wnt/β-catenin 
pathway failed to affect Mct1 mRNA level, but increased its protein’s expression on 
cellular surface. MCT1 in RBE4 cells is regulated by endosomal-lysosomal, but not 
proteasomal degradation. Inhibition of deubiquitinases (DUBs) caused an upregulation 
of MCT1, implying a possible involvement of ubiquitination in MCT1’s regulation by Wnt 
pathway. Notch inhibition by a γ-secretase inhibitor (DAPT) also elevated MCT1 protein 
level, and an intact Notch activity was required for the upregulation of MCT1 by Wnt/β-
catenin signaling, indicating a crosstalk between the two pathways. Furthermore, we 
tested a novel MCT inhibitor (MD1), a substantially more potent analog derived from α-
cyano-4-hydroxycinnamic acid (α-CHC), in suppressing human peripheral blood 
mononuclear cells (hPBMCs) and selected tumor cells proliferation. Our findings showed 
that MD1 inhibited hPBMCs proliferation at concentrations no less than 50μM. Under 
hypoxic culturing condition, it suppressed SW480 colorectal cancer cells and H4IIE 
hepatoma cells proliferation starting at concentrations of 25μM and 5μM, respectively. 
The same effects were not observed under normoxia. Besides, hypoxic culturing may 
sensitize tumor cells to metabolic inhibition of MCT1. A potential combinatorial usage of 
MD1 with other chemotherapeutic drugs is implied to achieve improved clinical 
outcomes. In summary, our results showed, for the first time, the regulation of brain 
endothelial MCT1 by PKA, Wnt/β-catenin and Notch signaling pathways; we also 
evaluated the inhibitory role of MD1 in suppressing hPBMCs and tumor cells by blocking 
lactate transport.  
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1. INTRODUCTION.  
Monocarboxylic acids are among the most common metabolic intermediates in living 
systems and exist in diverse forms.  They comprise the products of major catabolic 
pathways and include lactic and pyruvic acids from glycolysis (sugars), acetoacetic, β-
hydroxybutyric and butyric acids from β-oxidation (fatty acids) and fermentation (complex 
carbohydrates, dietary fiber) and α-ketoacids from protein degradation (ketogenic amino 
acids).  Passage of these highly hydrophilic compounds through membranes separating 
cellular compartments is highly restricted. Therefore, membrane embedded proteins that 
function as transporters are essential for metabolite trafficking.  Among the specialized 
proteins that function as small molecule carriers, there are three known protein families 
that transport monocarboxylic acids (MCAs).  These are members of the solute carrier 
families known as SLC16, SLC5 and the mitochondrial pyruvate carrier (MPC) family.  
MCA transporters are significant for their role in intermediary metabolism, pathology and 
genetic diseases.  They are also relevant to pharmacology because of their ability to 
transport carboxylated pharmaceuticals (drug delivery) and as targets of therapeutic 
agents.  Some properties of the members of the SLC5 and the SLC16 families have 
recently been summarized (1-4).  In this review, features of these transporters will be 
discussed with an emphasis on newer developments and advances in the past decade. 
2. MITOCHONDRIAL PYRUVATE TRANSPORTER FAMILY.   
Pyruvic acid generated by glycolysis must enter the mitochondria to reach the pyruvate 
dehydrogenase complex and assimilate into the tricarboxylic acid (TCA) cycle.  That a 
pyruvate transporter existed in the inner mitochondrial membrane was hypothesized by 
transport kinetics and inhibitor studies almost 40 years ago (5).  Despite expansion of 
the plasma membrane transporter field, the mitochondrial carrier remained elusive until 
recent studies using genetic tools in model organisms (6, 7).  Evidence suggests that at 
least two proteins, MPC1 and MPC2 (originally designated BRP44 and BRP44L), 
participate in forming a large heterocomplex responsible for mitochondrial pyruvate 
import and are conserved in yeast, flies and mammals.  Furthermore, mutation in the 
MPC1 gene is believed to lead to a dysfunctional carrier and a serious disease condition 
in humans (6).   
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The human MPC1 gene is located on chromosome 6 and encodes a 109 amino acid 
protein (MW 12,347Da) that is processed to a 66 amino acid mature form. The paralog 
of MPC1 is MPC2 and is a gene located on chromosome 1 and encodes a protein with 
127 amino acids (MW 14,279Da). The mature MPC1 and MPC2 proteins each contains 
two transmembrane segments and is located in the inner mitochondrial membrane.  The 
two proteins are believed to form a heterodimer and with other proteins form a 150kD 
complex that carries pyruvate into the mitochondria.  
Recent reports have linked thiazolidinediones (TZDs) with the MPC complex (8, 9).  
TZDs, such as pioglitazone, are indicated for adult hyperglycemia because they prevent 
the conversion of this condition to type-2 diabetes and they increase insulin sensitivity.  
The target of TZDs now appears to be MPC1, thus suggesting that regulation of the 
complex is critical for glucose metabolism regulation and that the complex is a potential 
target for improving diabetes therapies.  Future studies to characterize the MPC complex 
and its regulation promise to be revealing, if not critical for discovering new disease 
treatments. 
3. SLC5 TRANSPORTER FAMILY.   
3.1. Structure.  
Based on sequence homologies the SLC5 transporter gene family consists of 12 
members and their related protein products (Figure I-1).  All members are symporters 
and have an obligate anion, Na+, as a cotransported species.  The substrate of several 
SLC5 transporters is a carbohydrate (glucose, myoinositol) and because of their role in 
energy metabolism, nutrition and disease (altered glucose metabolism, diabetes) and 
their electrogenic properties some SLC5 members have been subjected to intensive 
study both in vitro and in vivo (for review see (1, 10)).  Two members, SLC5A8 and 
SLC5A12, transport physiological monocarboxylates including lactate, pyruvate and 
butyrate and are known as SMCT1 and SMCT2, respectively. In humans SMCT1 is 
composed of 610 amino acids (MW 66,447Da) and is located on chromosome 12 
(12q23.1) while SMCT2 is composed of 618 amino acids (MW 67,516Da) and is located 
on chromosome 11 (11p14.2).  The putative structures of SMCT1 and SMCT2 are 
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similar and both contain 13 transmembrane segments with the amino terminal 
(endofacial) and carboxyl terminal (exofacial) ends on opposite sides of the membrane.  
A 3D model structure can be predicted by threading the sequence to a previously 
structurally characterized transporter protein (Figure I-2).  
3.2. Location and Function.  
Cloning of the SMCT1 (SLC5A8) and SMCT2 (SLC5A12) open reading frames and 
examining the tissue distribution patterns provides insight into their biological functions 
(11, 12). SMCT1 is a higher affinity transporter for a substrate such as L-lactate with 
SMCT2 having a lower affinity, but often higher capacity.  Based on careful examination 
using an oocyte expression system, the stoichiometry of SMCT1 is 2:1 with respect to 
sodium and lactate and the same is presumed to exist for SMCT2 (13).  Transcript and 
protein analysis suggests that SMCT1 and SMCT2 play important roles in transepithelial 
cell transport in the kidney and in the gut.  
A major function of the SMCTs is absorption of lactate from the renal ultrafiltrate as it 
passes through the kidney tubules. Reabsorption of lactate is mediated by the low-
affinity Na+-coupled lactate transporter SMCT2 in the initial part of the proximal tubule 
and by the high-affinity Na+-coupled lactate transporter SMCT1 in the distal proximal 
tubule (14).  The result is that the concentration of blood lactate is maintained at about 
1.5 mM. Deletion of the SMCTs leads to very high excretion of lactate in the urine and 
also a lowering of lactate in the blood (11, 14-16).  An interesting feature is that in renal 
tissues the SMCTs are transcriptional targets of the transcription activator, c/ebpδ (16). 
Thus, studies of homozygous deletion of the c/ebpδ gene leads to nearly total ablation of 
the SMCTs from the kidney tubules (essentially a tissue-specific double knockout) while 
non-renal tissue expression remains intact. 
Immunohistochemical analysis indicates that SMCT1 is primarily located in the rat colon 
and distal end of the small intestine (17). By contrast, SMCT2 is primarily located further 
upstream in the proximal end of the jejunum near its entrance from the stomach.  
Functional transport studies have corroborated these observations (18). Closer 
localization studies reveal that the SMCTs are located on the apical side of the epithelial 
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cells in both the proximal tubules of the kidney and the intestinal brush border, thus, 
serving to capture carboxylic acids from the tubule and intestinal contents (11, 17). 
3.3. Pharmaceutical Substrates and Disease.  
Another substrate that is effectively transported by the SMCTs is nicotinic acid, a 
carboxylic acid and vitamin precursor of nicotinamide adenine dinucleotide (19) (14, 18, 
20).  Absorption of this vitamin B3 is accomplished primarily by SMCT1 along the 
intestinal tract and colon. Of importance is that transport is inhibited significantly by 
physiological carboxylates (lactate, β-hydroxybutyrate) and by short chain fatty acids and 
various monocarboxylate drugs such as benzoate, salicylate and 5-aminosalicylate (14).  
Many nonsteroidal anti-inflammatory drugs (NSAIDs) are monocarboxylates.  In a study 
to examine interactions between NSAIDs and SMCT1 it was found that ibuprofen and 
structurally related compounds inhibit SMCT1 transport (21).  However, despite its ability 
to block transport ibuprofen is not itself transported.  
Evidence has also been reported that SMCT1 is essential for the transport of 5-
oxoproline, an intermediate in the γ–glutamyl cycle in glutathione biosynthesis.  
Transport appears to function in kidney where robust reabsorption of 5-oxoproline 
occurs in the tubules (22). Furthermore, SMCT1 is expressed in the retinal pigment 
epithelium and other cells of the retina, a tissue that with age may suffer macular 
degeneration resulting in part from oxidative stress and low glutathione levels. As a 
therapeutic strategy glutathione levels may be enhanced by providing precursors or 
prodrugs such as 2-oxothiazonlidine-4-carboxylate (OTC).  Following recent studies, it 
appears that OTC is an SMCT1 substrate and glutathione is elevated in retinal tissue 
following OTC treatment (23).  Thus, the expression and function of SMCTs may be 
important factors in treating this debilitating disease. 
SMCT1 (SLC5A8) is associated with cancerous tissues. In a study examining aberrantly 
methylated genes that result in gene silencing, it was discovered that the promoter 
region of SMCT1 is hypermethylated and is a common and early event in colon cancers 
(24). In over half of human colon cancers and related cell lines SMCT1 is silenced and, 
thus, SMCT1 is a tumor suppressor gene.  This property is attributed to the fact that 
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SMCT1 is responsible for influx of butyrate into colonic epithelial calls and this 
monocarboxylic acid is a known potent inhibitor of histone deacetylases (HDACs) (25).  
In tumor cells, HDAC inhibition results in cellular differentiation and activation of cell 
death pathways (26).  Tumor cell apoptosis involves cell specific induction of death 
receptor pathways and activation of pro-apoptotic proteins (27, 28). For some non-
colonic tumors, pyruvate may be taken up by monocarboxylic acid transporters including 
SMCT1 and cause inhibition of HDACs and activate tumor cell apoptosis (29). New 
insights into the mechanisms of tumor cell differentiation and progression related to 
SMCTs (30) and their targeting by therapeutic drugs remain to be discovered.  
4. SLC16 TRANSPORTER FAMILY.  
4.1. Introduction.  
The family of mammalian monocarboxylic acid transporters is officially assigned the 
name SLC16 and there are 14 unique members designated SLC16A1 through 
SLC16A14 (31). Before the genes were fully sequenced and annotated, several proteins 
from this family were independently reported in the literature using the abbreviations 
MCT1, MCT2 and so forth and, consequently, the numerical designations of the protein 
and gene names do not necessarily match. The MCT nomenclature is primarily used 
below.  
Of the 14 members, five gene products appear capable of transporting the common 
short chain acids of lactate, pyruvate, butyrate, β-hydroxybutyrate, acetate, and similar 
carboxylic acids. The transporters MCT1, MCT2, MCT3 and MCT4 were first identified, 
characterized and continue to be the focus of many studies. Recently, evidence strongly 
suggesting that MCT7 (SLC16A6) plays an important role in monocarboxylic acid efflux 
from hepatocytes during fatty acid catabolism (fasting ketogenesis) was reported (32). 
Further studies to confirm this observation and to describe additional features are 
needed.  
The MCTs typically contain 12 transmembrane segments with their carboxyl and amino 
termini on the cytoplasmic membrane side.  To form a functional transporter unit MCTs 
combine with a member of the immunoglobulin superfamily such as basigin (CD147, 
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EMMPRIN) or embigin. Formation of this heterodimer appears to be essential for 
trafficking and insertion of the MCT into the plasma membrane. Current reviews are 
available that detail many additional characteristics of the structure and function of MCTs 
(2, 33, 34).  
4.2. Functional Roles of MCTs under Physiological Conditions and in Drug 
Transport. 
4.2.1. Brain Functions.  
MCTs have been implicated in important brain functions because of their role in 
transporting lactate or other monocarboxylates between cell types. In the hypothalamus, 
the brain structure involved in sensing glucose levels, MCT1 and MCT4 are expressed 
on tanycytes (hypothalamic glial cells) while MCT2 is enriched on neurons (35). The 
glucose sensing mechanism is governed by a metabolic interaction between tanycytes 
and neurons via lactate efflux through MCT1 and MCT4 from the former cells and 
subsequent influx through MCT2 into the latter, in order to stimulate neuronal ATP 
synthesis and their activation (36). Furthermore, in long-term memory (LTM) formation, it 
is proposed that MCT1 and MCT4 transport lactate generated from hippocampal 
astrocytes into neighboring neurons that express MCT2 for importing this substrate. This 
metabolic interaction is essential for LTM by supporting neuronal synaptic plasticity as 
well as the formation of new synapses (37). In addition, oligodendrocytes support axonal 
survival and integrity by supplying energy metabolites and performing myelination. 
MCT1 is found highly enriched on these glial cells, and its disruption leads to axon 
damage and neuron loss in Mct1 heterozygous knockout mice (Mct1+/-). In patients with 
amyotrophic lateral sclerosis, a reduction of MCT1 expression is observed in 
oligodendrocytes, suggesting a critical role for MCT1 on these glial cells in brain 
pathogenesis (38).  
4.2.2. Obesity and Abnormal Insulin Secretion.  
MCT1 is implicated in the metabolism of adipose tissue, whose dysfunction is a key 
factor associated with obesity and later occurrence of insulin resistance. Hypoxia, a 
critical feature of fat tissue proposed during its mass expansion in obesity, increases 
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MCT1, but decreases MCT2 expression in adipocytes. These changes are likely key 
adaptations of adipose tissue to low oxygen tension (39). Despite a universal expression 
across other tissues, MCT1 is not normally transcribed in β cells, disallowing uptake of 
lactate/pyruvate, two ideal mitochondrial fuels for generation of ATP for insulin 
exocytosis. However, in β cells of patients with exercise-induced hyperinsulinism (EIHI) 
mutations identified within the MCT1 promoter region result in marked transcriptional 
stimulation and expression of this gene. MCT1, thus enables pyruvate/lactate uptake 
from circulating blood and subsequent inappropriate release of insulin, which causes 
hypoglycemia (40). Transgenic mice that overexpress MCT1 in a β-cell specific manner 
recapitulate all the features of EIHI, including stimulated insulin secretion from β cells 
upon exercise exposure (41). All these findings demonstrate that silencing of MCT1 
expression is critical for normal insulin secretion by β cells.    
4.2.3. Drug Transport.  
Many pharmaceutical agents contain a carboxylate group and, therefore, have structural 
similarities to MCT substrates such as the MCAs and short-chain fatty acids. The 
expression profile of MCT1 along the gastrointestinal tract, the neurovascular unit 
(blood-brain barrier) and other epithelial tissues makes this transporter an attractive 
route for passage of monocarboxylate-containing drugs through cellular membranes for 
absorption and for reaching their target sites. For example, benzoic acid is transported 
by porcine brain capillary endothelial cells (BCECs) in a saturable manner, with a Km 
value of 3.05 mM (42). The same drug is reportedly transported by MCT1 in corneal 
epithelium where drug absorption is dominant, suggesting that MCT1 may play a role in 
the ocular drug absorption (43).  
MCTs have also been documented as responsible for uptake of many other drugs 
across different biological membrane barriers. For example, as an antiepileptic drug, 
valproate must cross both the intestinal epithelial and blood-brain barrier for absorption 
and to reach the target cells in the central nervous system (CNS). In both Caco-2 and rat 
brain endothelial RBE4 cells, valproate transport is strongly stimulated by an inwardly 
directed H+ gradient. The uptake rate is saturable with Kt values of 0.6mM and 0.8mM 
for Caco-2 and RBE4 cells, respectively. Lactate and pyruvate only inhibit its uptake at 
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RBE4 cells, but not at Caco-2 cells, indicating that MCT1 is responsible for valproate 
transport across blood-brain barrier, but suggesting the possibility for another yet 
unidentified H+-dependent monocarboxylate transporter in intestinal epithelial cells (44). 
As an approved therapeutic agent for cataplexy with narcolepsy and a widely abused 
euphoriant, γ-hydroxybutyrate (GHB) uptake of GHB into Caco-2 cells is confirmed to be 
pH- and concentration-dependent and is best described by a Michaelis-Menten equation 
with Km=17.6±10.5mM. Transport is inhibited by the known MCT inhibitor α-cyano-4-
hydroxycinnamic acid (α-CHC). All of the above demonstrate that GHB uptake across 
Caco-2 cells is consistent with a proton-dependent MCT transport (45). Additional 
studies suggest that flavonoids (luteolin, phloretin and morin) may decrease the 
transport of GHB by MDA-MB231 cells transfected with the rat Mct1 gene. Consistent 
with these in vitro studies, concomitant in vivo administration of GHB with luteolin 
increases its renal and total clearance, probably via inhibited renal reabsorption of GHB 
by luteolin (46). The interaction between these two drugs may suggest a potential clinical 
strategy to ameliorate GHB abuse (47).  
With the aim to enhance drug uptake into CNS, betreliesoxybutyric acid (HBA) grafted 
docetaxel loaded solid lipid nanoparticles (HD-SLNs) have been explored to deliver 
docetaxel across blood-brain barrier. The HD-SLNs transportation relies on the transport 
of HBA through brain endothelial MCT1 and a significant resulting increase of 
accumulated docetaxel in the brain has been observed (48).  More strikingly, a potent 
role of MCT1 as a drug transporter in treating cancers has been reported. The 
reprogrammed metabolism of tumor cells with a prominent glycolytic phenotype makes 
them sensitive to an anti-cancer reagent 3-bromopyruvate (3-BrPA), a drug that inhibits 
glycolysis (49). MCT1 is necessary and sufficient for 3-BrPA uptake by cancer cells, and 
its forced expression in 3-BrPA resistant cancer cells sensitizes tumor xenografts to the 
drug treatment in vivo. This reveals the concept that the selectivity of cancer-expressed 
transporters can be exploited for delivering toxic compounds to tumors.  
4.3. Regulation of MCTs Activity 
4.3.1. Regulation by Ancillary Proteins. 
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As membrane transporters with multiple transmembrane domains (TMs), MCTs require 
an association with a single TM glycosylated protein in order to be correctly targeted to 
plasma membrane.  In most cases, this glycoprotein is CD147 (basigin, emmprin) for 
MCT1, MCT3 and MCT4, whereas it can be a different glycoprotein, embigin, in rat 
erythrocytes for MCT1 (50, 51). MCT2 requires embigin (also known as gp70) as its 
ancillary protein (52), although this transporter associates with CD147 in murine sperm 
(53). Enhanced association between MCT1 and CD147 has been reported to cause 
increased plasma membrane expression of this transporter protein (53, 54). Furthermore, 
silencing or knockout of CD147 in cultured cells or genetically modified animals results in 
decreased MCT1 plasma membrane localization, impaired MCT1:CD147 interaction, as 
well as altered tissue distribution of this transporter (55, 56). In malignant breast 
carcinoma cells, both MCT1 and MCT4 are associated with CD147 and another protein, 
CD44 (57). Interestingly, the destruction of CD44-hyaluronan interactions destabilizes 
assembly of the MCT1 and MCT4 complexes in the plasma membrane and the MCTs 
are retained in the cytosol. The molecular mechanism underlying MCTs’ interaction with 
and regulation by CD147 involves hydrophobic residues residing in both the N-terminal 
and C-terminal ends of the single TM of CD147 (58). However, the conserved glutamate 
amino acid within the same TM domain, which was thought to be critical for mediating 
the interaction between these two proteins (59), now is reportedly not involved in this 
interaction (60, 61). MCT1 itself does not contain a basolateral sorting signal (BLSS) in 
its amino acid sequence. Therefore, its cellular polarity may be dictated by CD147 that 
has a weak BLSS that may be sufficient to shift some apical markers onto the 
basolateral membrane (62).  
CD147 is also essential for maintaining protein expression levels of MCTs. For example, 
in human pancreatic ductal adenocarcinomas, silencing CD147 inhibits the expression 
and function of MCT1 and results in an increased intracellular lactate concentration (63). 
In addition, CD147 knockout animals show severely reduced intensity of MCT1 
immunostaining in the regions where both CD147 and MCT1 are expressed (56). During 
tumorigenesis, the co-expression of MCT1, MCT4 and CD147 is commonly observed in 
cancer cells. Specifically, co-expression of MCT1 with CD147 is associated with low 
patient’s overall survival in gastrointestinal stromal tumors (64). The expression of MCT1 
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and CD147 is correlated with primary and metastatic prostate cancer (65). In epithelial 
ovarian cancer (EOC) samples of primary tumors and in matched metastatic lesions, co-
expression of CD147 with MCT1 and MCT4 is found and significantly associated with 
tumor stage, suggesting that over-expression of MCT1, MCT4 and CD147 is correlated 
with drug resistance during EOC metastasis. Thus MCT1 and MCT4 may be useful 
therapeutic targets (52, 66). Because of the close association, some inhibitors can target 
CD147 for suppressing MCTs transport function. For example, pCMBS inhibits MCT1 
and MCT4 activity through targeting their common ancillary protein CD147, causing 
dissociation of these proteins by modifying the disulfide bridge in the Ig-like C2 domain 
of CD147 (52). 
4.3.2. Regulation of MCT Intrinsic Activity.  
Some studies have shown that the kinetics of MCTs transport can be modulated by 
signaling pathways and other intracellular molecules. For example, activation of the 
cAMP-dependent PKA pathway decreases MCT1’s transport function [lower Vmax, but no 
change in apparent Michaelis-Menten constant (Km)] in RBE4 cells (67). Follow-up 
studies from the same group confirm that the observed reduction of MCT1 activity is due 
to dephosphorylation, and subsequent enhanced internalization of this transporter into 
early endosomes in a caveolae dependent manner (68).  In Caco-2 intestinal epithelial 
cells, the p38 MAP kinase pathway increases the Vmax of MCT1 transport by 
approximately two-fold without any changes in Km. This higher transport activity is 
consistent with an increase in the apical membrane level of MCT1 parallel to a decrease 
of this protein in the intracellular pool (69). In addition, MCT1 transport activity of lactate 
in mouse cerebral astrocytes is augmented by carbonic anhydrase 2 (CAII). In a 
Xenopus expression system, MCT4 transport function is augmented by CAII as well (70). 
The mechanism is found to be independent of this enzyme’s catalytic activity, but 
requires the binding of CAII to the C-terminus of MCTs, thus suppressing the formation 
of lactate microdomains at the transporter-core and therefore enhancing lactate flux (71). 
In other words, it is acting as an “H+-collecting antenna”. The amino acid His64 in the 
side chain of CAII is essential for this enhancement (72). MCT2’s transport function can 
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be augmented by a different, extracellular membrane bound carbonic anhydrase isoform 
of CAIV, in a non-catalytic manner as well (73).  
4.3.3. Regulation of MCT1 (SLC16A1) Gene Expression. 
MCT1’s expression has been associated with and thus regulated by tumorigenesis, with 
lines of evidence supporting both positive and negative modulations. A metabolic 
symbiosis has been suggested to explain enhanced glycolysis commonly observed 
during tumor progression, where lactate products from a highly glycolytic tumor core are 
extruded through MCT4 and then taken up via MCT1 into neighboring cells (74). As a 
result, increases in MCT1 expression, either mRNA or protein level or both, are 
observed in various tumors, e.g. breast (75-77), ovarian (66), prostate (78), melanoma 
(79, 80), non-small cell lung carcinoma (81) and leukemia (49). For example, MCT1 
expression is elevated during nevus to melanoma progression as revealed by tissue 
microassay analysis, as well as in metastatic cells. Also, MCT1 mRNA levels are found 
elevated in glycolytic leukemia. In contrast, MCT1 expression is down regulated in 
colorectal cancer, where butyrate (a substrate for MCT1) plays a critical role in 
maintaining colonocyte homeostasis (82-84). Compared with healthy colonic epithelium, 
MCT1 expression in the luminal membrane is decreased in colonic carcinoma (85) and 
in the transition to malignancy (86). In concurrence, MCT1 expression is not found on 
colorectal tumor vessels compared with normal tissues, although conflicting results are 
reported (87).  
MCT1 is predominantly expressed in type I fibers in red skeletal muscle and in cardiac 
muscles, both of which have a more oxidative metabolic status (88-90) when compared 
to white muscles with more type II fibers and a glycolytic metabolism (91, 92). In 
developmental processes, MCT1 is detected as early as during oocyte maturation and 
its expression is maintained through the embryonic stage (93). In general, MCT1’s 
expression level changes during development with a peak level at early postnatal life 
and rapidly declining towards adult age. Specifically, Mct1 expression in mouse brain 
peaks around postnatal day 15, declining rapidly by 30 days at levels of adults (94). 
Similarly, 17-day old suckling rats have 25 times more MCT1 labeling than adults in the 
membranes of capillary endothelial cells, 15 times more in pericyte membranes and 19 
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times more in the membranes of astrocytic end feet adjacent to microvessels (95). 
Similar fluctuations of brain endothelial MCT1 levels are observed in both rodents and 
monkeys (96, 97). In mouse brown adipose tissue Mct1 mRNA is more abundant in 
fetuses (E17.5) and neonates than in adult animals (98). In soleus muscle, MCT1 
expression is lower in older rats than young rats, due to aging (99). However, in some 
other tissues, MCT1’s regulation appears to be the opposite. For example, MCT1 
expression is increased in adult bovine liver hepatocytes by 7-8 fold than in pre-ruminant 
animals (100). Furthermore, MCT1 protein levels are greater in horse gluteus medius 
muscle at 24 months compared to 2 months old (101). In conclusion, MCT1’s regulation 
during development is complicated and variable in a tissue specific manner. 
The expression levels of MCT1 have also been regulated by diets and nutrients. 
Specifically, a ketogenic diet increases MCT1 expression by 8-fold on rat brain 
endothelial cells and neuropil compared with animals on a normal control diet (102). This 
is supported by another study, where rat brain endothelial MCT1 level is elevated by 2-
fold during a ketogenic diet (103) and suggests the neuroprotective potential of ketones 
(104, 105). Caloric restriction and protein malnutrition cause Mct1 expression to 
decrease in Pla and EDL muscles, respectively (92, 106). In addition, folate deficiency 
causes reduced MCT1 mRNA level in Caco-2 cells (107), whereas low digestible starch 
decreases MCT1 expression in ileum but increases its expression in colon (108). As for 
a regulatory role by hypoxia, 1% O2 elevates MCT1 mRNA and protein levels by 8.5- 
and 2.7-fold respectively in human adipose tissue, via a HIF-1 dependent manner (39, 
109). In cervix, breast and colon cancer cell lines, MCT1 expression is also upregulated 
by hypoxia via NF-κB signaling pathway, but only in the absence of p53 (110).  
Because MCT1 has been implicated in the alteration of cellular metabolism during many 
physiological progressions, its expression thus can be regulated by a variety of 
pathological conditions. In a rat focal ischemic hemisphere model, increase in Mct1 
mRNA expression is observed in cortex and hippocampus, as well as in peri-lesional 
macrophage/microglia (111). MCT1’s regulation by insulin resistance during 
obesity/diabetes seems to be dependent on tissue types. MCT1 content of skeletal 
muscles in both STZ-induced diabetic rats and type 2 diabetic patients is reduced 
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compared with controls (112, 113). In contrast, elevated expression of brain MCT1, 
especially in the cortex and hippocampus, is observed in obese/diabetic mice (114).  
During hyperglycemia, rat brain MCT1 density is elevated by 12% within endothelial cells 
and astrocytes (115). Furthermore, epilepsy affects hippocampal MCT1 expression in 
patients with temporal lobe epilepsy by decreasing its expression on microvessels (116), 
but elevating that on astrocytes in epileptic models (117). Similarly, patients with 
temporal lobe epilepsy show decreased expression of endothelial MCT1 in hippocampus 
(116). In autoimmune diseases such as inflammatory bowel disease, MCT1 mRNA and 
protein levels in the inflamed colonic mucosa are markedly decreased (118). 
MCT1’s expression can also be modulated by a variety of signaling pathways. Protein 
kinase C (PKC) pathway increases MCT1 expression in colonic epithelial Caco-2 cells 
via the transcription factor activator protein 2 (AP2) (69). Similarly in muscle cells, 
phorbol 12-myristate 13-acetate (PMA) activates PKC, which then increases the Vmax as 
well as the total expression level of MCT1 (119). PGC-1α, a key transcription factor for 
mitochondrial homeostasis, is positively correlated with and increases MCT1 expression 
levels in tibialis muscles (120, 121). NF-κB signaling is the mechanism of MCT1’s 
regulation by butyrate in colonic Caco-2 cells (122, 123). Besides, activation of this 
pathway is required for MCT1 upregulation by hypoxia in p53-deficient cells (110). As 
MCT1’s substrates, monocarboxylates (butyrate, lactate and pectin) can regulate its 
expression and function to adjust for metabolic needs. For example, butyrate has been 
known to increase MCT1’s transcription and mRNA stabilization in colonic epithelial cells 
(122, 124), as well as this transporter’s functional expression on plasma membrane in 
breast cancer cells (125). In skeletal muscle L6 cells, addition of lactate increases MCT1 
expression at both mRNA and protein levels within 1h (126). Lactate produced by tumor 
cells and taken up by human mesenchymal stem cells increases their MCT1’s 
expression (127).  
4.3.4. Regulation of MCT2 (SLC16A7) Gene Expression. 
Compared with normal tissues, MCT2 expression is consistent and ubiquitous in both 
prostate and gastrointestinal stromal tumor samples, demonstrating a significant 
elevation within cytoplasma granules (64, 128). Similar to MCT1, the expression pattern 
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of MCT2 in rodent brain during developmental processes peaks around early postnatal 
days and rapidly declines to the level observed at adulthood (94, 129). For example, 
neuronal MCT2 is most abundant in the first 3 postnatal weeks and thereafter decreases 
towards adulthood levels (130). The expression of MCT2 is also influenced by 
diets/nutrients. Studies have shown that fasting increases Mct2 mRNA levels in the area 
postrema-solitary tract nucleus, whereas under-nutrition causes brain cortical MCT2 
protein expression to be decreased (131, 132). In addition, pectin feeding increases 
MCT2 protein level in rat adrenal gland (133). Regulation of MCT2 by hormones has 
been reported. For instance, in cultured cortical neurons, brain-derived neurotrophic 
factor and insulin or IGF-1 significantly increase MCT2 protein levels at a translational 
level, requiring the PI3K-Akt-mTOR-S6K signaling axis (134, 135). Besides, removal of 
estrogen by ovariectomy induces the expression of neuronal MCT2 (136). In contrast, 
adrenalectomy decreases Mct2 transcription in dorsal vagal complex of hypothalamus 
(137). MCT2 expression can also be regulated by various pathological conditions. For 
example, ischemic insult increases MCT2 protein expression in cells within the infarct 
and bordering the scar (138). In mice fed a high fat diet, genetically obese and diabetic 
mice, brain MCT2 expression is increased significantly as compared to controls (114). 
Finally, in a lithium-pilocarpine model of temporal lobe epilepsy, the expression of MCT2 
is increased in adult animals and mostly enriched in the region of seizures (139). 
4.3.5. Regulation of MCT4 (SLC16A3) Gene Expression. 
As a prominent lactate extruder, MCT4 is associated with tumors and with tumor 
progression. These cancerous tissues are also characterized by the Warburg effect, a 
switch to aerobic glycolysis and lactate production and efflux. In prostate tumor samples, 
MCT4 expression in the cytoplasm of tumor cells is increased when compared with 
control tissue (128). In sections of human breast cancer samples, MCT4 immunostaining 
shows elevated expression level in the stroma, implying a metabolic reprogramming that 
supports tumor progression (75). The metastatic renal cell carcinomas have a 
significantly higher expression level of MCT4 compared with localized tissues, implying 
its significant role in metastasis (140). MCT4 has been considered to be the major efflux 
transporter of lactate from glycolytic muscles. As a result, its regulation in skeletal 
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muscles is correlated with type II fiber composition (141). The testosterone-induced 
increments of MCT4 expression are strongly correlated with fast-twitch fiber composition 
of rat muscles (89). Regulation of MCT4 expression by hormones has been documented 
substantially. T3 hormone increases both mRNA and protein expression levels of MCT4 
in rat skeletal muscles (142). In human skin fibroblasts, T3 hormone induces MCT4 
mRNA and protein expression in a PI3K signaling dependent manner (143). In human 
sertoli cells, insulin deprivation decreases MCT4 transcription, consistent with an altered 
glucose metabolism (144).  
MCT4 has been shown to be both positively and negatively regulated by exercise. 
Specifically, MCT4 protein expression is increased in rat red gastrocnemius and soleus 
muscles by a single bout of exercise, with peak expression 10h post training (145). 
Endurance training increases MCT4 expression in fasted skeletal muscles (146). After 
prolonged submaximal exercise in untrained volunteers, MCT4 expression in vastus 
lateralis is found modestly increased at recovery day 1 (147). In contrast, some studies 
have shown the opposite. In moderately endurance-trained runners, progressive sprint 
training does not result in any changes of MCT4 expression in vastus lateralis muscles 
before and after a single supramaximal running test to exhaustion (148). High-intensity 
training in women for five weeks fails to change MCT4 expression in vastus lateralis 
(149). MCT4 expression is influenced by a series of pathological conditions. In chronic 
obstructive pulmonary disease, MCT4 expression in vastus lateralis muscles is found to 
be 35% lower than control (150). In genetically obese or diabetic mice, increased brain 
MCT4 expression is observed compared to control animals (114). During ischemic insult, 
like MCT1 and MCT2, MCT4’s expression also increases in cells within the infarct and 
bordering the scar after a permanent occlusion of the left middle cerebral artery (138). 
There are many mechanisms for regulation of the MCTs expression and activity. Given 
the central role of monocarboxylic acids such as lactate and β-hydroxybutryate in cellular 
energy metabolism, it is not surprising that there are multiple types and levels of 
regulation.  Further studies including examining micro-RNAs, protein-protein and protein-
lipid interactions will be needed to provide a more complete picture of the role of MCTs 
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during development, under physiological and pathological conditions, and during delivery 
of drugs to the whole organism. 
Table I-1: Representative substrates of MCTs and SMCTs 
Transporter Species Expression System Substrate Km (mM) Refs 
MCT1 
Mouse Ehrlich-Lettre cells D/L-2-HB 2.62 
(151-
157) 
Rat 
Xenopus Oocytes 
Acetate 
L-Lactate 
D-Lactate 
Pyruvate 
2.2 
3.5 
>60 
1.01 
REBC1 Benzoic acid 1.15 
Red Blood Cells GHB 2.2 
Human BCS-TC2 cells Butyrate 0.0179 
MCT2 Rat 
Xenopus Oocytes 
Acetate 
L-Lactate 
D/L-β-HB 
Pyruvate 
2.6 
0.74 
1.2 
0.08 
(156, 
158, 
159)  
Hepatocytes HA 
0.182-
0.39 
MCT4 
Human Xenopus Oocytes 
L-Lactate 
D-Lactate 
Pyruvate 
28 
519 
153 
(154, 
160-
162) 
Rat 
Xenopus Oocytes 
Acetate 
L-Lactate 
D-Lactate 
D/L-β-HB 
Pyruvate 
>100 
17 
55 
64.7 
16.2 
Mesangial cells Lovastatin 37.3 
Astrocytes Nicotinate 2.8 
SMCT1 
Human Xenopus Oocytes 
3-bromopyruvate 
Acetate 
Butyrate 
D-Lactate 
L-Lactate 
Nicotinate 
Pyruvate 
0.5 
2.46 
0.08 
1.09 
0.18 
0.23 
0.39 
(14, 
163-
166)  
Rat Thyroid follicular cells GHB 0.68 
SMCT2
*
 Human hRPE cells 
Lactate 
Butyrate 
Nicotinate 
17-49 
2.6-16 
3.7-9.5 
(12, 
167)  
 
RBEC1, rat brain endothelial cell line; BCS-TC2 cells, Colon adenocarcinoma cells; 
hRPE, human retinal pigmented epithelial cells; D/L-2-HB, D/L-2-Hydroxybutyrate; GHB, 
γ-Hydroxybutyrate; D/L-β-HB, D/L-β-Hydroxybutyrate; HA, Hippuric acid.  
* Values derived from IC50.  
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Table I-2: Representative inhibitors of MCTs, SMCTs and MPCs. 
Transporter Species Expression System Inhibitor Ki or IC50 (μM) Refs 
MCT1 
Mouse Ehrlich-Lettre cells 
α-CHC 
UK5099 
DIDS 
Niflumic acid 
NPPB 
pCMBS 
166 
8.1 
434 
6.1 
9.3 
112 
(46, 51, 
168-171) 
Rat 
Erythrocytes 
GW604714X 
AR-C155858 
<10 
0.0023 
MDA231 cells 
Luteolin 
Phloretin 
0.41 
2.57 
Human Caco-2 cells 
Naproxen 
Ketoprofen 
Naringenin 
Silybin 
220 
380 
15.3 
19.7 
MCT2 Rat 
Xenopus Oocytes 
α-CHC 
Phloretin 
Benzbromaron 
Quercetin 
24 
14 
9 
5 
(151, 
158) 
Hepatocytes 
UK5099 
DBDS 
Niflumic acid 
45.2 
181 
20 
MCT4 Human 
Xenopus Oocytes 
α-CHC 
pCMBS 
Phloretin 
NPPB 
991 
21 
41 
240 
(154, 
172) 
LLC-PK1 cells 
Fluvastatin 
Lovastatin acid 
32.4 
44.2 
SMCT1 
Rat 
Thyroid follicular 
cells 
Ketoprofen 
Ibuprofen 
Probenecid 
31.6 
64.4 
380 
(21, 164, 
173) 
Human 
HRPE cells Fenoprofen 119 
IEC-6 cells CDCA n.a 
MPCs Rat Heart Mitochondria 
α-CHC 
UK5099 
α-
Cyanocinnamat
e 
GW604714X 
6.3 
0.05 
 
0.2 
0.000057 
(5, 169) 
 
α-CHC, α-cyano-4-hydroxycinnamate; DIDS, 4,4'-Diisothiocyano-2,2'-stilbenedisulfonic 
acid; DBDS, 4,49-dibenzamidostilbene-2,29-disulfonate; NPPB, 5-nitro-2-(3-
phenylpropylamino)benzoic acid; pCMBS, p-chloromercuribenzene sulfonate; CDCA, 
Chenodeoxycholic acid; n.a., not available 
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Figure I-1.  Phylogenic Relationships of SLC5 Family Members.  The carriers in this family 
that are sodium-dependent monocarboxylate transporters (SMCTs) are highlighted in the shaded 
box. Abbreviations for other SLC5 members and their substrates are also shown. 
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Figure I-2. Putative Membrane Structure of SMCT1.  The amino acid sequence of SMCT1 was 
threaded onto a previously characterized 3D structure of a membrane transporter, the Vibrio 
parahaemolyticus sodium/galactose symporter (vSGLT), based on sequence homology. Each 
colored ribbon represents one of the thirteen transmembrane segments. 
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In the cerebrovascular endothelium, monocarboxylic acid transporter 1 (MCT1) controls 
blood–brain transport of short chain monocarboxylic and keto acids, including pyruvate 
and lactate, to support brain energy metabolism. MCT1 function is acutely decreased in 
rat brain cerebrovascular endothelial cells by β-adrenergic signaling through cyclic 
adenosine monophosphate (cAMP); however, the mechanism for this acute reduction in 
transport capacity is unknown. In this report, we demonstrate that cAMP induces the 
dephosphorylation and internalization of MCT1 from the plasma membrane into 
caveolae and early endosomes in the RBE4 rat brain cerebrovascular endothelial cell 
line. Additionally, we provide evidence that MCT1 constitutively cycles through clathrin 
vesicles and recycling endosomes in a pathway that is not dependent upon cAMP 
signaling in these cells. Our results are important because they show for the first time 
the regulated and unregulated vesicular trafficking of MCT1 in cerebrovascular 
endothelial cells; processes which have significance for better understanding normal 
brain energy metabolism, and the etiology and potential therapeutic approaches to 
treating brain diseases, such as stroke, in which lactic acidosis is a key component. 
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Introduction 
Cerebral lactic acid levels are dependent on the activity of the monocarboxylic acid 
transporter 1 (MCT1) in the cerebral microvasculature where it is the only facilitator of 
lactic acid transport across the blood–brain barrier (174, 175). Because lactate is a 
critical energy substrate that has important roles in brain health and disease, 
understanding MCT1’s physiological regulation in cerebrovascular endothelial cells is of 
great significance (67, 176). This is illustrated by the importance of MCT1 in controlling 
post-ischemic brain lactate concentrations, a key biochemical indicator of outcomes 
following stroke and brain injury (177-181). MCT1 is further implicated in metabolic 
coupling between astrocytes and neurons for brain energy metabolism, for regulating 
tumor growth, inflammatory responses, and for long term memory consolidation (37, 
177-179, 181-185).  
Previously, we have shown that the function of MCT1 is acutely regulated in a 
cerebrovascular endothelial cell line (RBE4) by a β-adrenergic receptor-mediated 
pathway that signals through adenylyl cyclase, cyclic adenosine monophosphate (cAMP), 
and protein kinase A (PKA). The regulation reduced the Michaelis–Menten parameter 
Vmax, but not Km, consistent with stimulus dependent reduction in the number of 
functional transporters on the cell surface (67). However, the mechanism linking PKA 
activation to reduced MCT1 function was not elucidated and questions remain regarding 
MCT1’s plasma membrane location, phosphorylation status and trafficking.  
PKA-dependent phosphorylation has been well characterized in having direct effects on 
the gating and kinetic function of various ion channels and transporters. This type of 
regulation is often associated with changes in Km; however, this was not observed in our 
previous studies with RBE4 cells. Alternatively, phosphorylation-dependent vesicular 
trafficking to and from the plasma membrane also controls the cellular function of a 
diversity of membrane proteins and transporters, and is a plausible hypothesis for the 
cAMP-dependent changes in MCT1’s Vmax that we observed (186-190). Included among 
the transporters that are regulated by vesicular trafficking are monoamine transporters, 
aquaporins, sodium–hydrogen exchangers, proton pumps, and glucose transporters (19, 
191-196). Vesicular trafficking occurs by different mechanisms including most notably 
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the clathrin and caveolin-dependent vesicular pathways. The caveolar pathway has 
been particularly well characterized in capillary endothelial cells, where it mediates not 
only the surface expression of proteins but also transcytosis of molecules between the 
luminal and abluminal surfaces of the endothelial barrier (197-199). Both clathrin- and 
caveolin-dependent endocytosis deliver protein cargos to various internal compartments 
including lysosomes, trans-Golgi, endoplasmic reticulum, and Rab 11 positive recycling 
endosomes. The specificity of protein trafficking to these organelles is controlled through 
processes involving early sorting endosomes, which are identified by their expression of 
the small GTPase Rab5, and EEA1. Therefore, we predicted that treatment of RBE4 
cells with cAMP analogs would reduce the levels of MCT1 on the plasma membrane and 
increase MCT1 in clathrin coated pits or caveoli, early-sorting endosomes, and targeted 
cytoplasmic organelles. Identification of such a regulatory pathway, and whether direct 
MCT1 phosphorylation is involved, would greatly increase our understanding of the 
mechanism linking PKA activation to reduced MCT1 function, and could contribute to the 
development of new treatments for diseases in which monocarboxylate transport across 
the cerebral microvasculature is important. 
 
Materials and Methods 
RBE4 cell culture. RBE4 cells, a gift from F. Roux, were cultured as previously 
described (200-202). Briefly, cells were grown on collagen-coated polystyrene tissue 
culture dishes or collagen-coated number 1 coverslips in minimum essential medium 
alpha and F-10 nutrient (Ham’s) (1:1) with 10% fetal bovine serum, 1% antibiotic–
antimycotic, 0.3 mg/ml geneticin, and 1.0 ng/ml basic fibroblast growth factor. Cells were 
trypsinized, replated between 3 and 8 h prior to experimentation, and used at 
subconfluency. 
Whole-cell protein isolation and western blot detection. Cells were lysed on ice for 
45 min in pH 8 lysis buffer containing 10 mM Tris–Cl, 5 mM NaCl, 135 mM KCl, 2.5 mM 
EDTA, 2.5 mM iodoacetamide, 1% Triton X-100, 1 mM phenyl-methylsulfonyl fluoride 
(PMSF), protease inhibitor cocktail (Roche), and phosphatase inhibitor cocktail (Santa 
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Cruz Biotechnology). Lysates were sonicated for 10 min at 4oC and centrifuged at 
13,000 g for 8 min at 4oC to remove debris and total protein was quantified with a BCA 
assay (Pierce Thermoscientific). Equivalent masses and volumes of protein were 
electrophoresed on 10% SDS-PAGE gels electrophoretically transferred to 
polyvinylidene fluoride membranes. Membranes were blocked in 50 mM Tris-buffered 
saline (pH=8.0), 5% non-fat milk, 1% Tween-20, and probed with primary antibodies 
overnight at 4oC. Primary antibodies were diluted as follows: rabbit anti caveolin-1 
(1:1000; Cell Signaling Technology), phospho-caveolin-1 (1:1000; Cell Signaling 
Technology), and chicken anti MCT1 antibody (1:5000) produced as previously 
described (102). Membranes were washed in blocking buffer and incubated in a goat 
anti-rabbit IgG-HRP to detect caveolin antibodies, (1:3000; Santa Cruz Biotechnology) or 
a rabbit anti chicken IgY-HRP (1:5000; Pierce Thermoscientific) to detect MCT1 
antibodies. Blots were visualized using a Bio-Rad ABC chemiluminescence detection kit 
and imager. 
Surface biotinylation and internalization. Cell surface proteins were biotinylated using 
reagents as described by the vendor’s instructions (Pierce Thermoscientific; kit #89881) 
and quantified by immunoblotting. Briefly, RBE4 cell cultures (75 cm2 flasks) were 
exposed for 30 min. at room temperature to Hepes Buffered Saline (HBS) or HBS 
containing 500 mM dibutyryl cyclic 3’,5’-adenosine monophosphate (db-cAMP). Protein 
concentration was determined using the Pierce 660 nm Protein Assay kit including the 
Ionic Detergent Compatibility reagent (Pierce Thermoscientific). Proteins were run on 
SDS-Page gels, transferred to nitrocellulose membranes, blotted with chicken anti MCT1 
IgY (1:5000) and mouse anti β-actin (1:10,000; Millipore). The proteins were detected 
using a secondary antibody consisting of HRP conjugated goat anti mouse IgG 
(1:10,000; Pierce Thermoscientific) or rabbit anti chicken IgY-HRP (1:5000; Pierce 
Thermoscientific) followed by Super Signal West Pico Chemiluminescent substrate 
(Pierce Thermoscientific). MCT1 and β-actin specific bands were imaged and quantified 
by spot densitometry using a ccd camera (Alpha Innotech) and related software. 
MCT1 phosphorylation assay. RBE4 cell cultures (75 cm2 flasks) were exposed for 30 
min. at room temperature to HBS or HBS containing 500 mM db-cAMP followed by a 
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rinse with ice cold HBS. Cells were scraped in 800 μl homogenization buffer (20 mM 
Tris–Cl pH 7.4, 40 mM NaCl, 1 mM dithiothreitol with Complete Protease Inhibitor 
Cocktail (Roche)), homogenized using a motorized homogenizer, and ultracentrifuged at 
50,000 rpm (100,000g) for 30 min. at 4oC. Membrane pellets were solubilized and 
phosphoproteins separated using a Phosphoprotein Purification Kit according to the 
vendor’s instructions (Qiagen). Briefly, solubilized membrane proteins were applied to an 
agarose column with high affinity for phosphoproteins. Unphosphorylated proteins do not 
bind and were present in the flow through. Bound phosphoproteins were eluted with high 
phosphate and high salt buffer. Protein determinations were made using a BCA protein 
assay (Pierce Thermoscientific). Representative aliquots of the flow through and eluate 
were subjected to SDS-PAGE gel electrophoresis, Western blotting, and quantitation by 
densitometry (normalized with actin) as described above. The phosphorylated fraction 
was reported as the percentage of the total MCT1 (see Figure II-1 legend). 
Triton X-100 solubilization assay. Following treatment, RBE4 cells were lysed in situ 
on ice for 10 min in the lysis buffer described above. The supernatant (soluble fraction) 
was collected and the remaining insoluble cellular material was scraped from the culture 
substrate and resuspended in lysis buffer (insoluble fraction). Lysates were sonicated for 
10 min at 4oC. Equivalent volumes of each sample were mixed with DNase I (Invitrogen) 
and loaded onto gels for SDS-PAGE as described above. 
Immunofluorescence staining. RBE4 cells were fixed in 3.7% formalin/PBS for 25 min 
followed by permeabilization with 0.5% Triton X-100 for 2.5 min at room temperature. 
Cells were rinsed with PBS, blocked with 1.5% goat serum, and stained with anti-MCT1 
chicken diluted 1:1000 (Millipore) and anti-caveolin-1 rabbit diluted 1:700, anti-clathrin 
rabbit diluted 1:100, anti-EEA1 rabbit diluted 1:500, or anti-Rab11 rabbit diluted 1:300 
primary antibodies (Cell Signaling) followed by detection with Alexafluor 488 diluted 
1:125 and Alexafluor 568 diluted 1:75 secondary antibodies (Molecular Probes). Slides 
were mounted in ProLongs Gold Antifade Reagent (Molecular Probes). 
Laser scanning confocal microscopy and colocalization analysis. Images were 
acquired using an Olympus FV10i laser scanning microscope using a 60x oil immersion 
objective and internally standardized illumination and detection-sensitivity parameters. Z-
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slices were acquired at 0.646 mM/slice and Z-stacks spanned the thickness of each 
specimen. Colocalization analysis was performed using the colocalization function of 
Olympus Fluoview software version 3.1. 
BCECF-AM ratiometric pH imaging. Internal pH measurements in RBE4 cells were 
made in HEPES-buffered saline (HBS) essentially as described previously (67, 202). 
Briefly, BCECF-AM loaded cells were exposed to 25 mM L-lactate and the initial rate of 
acidification was fit with a linear regression over the first ten seconds of the response. 
Image pairs, generated alternately with 440 and 495 nm excitation filters and 530 nm 
emission filter, were sampled at 60 Hz during the response. Following the response, the 
lactate-containing HBS was replaced with fresh HBS to allow the cells to recover and a 
two point calibration was made in nigericin-containing high K+ HBS at pH 7.8 and 6.5. 
The ratio data was transformed to indicate intracellular pH by linear regression. 
Drugs and statistics. All drugs were purchased from Sigma-Aldrich. Pearson’s 
coefficients (203) were compared with a 2 sample t-test. Initial rates of L-lactate 
dependent acidification were measured in groups of a few hundred individual cells by 
BCECF imaging and binned by the intracellular pH determined at the start of each 
experiment in 0.01 increments. Responses from cells in each pH bin were averaged and 
the averages were paired across treatment groups for analysis using a paired t-test. 
Western blots were repeated at least 3 times and compared by a t-test. 
 
Results 
i. MCT1 phosphorylation and surface expression were reduced by cAMP  
MCT1 transport function was reduced by more than 25% when RBE4 cells were treated 
for 10 min with membrane-permeant cAMP analogs (8-BrcAMP or db-cAMP), a result 
that is consistent with our previous report ((67); see also Figure II-6). Because we 
previously determined that this reduction was PKA-dependent, we assessed whether 
treatment with cAMP analogs causes a change in MCT1’s phosphorylation status. This 
was achieved by purifying cellular membrane phosphoproteins from treated and 
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untreated RBE4 cell cultures followed by Western blot analysis and densitometry. Under 
basal conditions, 41% of the MCT1 signal was present in the phosphoprotein fraction 
and cAMP analogs reduced the signal to 29% (Figure II-1 A). This reduction was 
statistically significant (p<0.05), thus, cAMP signaling via PKA does not directly 
phosphorylate MCT1, but rather reduces the phosphorylation of MCT1.  
Because the phosphorylation status of membrane proteins can control their surface 
expression, and because we previously showed that adrenergic signaling through cAMP 
decreases MCT1’s Michaelis–Menten parameter Vmax (67), we next assessed whether 
the surface expression of MCT1 was affected by elevated cytoplasmic cAMP. This was 
accomplished by brief treatment of RBE4 cells with cAMP analogs followed by 
biotinylation of the cell surface proteins that were isolated on streptavidin columns and 
subjected to Western blot detection and densitometry. Treatment resulted in a 16% 
reduction (p<0.02) in the level of MCT1 detected at the cell surface when compared to 
untreated controls or non-trafficking controls that were treated at 4oC (Figure II-1 B). 
Therefore, our combined results (Figure II-1) demonstrate that elevated cytoplasmic 
cAMP causes dephosphorylation of MCT1 and that it becomes internalized from the 
surface of RBE4 cells. Thus, the cAMP dependent reduction of Vmax is a result of MCT1 
dephosphorylation and internalization. 
ii. Colocalization of MCT1 with caveolin-1, but not clathrin, was increased by 
cAMP  
To explore further the pathway for internalization of MCT1, we used dual 
immunostaining and fluorescence confocal imaging of MCT1 combined with either 
clathrin or caveolin-1 in RBE4 cells (Figure II-2). Widespread expression of MCT1 on the 
plasma membrane and especially at the leading edge of lamellipodia was observed. 
MCT1 was also detected across the cytoplasmic face in numerous puncta of different 
sizes and shapes as well as in a large perinuclear compartment that stained very brightly 
in most cells (Figures II-2 and -3, green). Clathrin-immunoreactivity (Figure II-2 A, red) 
was present in numerous round puncta that were distributed across the cytoplasmic face 
and in the large perinuclear compartment. Overlap between MCT1 and clathrin (yellow) 
was present in a subset of the round puncta that appeared to be very close to the 
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Figure II-1: MCT1 phosphorylation and surface expression were reduced by cAMP. (A) 
Cultured RBE4 cells were treated briefly with 500μM db-cAMP (cAMP) or with vehicle (control). 
Total cellular phosphoprotein was fractionated using a phosphoprotein purification column 
(Qiagen)-both flow through (unphosphorylated) and eluate (phosphoproteins) fractions were 
collected. MCT1 was detected in equal μg amounts of flow through and eluate proteins by 
Western blotting and quantified by densitometry using actin as a normalizing control. A 
representative blot is shown (above). The percentage of phosphorylated MCT1 was determined 
as elute/(elute+flow through) (below). The mean +/- s.e.m. from 4 independent experiments is 
shown and values were compared using the student’s t test (*P<0.05). (B) The percentage of 
MCT1 in the plasma membrane was measured following treatment with cAMP analogs. Following 
treatment, surface proteins were biotinylated, solubilized, and purified on an avidin column. MCT1 
was detected by Western blot and quantified by densitometry. A representative blot is shown 
(above). The amount of plasma membrane MCT1 was normalized to control. As an additional 
non-trafficking control some cells were treated with cAMP analogs but kept at 4
o
C for the entire 
process to halt intracellular trafficking (4
o
C). Values represent the mean +/- s.e.m. from 4 
independent experiments. Differences in means were compared to control using the student’s t 
test (*P<0.05). 
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plasma membrane, within the cytoplasm, and especially prominent in the brightly 
staining large central compartment. As has been reported in brain endothelial, smooth 
muscle, C6 glioma cells and neurons, treatment of the RBE4 cells with cAMP analogs 
caused them to round up, often accompanied by retraction of the lamellipodia (204, 205). 
However the overall patterns of MCT1, clathrin, and the overlap in staining, was not 
obviously changed. Pearson’s coefficients of overlap (Rr) were calculated for Z stacks of 
multiple images and compared by two-sample t-tests. Rr values near 1 indicate the 
highest level of overlap and range to -1 when repulsion is present (203). Rr was near 0.8 
for MCT1–clathrin pairs, consistent with MCT1’s presence in clathrin coated vesicles; 
however, treatment with cAMP analogs did not appreciably change Rr (Figure II-4), 
suggesting that signaling through cAMP does not regulate MCT1’s association with 
clathrin coated vesicles.  
Caveolin-1 staining (Figure II-2 B, red) was present in vastly elongated regions on the 
plasma membrane, in numerous slightly elongated or round cytoplasmic puncta, and in 
larger clusters within the cytoplasm. It was largely absent in lammellipodia and the large 
central compartments that contained MCT1 and clathrin. In control cells, the overlap 
between MCT1 and caveolin-1 was diffusely localized in scattered cytoplasmic puncta 
and at the plasma membrane, particularly where some of the cells contacted one 
another. A cAMP-dependent increase in yellow overlap signal was obvious and 
widespread within intracellular puncta, cytoplasmic clusters, and in vastly elongated 
regions on the plasma membrane. The coefficient of overlap, Rr, for MCT1-caveolin-1 
stained cells was in the range of 0.5 and was statistically significantly increased upon 
treatment with cAMP analogs (Figure II-4). Combined, the above results are consistent 
with a cAMP-dependent increase in endocytosis of MCT1 into caveolae via a clathrin-
independent pathway. 
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Figure II-2: Colocalization of MCT1 with caveolin-1, but not clathrin, was increased by 
cAMP. (A) Images of RBE4 cells that were dual-immunostained to visualize MCT1 (green) and 
clathrin (red) as indicated in the Figure. Merged images showed colocalization (yellow) in 
scattered puncta across the cytoplasmic face (arrowheads) and in a prominent perinuclear 
compartment (arrows) that was present in most cells. Treatment with 8Br-cAMP (right hand 
panels) did not appear to change the pattern of staining. (B) Images of RBE4 cells that were dual-
immunostained to visualize MCT1 (green) and caveolin-1 (red) as indicated in the Figure. 
Caveolin-1 staining was present in localized areas close to the plasma membrane and in 
numerous slightly elongated puncta on the cytoplasmic face (arrowheads). Merged images from 
untreated cells showed less colocalization (yellow) in contrast to the more widespread 
colocalization observed in cells that were treated with cAMP analogs (arrows in right hand panel). 
Images are max-z projections of confocal images and the scale bar for merged images is 10 μm. 
(For interpretation of the references to color in this figure legend, the reader is referred to the web 
version of this article.) 
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iii. Colocalization of MCT1 with EEA1 but not Rab11 was increased by cAMP  
The pathway of cAMP-induced internalization of MCT1 was further explored by confocal 
imaging of MCT1 with markers for early endosomes, EEA1 and Rab5, or with a marker 
for recycling endosomes, Rab11. EEA1 was readily detected in numerous round puncta 
that were spread across the cytoplasmic face and crowded along the perimeter of the 
plasma membrane of RBE4 cells (Figure II-3 A, red). Furthermore, EEA1 was present in 
the large perinuclear compartments described above. Colocalization between MCT1 and 
EEA1 was apparent in sparsely distributed puncta in the cytoplasm, near the plasma 
membrane, and in the large perinuclear compartment (Figure II-3 A). Supporting the 
notion of colocalization between MCT1 and EEA1, Rr for these images was near 0.7, 
and most importantly, a brief exposure to cAMP analogs significantly increased the Rr 
values for the MCT1–EEA1 pairs (Figure II-4). In many cells, the overlap appeared most 
prominent just adjacent to the plasma membrane (Figure II-3 A). Similar results were 
seen with immunostains for Rab5, a different marker of early endosomes; however, the 
change induced by cAMP did not reach statistical significance, possibly reflecting subtle 
differences among the endosomal populations identified or labeling efficacy achieved 
with the different markers (data not shown). Overall, these results are consistent with 
cAMP-dependent internalization of MCT1 into an EEA1-positive population of early-
sorting endosomes.  
As described above, MCT1 staining was very bright in a large and well-defined 
cytoplasmic region near the nucleus of many RBE4 cells. Clathrin, EEA1, and Rab5, 
invariably stained strongly in these regions as well; however, the boundaries of the 
region were broader and more diffuse for these markers than for MCT1. Interestingly, 
Rab11, a marker of recycling endosomes also strongly labeled these regions with a 
pattern similar to that seen for EEA1, Rab5 and clathrin (Figure II-3 B, red). Rab11 
staining was also detected in fine puncta at the plasma membrane, and across the 
cytoplasmic face. In some images the cytoplasmic puncta appeared to form lines that 
radiated from the central region to the plasma membrane. Overlap between MCT1 and 
Rab11 was most prominent in the large cytoplasmic regions, and also occurred in finer 
puncta at the plasma membrane, cytoplasm, and along some of the radial lines. Rr 
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values for this pair were near 0.8; however, treatment with cAMP analogs did not cause 
an appreciable change in the level of overlap (Figure II-4). These results indicate that 
MCT1 was present in recycling endosomes, but that its presence therein was not 
regulated by cAMP. 
 
 
Figure II-3: Colocalization of MCT1 with EEA1 but not Rab11 was increased by cAMP. (A) 
Images of RBE4 cells that were dual-immunostained to visualize MCT1 (green) and EEA1 (red) 
as indicated in the Figure. Merged images showed colocalization (yellow) in scattered puncta 
across the cytoplasmic face (arrowheads) and in a prominent perinuclear compartment (solid 
arrows) that was present in most cells. Treatment with cAMP analogs appeared to increase 
colocalization near the plasma membrane of some cells (open arrows). (B) Images of RBE4 cells 
that were dual-immunostained to visualize MCT1 (green) and Rab11 (red) as indicated in the 
Figure. Merged images showed colocalization (yellow) in scattered puncta (arrowheads) and in a 
prominent perinuclear compartment (arrows) that was present in most cells and very strongly 
immunoreactive against Rab11 (a and b). Treatment with 8Br-cAMP did not appear to change the 
pattern of staining. Images are max-z projections of confocal images and the scale bar for 
merged images is 10 μm. (For interpretation of the references to color in this figure legend, the 
reader is referred to the web version of this article.) 
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Figure II-4: Pearson’s Coefficients of Overlap (Rr) for dual immunofluorescence images of 
untreated control and 8Br-cAMP treated RBE4 cells. In MCT1/clathrin stained cells Rr was 
0.82+/-0.008 in control images and 0.082+/-0.007 in images from treated cells (p=0.775 showed 
no significant difference between groups, n.s.). In MCT1/caveolin-1 stained cells Rr was 0.56+/-
0.014 in control images and 0.62+/-0.016 in images from treated cells (p=0.01). In MCT1/EEA1 
stained cells Rr was 0.74+/-0.008 in control images and 0.78+/-0.012 in images from treated cells 
(p=0.02). In MCT1/Rab11 stained cells Rr was 0.79+/-0.01 in control images and 0.77+/-0.005 in 
images from treated cells (p=0.12, n.s.). For each bar, N=10 images like those represented in 
Figures II-3–6. Similar results were seen when these experiments were repeated. 
 
iv. cAMP reduced the level of caveolin-1 phosphorylation  
Because our results suggested that the major pathway for cAMP-dependent 
internalization of MCT1 from the plasma membrane of RBE4 cells is mediated through 
caveolae, and because phosphorylation of caveolin-1 changes its functional status, we 
used Western blotting to see whether phosphorylation of caveolin-1 changed in RBE4 
cells after treatment with cAMP analogs. Under non-stimulated conditions caveolin-1 
was detected in whole cell lysate from RBE4 cells using an antibody that recognizes the 
Y14 phosphorylated form of the protein (Figure II-5 A). Similarly we detected total 
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Figure II-5: cAMP reduced the levels of caveolin-1 phosphorylation and Triton X-100 
soluble MCT1. (A) Cytoplasmic cAMP reduced caveolin-1 phosphorylation, a single band of 23 
kD was detected with antibodies against phosphorylated caveolin-1 and caveolin-1 independent 
of its phosphorylation status. Treatment for 10 min with 500 μM 8-BrcAMP significantly reduced 
the level of phosphorylated caveolin-1, measured by the density of the band (ρ), by 40+/-5% (n=3 
experiments, p=0.02). The level of total caveolin-1 that was detected was unchanged. (B) 
Adherent RBE4 cells were incubated in Triton X-100 and the supernatant was probed with an 
antibody against MCT1 to determine the level of MCT1 protein solubilized by this treatment. Cells 
that were treated for 10 min with 500 μM 8-BrcAMP showed a significant 12.5+/-1.6% decrease in 
MCT1 solubility (n=3 experiments, p=0.02). 
 
caveolin-1 in these samples with an antibody that recognizes caveolin-1 independent of 
its phosphorylation status. Supporting the notion that cAMP leads to a change in 
caveolin-1 activity, brief cell treatment with cAMP analogs caused a statistically 
significant reduction in the phospho-caveolin-1 signal (p<0.02). However, the signal 
generated with the phosphorylation-independent antibody was unchanged. The 
specificity of the anti-phospho-caveolin-1 antibody and consistency in the loading of 
sample volumes was shown by the lack of a treatment-dependent change in the signal 
  38 
generated with the control antibody. Thus, cAMP led to a change in the activation status 
of caveolin-1 consistent with its involvement in the regulation of MCT1. 
v. cAMP reduced the level of Triton X-100 soluble MCT1  
Next, whether cAMP signaling increases the association between MCT1 and caveolae 
was further investigated by taking advantage of the complete resistance of caveolae, 
and proteins associated with them, to solubilization in ice cold Triton X-100. Therefore, 
we extracted cAMP treated and untreated RBE4 cells with ice cold 1% Triton X-100 for 
10 min and measured the level of MCT1 that was solubilized using Western blot and 
densitometry. The Triton X-100 solubility of MCT1 was significantly reduced in RBE4 
cells that were treated for 10 min with 500 μM 8-BrcAMP (Figure II-5 B). This result is 
consistent with cAMP causing MCT1 to be internalized into caveolae and supports the 
findings of our confocal imaging data. 
vi. Methyl-β-cyclodextrin and cAMP inhibited MCT1, but the inhibition was not 
additive  
To evaluate further whether caveolae are involved in the functional regulation of MCT1 
by cAMP, we conducted intracellular pHi imaging experiments with BCECF to assess 
how MCT1 dependent transport of L-lactate was affected by cAMP and the cholesterol-
depleting agent methyl-β-cyclodextrin (MβCD). MβCD has been shown to disrupt 
caveolae in numerous cell types. When RBE4 cells were exposed to 500 μM 8-BrcAMP 
for 10 min the transport rate was inhibited to 74+/-11% of control (Figure II-6, p<0.01). 
Treatment with 5 mg/ml MβCD for 30 min also inhibited MCT1 to 72+/-5% of control 
(p<0.002), and in experiments where MβCD was combined with 8-BrcAMP, MCT1 
function was reduced to 77+/-5% of control (p<0.01). Because we have previously 
shown that MCT1’s transport rates are heavily dependent on pHi, in these experiments 
we paired the data by the resting pHi to negate pHi dependent effects that treatments or 
random variability may have produced (202). Thus, the effects of cAMP and MβCD were 
similar in magnitude, but not additive, consistent with both agents utilizing the same, 
caveoli-dependent, mechanism to reduce MCT1 function. 
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Figure II-6: cAMP and methyl-β-cyclodextrin (MβCD) inhibited MCT1 but the inhibition was 
not additive. In BCECF pHi imaging experiments, all RBE4 cells responded to 25 mM L- lactate 
with an immediate cytoplasmic acidification. The acidification for each cell was fit with a linear 
regression over the first 10s of the response to quantify the transport rate. These rates were 
normalized to the average control rate and are presented in the upper panel +/- the SEM (n=177 
to 225 cells per group combined from 4 experiments). Statistical significance in comparison to 
control is indicated by a star and described numerically in the text. 
 
Discussion 
Overview of the major results of this paper  
Our previous work demonstrated a pathway in which β adrenergic signaling through 
adenylyl cyclase, cAMP, and PKA reduces Vmax for MCT1, suggesting a mechanism 
involving a reduction in the cell surface expression of functional transporters (67). In this 
report we extend that result and show a detailed mechanism in which cAMP signaling 
causes dephosphorylation of MCT1 and caveolin-1 with an associated internalization of 
MCT1 from the plasma membrane into caveolae and EEA1 positive early/sorting 
endosomes. While caveolar pathways are less prominent in brain endothelium as 
compared to other endothelial cell types, the role of caveolae in regulating MCT1 is not 
surprising given (1) the prominent role that caveolae are known to play in endothelium in 
general, and (2) that major components of the β-adrenergic pathway, including β–
adrenergic receptors, adenylyl cyclase, and PKA also localize to caveolae where they 
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are thought to form microdomains and focus the signaling pathway spatially and 
temporally (206, 207). Additionally, our data indicate that pathways involving clathrin 
dependent endocytosis and Rab11 positive recycling endosomes may be part of MCT1’s 
trafficking pattern, but that this is constitutive and unregulated by cAMP. In this work, we 
chose RBE4 cells as a model for brain endothelial cells to be consistent in extending our 
previous work (67). RBE4 cells are a cell line derived by immortalization of rat brain 
endothelial cells and, therefore, represent an in vitro model useful in brain barrier 
research. A relatively short sub-culture period and the use of the cells at sub-confluence 
standardized our model as a more fundamental cellular, rather than barrier, model of 
brain endothelial cells which helped to avoid confusion associated with controversy 
surrounding the expression of MCT1 in the three dimensional blood–brain barrier (208). 
Mechanism for cAMP dependent endocytosis of MCT1 into caveolae  
The events in which cAMP leads to the removal of MCT1 from the membrane were 
consistent with activation of a phosphatase that dephosphorylated MCT1 and caveolin-1 
concurrent with entry of MCT1 into caveolae. The identity of the phosphatase remains 
unknown, although, a number of prominent phosphor-serine,-threonine protein 
phosphatases and a phosphotyrosine phosphatase are known to be activated by PKA in 
endothelial cells, including alkaline phosphatase and myosin light chain phosphatase. 
The latter plays an important role in cytoskeleton remodeling and the breakdown in 
vascular barrier permeability during disease (209-211). Therefore, PKA-dependent 
dephosphorylation of MCT1 may be a component of such pathological processes and it 
will be important to identify the phosphatase in future studies.  
In brain, MCT1 is phosphorylated at 11 different serine and threonine residues 
suggesting that dephosphorylation at one or more of these residues may facilitate its 
entry into caveolae (212). Two possible mechanisms are that (1) dephosphorylation 
increases MCT1’s affinity for caveolae or (2) dephosphorylation decreases MCT1’s 
affinity for a substrate that restricts its entry into caveolae. Regarding the first possibility, 
binding of cargo proteins to caveolin-1 facilitates their entry into caveolae; however, 
MCT1 does not contain one of the known φXXXφ motifs that facilitate direct interactions 
with caveolin-1, suggesting that this pathway is unlikely. On the other hand, MCT1’s 
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molecular chaperone, CD147, contains an φXXXφ motif and it reportedly facilitates a 
specific interaction with caveolin-1 (207, 213, 214). Thus, similar to its known role as the 
determinant of apical/basolateral sorting of MCT1 in epithelial cells, one of CD147’s 
functions may be to chaperone MCT1’s entry into caveolae (62). Despite this, MCT1’s 
interaction with CD147 involves transmembrane domains in the two proteins making 
regulation by dephosphorylation of MCT1 in a cytoplasmic domain less plausible (59). 
However, considering the second possible mechanics, dephosphorylation of MCT1 may 
cause it to be released from a factor that otherwise prevents it and CD147 from entering 
caveolae as a complex. Of the residues known to be phosphorylated in MCT1, S230 in 
its large intracellular loop, and S476 in the C-terminus, have the correct sequences to be 
binding motifs for type 4 WW domains, and Y11 in the N terminus is part of a PY domain 
which is a ligand for a type 1 WW domain. WW domains are analogous to SH3 and SH2 
domains and mediate protein–protein interactions that can be regulated through 
phosphorylation, while PY motifs have been shown to bind to the WW domains of 
ubiquitin ligases and mediate phosphorylation dependent internalization and protein 
degradation (215). Also, S492 at the extreme C-terminus of MCT1 is within the correct 
sequence to be a PDZ ligand that could facilitate a dephosphorylation dependent 
release of MCT1 from a protein to protein interaction that otherwise prevents its 
translocation into caveolae. It is clear that the dynamics of MCT1/CD147 heterodimer 
formation and its interactions with membranes is complex and requires more detailed 
analysis in cerebrovascular endothelial cells.  
Finally, our result that cAMP caused dephosphorylation of caveolin-1 at Y14 not only 
backs-up the idea that cAMP signaling activates a phosphatase in RBE4 cells, but also 
suggests a complementary role for caveolin-1 dephosphorylation in facilitating MCT1’s 
entry into caveolae. Phosphorylation of caveolin-1 at Y14 is required for caveolin-1 to 
bind SH2 or PTB domain-containing proteins, so dephosphorylation at this site may 
prevent its binding to a protein that blocks interactions with CD147-MCT1 complexes. 
Release of such a block may allow binding to the scaffolding domain of caveolin-1 to 
facilitate entry of MCT1-CD147 into caveolae. These possibilities suggest a detailed plan 
for future work that will show the precise molecular determinants of cAMP dependent 
internalization of MCT1 into caveolae. 
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Intracellular pathways and potential significance of regulated MCT1 trafficking  
A second major contribution of this work is showing basic trafficking patterns of MCT1 in 
brain endothelial cells for the first time. Our results showing a cAMP dependent 
reduction in MCT1 surface expression and increased colocalization with EEA1 and 
caveolin-1 demonstrates that the regulatory pathway includes increased trafficking of 
MCT1 through caveolae to early/sorting endosomes. That the regulation was mimicked 
by the caveolae disrupting compound MβCD, and the decreased solubility of MCT1 in 
TritonX-100 following 8Br-cAMP treatment further supported a role for caveolae in the 
regulatory pathway. On the other hand, the presence of MCT1 in Rab11 positive 
recycling endosomes and clathrin vesicles was not affected by cAMP in our 
colocalization analyses, suggesting that clathrin dependent endocytosis into recycling 
endosomes must be part of a constitutive MCT1 trafficking pathway that is not regulated 
by cAMP. Supporting this idea, MCT1 contains an YXXφ motif in its C terminus that 
would facilitate interactions with AP-2 complexes to promote clathrin dependent 
internalization (215). An illustration of the regulated and constituitive pathways of MCT1 
trafficking reported here is presented (Figure II-7). 
Finally, in a number of brain pathologies, lactic acidosis is either causal or a key 
indicator of brain damage. For example, in ischemic stroke, hyperglycemic stroke, and 
brain injury, the severity of lactic acidosis is a principle indicator of outcomes (177-179, 
181, 216-221). MCT1 is ideally positioned in the cerebrovascular endothelial cells of the 
blood–brain barrier to counter lactic acidosis; however, lactic acid fails to flow readily 
from brain to blood during stroke and brain injury indicating that MCT1 is an ideal 
pharmacological target for modulating lactic acidosis in a novel therapeutic approach. 
Precedence for such a caveolar-based strategy comes from studies in cardiac tissue in 
which caveolae were targeted to modulate glucose transporter trafficking to improve 
reperfusion injury (222). The results presented here are also relevant for cancer because 
MCT1 controls lactate efflux from tumor cells, a factor that limits hyperplasia, and 
because CD147-caveolin-1 interactions reduce extracellular matrix remodeling which is 
necessary for tumor invasion (213, 223-225). Therefore, the results presented here 
advance our understanding of the biochemical regulatory mechanism by which cAMP 
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signaling controls MCT1 function in cerebrovascular endothelial cells, and is important 
for understanding molecular transport processes in the neurovascular unit in both health 
and disease. 
 
 
Figure II-7: Regulation of MCT1 by cAMP-dependent internalization into caveolae and early 
endosomes, and an unregulated clathrin-dependent recycling pathway. Right side: in the 
regulated pathway, activation of β-adrenergic receptors leads to cAMP production and activation 
of a phosphatase which dephosphorylates plasma membrane MCT1, and caveolin-1 (hairpin 
structures), facilitating an interaction between MCT1 and caveolin-1 to promote internalization of 
MCT1 into caveolae (CAV) and early endosomes (EE). From here MCT1 could be trafficked to 
various compartments such as late endosomes and lysosomes (LE/LYS), similar to the protein-
kinase dependent trafficking of kainite receptors and aquaporins (226, 227). Left side: in the 
constitutive pathway, MCT1 is internalized into clathrin coated vesicles (CCV) where it is 
trafficked to recycling endosomes (RE) for redistribution on the plasma membrane, however, 
adrenergic signaling does not affect this trafficking pathway. 
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Contributions 
In this paper, Z.Liu conducted the experiments of “MCT1’s reduced phosphorylation and 
subsequently decreased surface expression on RBE4 cells after cAMP treatment” as 
demonstrated in Figure II-1.  
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Chapter III 
Regulation of brain endothelial MCT1 expression by the 
canonical Wnt/β-catenin signaling pathway 
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Introduction: 
Monocarboxylic acid transporters (MCTs) are responsible for rapid bi-directional 
facilitated diffusion of monocarboxylates, such as lactate, pyruvate, β-hydroxybutyrate 
(BHB) and acetate, across cellular membranes. They cotransport their ionic substrates 
with protons in a 1:1 stoichiometry manner, making the whole process electroneutral 
(228). The MCTs belong to the solute carrier (SLC16) family, of which 14 members 
(MCT1-14) have been identified. Only MCT1-4 and MCT7 have been demonstrated 
experimentally to facilitate the transport of monocarboxylates (3, 32). MCT8 transports 
thyroid hormones (T3 and T4) and its defects have been associated with the X-linked 
Allan-Herndon-Dudley Syndrome, where patients exhibit severe mental retardation, 
dysarthria, muscle hypoplasia and spastic paraplegia due to the lack of thyroid 
hormones transport into neurons (229). Single nucleotide polymorphisms (SNPs) within 
MCT9 gene can influence human serum uric acid levels, as revealed by meta-analysis of 
genome wide association scans (230). MCT10, also known as T type amino acid 
transporter 1 (TAT1), transports aromatic amino acids (231). Different MCTs have 
distinct tissue distribution patterns and their transport affinity/capacity for certain 
substrates can be quite different. As the prominent transporters for the thermogenic 
intermediate metabolites, MCT1, 2 and 4 have been most extensively studied and 
functionally characterized, whereas studies for MCT3, MCT7-8 and MCT10 are limited. 
The roles of MCT5-6 and MCT11-14 still remain elusive.  
MCT1 is the first family member being identified as the transporter of lactate in rat 
erythrocytes as revealed by DIDS labeling (232). Its cDNA was then isolated from 
Chinese hamster ovarian (CHO) cells and the coded sequence was found to be identical 
to mevalonate transporter (Mev), except for one amino acid difference of Phe in MCT1 
from that of Cys in Mev (233). Human MCT1 gene lies on chromosome 1p13.2-p12 
(234). Its transcription unit encompasses almost 44kb, and consists of 5 exons and 4 
introns (Figure III-1; (235)). Rat MCT1 contains 494 amino acids, whose sequence 
shares 86% identity to that of human (236). The protein’s calculated molecular weight is 
about 53kD with a migrating size of ~49kD on SDS-PAGE electrophoresis. Like other 
MCTs, MCT1 has 12 transmembrane domains (TMDs) with a large intracellular loop 
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between TMD 6 and 7. Both the N- and C-termini are located within the cytoplasm (237) 
(Figure III-14). The successful targeting of MCT1 from intracellular pools onto plasma 
membrane requires its association with an ancillary protein called CD147 (also known as 
Basigin and Emmprin), which is a single TM glycoprotein with extracellular IgG-like 
domains along with a short intracellular C-terminus (50).  
 
 
Figure III-1: Genomic organization of human MCT1 gene (Adapted and modified from (235)). 
The whole transcript unit spans about 44kb, contains 5 exons (numbered on the top) and 4 
introns (thick black lines). Untranslated regions are represented by white boxes, while coding 
regions are indicated by black boxes. The size of each exon or intron is calculated and shown in 
parentheses. The complete mature transcript is shown at the bottom.  
 
The substrates of MCT1 include important metabolic intermediates such as lactate, 
pyruvate, BHB, acetate and butyrate. Their affinities are declining in the order of butyrate 
(0.02mM), pyruvate (1mM), acetate and BHB (2.5mM) to L-lactate (3.5mM). As a result, 
MCT1 is closely related with diverse metabolic pathways including glycolysis, 
gluconeogenesis, ketone body metabolism and lipogenesis (237). MCT1 is the most 
universally expressed isoform, sometimes in conjunction with other MCTs whose 
distribution can be quite different among cell types to respond to local physiological 
transporting demands (3). Its expression is enriched in brain endothelial cells, 
particularly during postnatal development stages (94, 95). It is the predominant MCT 
transporter present at the blood-brain barrier (BBB) (67, 174), thus it is mainly 
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responsible for the exchange of monocarboxylates between central nervous system 
(CNS) and peripheral blood.  
The function of MCT1 at BBB has many pathological implications. Firstly, during cerebral 
ischemia insult, the shortage of oxygen supply in arteries turns brain cells into an 
anaerobic metabolic state where glycolysis is the main route for ATP production. The 
concomitant byproduct, lactate, thus accumulates within CNS, a process called lactic 
acidosis that has been long observed and believed to contribute to the pathophysiology 
of ischemia (238, 239). Decrease in pH as a consequence of severe lactic acidosis 
injures and inactivates mitochondria, interferes with the function of enzymes and leads to 
irreversible damage of brain structures (240, 241). So, efficient clearance of excessive 
lactate from brain side into venous blood during and after ischemia is proposed to help 
alleviate its adverse effects on the CNS (242). In fact, higher cerebral lactate levels 
during incomplete ischemic anoxia are associated with worse brain injuries than in 
complete ischemia where lower lactate levels are observed (177, 178, 240, 242, 243). 
Secondly, MCT1 at BBB delivers ketone bodies that are generated by ketosis in liver as 
fuels into the brain. Glucose is the primary energy source for brain functions. However, 
the brain can also use monocarboxylates as metabolic substrates when the supply of 
sugars is low. For example, during suckling period, the mother’s milk provides abundant 
lipids that can be converted to ketone bodies that the brain relies on for survival (244). 
During starvation and for epileptic patients on ketogenic diets, ketones can supply the 
most of brain’s energy requirement as well as help to control occurrence of seizures, 
respectively (245, 246). In hibernating mammals with depressed body temperature and 
reduced metabolic rates, BHB is selectively used over glucose and metabolized by the 
tricarboxylic acid (TCA) cycle after its facilitated diffusion by brain endothelial MCT1 into 
the CNS. This adaptive mechanism implicates a potential use of BHB as therapeutic 
approach in treating pathologies like stroke, atrophies from muscle and hemorrhagic 
shock (247). Finally, MCT1 has been exploited as a drug transport route for delivering 
monocarboxylic acid like compounds into CNS. For example, the anticonvulsant reagent 
valproic acid (VA) has been widely used as an anti-epilepsy and anti-bipolar disorder 
drug (248). It has been well documented as a substrate for MCT1 in order to cross 
plasma membrane by a variety of studies (153, 249, 250). The predominant existence of 
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MCT1 at BBB ensures the rapid delivery of VA after oral administration into CNS (44). 
Other commonly used drugs that are known to be transported by MCT1 include but not 
limited to benzoic acid, salicylic acid and succinic acid (153, 251). Given the important 
roles of brain endothelial MCT1 in the above mentioned biological conditions, it is thus 
critical to better understand MCT1’s regulation as well as its functional modulation at 
BBB by external stimuli and signaling pathways, especially under devastating 
pathological situations where its expression or function is commonly altered or can be 
beneficially exploited, such as stroke (138, 252), Alzheimer’s disease (253, 254), 
epilepsy (116, 117) and diabetes (114, 115). A more detailed appreciation of the 
underlying mechanisms of its regulation can help restore or manipulate this transporter’s 
function for therapeutic purpose.  
The canonical Wnt/β-catenin signaling pathway was first discovered in Drosophila by 
genetic screening when the mutation of Wingless gene was found to cause a patterning 
defect during embryonic development (255). Its mammalian homologue, Wnt1, was 
identified couple years later by pro-viral tagging in breast carcinoma mouse model and 
became the founding member of the mammalian Wnt ligand family that contains 19 
highly conserved secreted glycoproteins to date (256). Wnt ligands initiate their signaling 
transduction cascade by binding to the extracellular portion of a frizzled family of 
receptors (FZDs) as well as to a low density lipoprotein receptor-related protein (LRP) 5 
or 6 as the co-receptor. 10 mammalian FZD genes have been identified, namely FZD1-
10 (257). In the absence of Wnt signal, an intracellular destructive multi-protein complex, 
consisting of adenomatous polyposis coli (APC), Axin, glycogen synthase kinase-3 β 
(GSK-3 β) and casein kinase 1 α (CK1 α), recruits cytosolic β-catenin and mediates its 
phosphorylation by GSK-3 β and CK1 α at threonine 41, serines 33, 37 and 45 (258). 
This phosphorylated β-catenin is recognized by the E3 ubiquitin ligase β-Trcp, leading to 
its ubiquitination and subsequent proteasomal degradation (259) (Figure III-2 A). When 
Wnt ligands bind to FZD and LRP5 (6) receptor complex, a cytoplasmic scaffolding 
protein called Dsh/Dvl is recruited to plasma membrane and interacts with the 
phosphorylated intracellular domain of LRP5 (6). Axin binds with Dsh/Dvl readily and is  
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Figure III-2: A schematic diagram of the canonical Wnt/β-catenin signaling pathway 
(Adapted from (260)). (A) In the absence of Wnt ligands, an intracellular multi-protein complex, 
consisting of APC, Axin, GSK-3 β and CK1α, targets β-catenin for phosphorylation. This 
phosphorylated β–catenin can be recognized by an ubiquitin E3 ligase β-Trcp, and subjected to 
ubiquitination-dependent proteasomal degradation. (B) In the presence of Wnt ligands binding to 
FZD and LRP5 (6) co-receptor, the intracellular domain of LRP is phosphorylated by GSK-3 β, 
which recruits the scaffolding protein Axin from the destructive complex to plasma membrane. 
The loss of Axin disassembles the multi-protein complex, leading to the stabilization of 
cytoplasmic β-catenin and its subsequent translocation into nucleus, where it interacts with 
TCF/LEF co-transcription factors to promote target genes expression.     
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thus liberated from the β-catenin destructive complex that becomes disassembled. As a 
consequence, cytoplasmic β-catenin cannot be phosphorylated and is now stabilized, 
which then translocates into nucleus, interacts with TCF/LEF transcription factors and 
promotes Wnt target genes expression (261) (Figure III-2 B). Lithium has been known to 
inhibit the activity of GSK-3 both directly and by increasing its inhibitory phosphorylation. 
Consequently even though the structure of the destructive complex stays together, 
lithium can block GSK-3’s capacity to phosphorylate β-catenin, thus causing β-catenin’s 
accumulation in the cytosol and its entry into nucleus (262) (Figure III-3). The target 
genes that are regulated transcriptionally by Wnt/β-catenin pathway depend substantially 
on cell types that are exposed to different biological environments (263, 264), however, 
those that have been well established include CyclinD1 (265), LEF1 (266) and c-Myc 
(267) in general, as well as p-glycoprotein (Pgp) in brain endothelial cells (268). 
The canonical Wnt/β-catenin signaling pathway has critical implications in a variety of 
biological processes, e.g. dorsal-ventral axis formation during embryonic development 
(269), human embryonic stem cells lineage-specific determination (270), cell proliferation 
(271), tissue self-renewal (272), de novo hair follicle regeneration (273) and cancer 
(especially colon cancer) progressions (274). Recently, it was discovered as a key 
requirement for initializing normal blood-brain barrier development and maturation in 
rodents (275, 276). Specifically on neural tube stage, secreted Wnt ligands from 
neuroepithelial cells act on the surrounding vascular endothelium, stimulate 
angiogenesis and new vasculature penetration into neuroepithelium, eventually leading 
to the formation of a mature BBB that are characterized by selective permeability, tight 
junctions as well as expression of nutrient transporters (e.g. GLUT1). Given the 
significance of brain endothelial MCT1 in CNS functions and the critical role Wnt/β-
catenin plays in BBB normal development, we wanted to investigate whether MCT1 is 
regulated by this important signaling pathway in brain endothelial cells.           
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Figure III-3: Inhibitory effects of lithium on glycogen synthase kinase 3 (GSK-3) (Adapted 
from (262)). Active GSK-3 (shown in blue) catalyzes its many substrates phosphorylation, 
requiring the participation of both Mg
2+
 and ATP. Lithium can directly inhibit GSK-3’s activity by 
competing with Mg
2+
, thus dampening its catalytic capacity. On the other hand, GSK-3 can be 
phosphorylated at a serine residue in the N-terminal domain by several kinases, leading to its 
inactivation (Shown in red). This process can be reversed by a phosphatase, whose action is 
reduced by the presence of lithium. In summary, GSK-3 activity can be inhibited both by a direct 
action of lithium and indirectly by increased phosphorylation of serine.    
 
Materials and Methods 
Cell Culture. Immortalized rat brain endothelial (RBE4) cells were cultured in equal 
parts minimum essential medium alpha (MEM-α) (Invitrogen; #12561-056) and F-10 
Nutrient (Ham’s) (Invitrogen; #12390-035), supplemented with 10% fetal bovine serum 
(Atlanta Biologicals; #S11150H), 0.3 mg/ml geneticin (Sigma-Aldrich, #A1720), and 1.0 
ng/ml basic fibroblast growth factor (Roche; #11363697001). 25-cm2 polystyrene tissue 
culture flasks (Corning Inc.; #CLS430372) were first coated with collagen by treating the 
surface area with 50ng/ml rat tail collagen type I (BD Biosciences; #354236) in 0.013% 
cyanamide solution (Sigma-Aldrich; C87908) for 2 hours, followed by water rinsing of the 
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same volume twice. Cells were then cultured on these collagen coated flasks in a 
humidified incubator at 37oC with 5% CO2. All the experiments were conducted when the 
cells reached 80%-90% confluence.  
Reagent Stocks. 1M lithium chloride (Sigma-Aldrich; #L-0505), 1M sodium chloride 
(Fisher Scientific; #S640-3) and 20mM chloroquine diphosphate (Sigma-Aldrich; #C6628) 
stocks were all made in H2O, sterile filtered and stored in 4
oC. 1M quercetin dihydrate 
(EMD Millipore; #551600), 10mM MG132 (Sigma-Aldrich; #C2211), 10mM clasto-
lactacystin beta-lactone (EMD Millipore; #426102), 1.5M N-Ethylmaleimide (NEM) 
(Sigma-Aldrich; #E3876) and 0.4M deubiquitinase inhibitor V, PR-619 (EMD Millipore; 
#662141) stocks were all made in DMSO (Sigma-Aldrich; #D2650) and stored in -80oC 
until use.  
Cellular proteins preparation. Cells were washed twice with 5ml ice-cold PBS 
(Mediatech, Inc.; #21-040-CV), supplemented with 1X protease inhibitor cocktail (Roche; 
#11697498001). Whole cellular protein samples were then prepared by direct in-flask 
scraping of cells within 100μl SDS boiling buffer (5% SDS, 10% v/v glycerol, 60mM Tris-
Cl pH=6.8), transferred into 1.5ml eppendorf tubes (Sarstedt; #72690001), homogenized 
and centrifuged at 13,000 rpm for 10 minutes. Nuclear protein samples were prepared 
according to the procedures reported by (277). Briefly, monolayer cells were scraped off 
flasks and pelleted before being resuspended in NP-40 lysis buffer (0.3% NP-40, 1mM 
HEPES pH=7.9, 1.5mM MgCl2, 10mM KCl, 0.5mM DTT and 1X protease inhibitor 
cocktail). After maximal centrifugation, pelleted nuclei were lysed using a high salt buffer 
(20mM HEPES pH=7.9, 25% v/v glycerol, 0.42M NaCl, 1.5mM MgCl2 and 0.2mM EDTA). 
All the protein samples were stored in -80oC until use.     
RNA isolation, reverse transcription, polymerase chain reaction (PCR) and 
quantitative real time PCR (qRT-PCR). Total cellular RNAs were isolated using 
RNeasy Mini Kit (Qiagen; #74104) according to the manufacturer’s instruction. After their 
concentrations being determined by ND-1000 NanoDrop spectrophotometer, the RNA 
samples were converted to cDNAs using QuantiTect Reverse Transcription Kit (Qiagen; 
#205311). Benchtop PCR was performed in a GeneAmp® PCR System 9700 machine 
using the Platinum Taq DNA polymerase (Invitrogen; #10966-034) within a 50μl reaction 
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volume: 1X PCR buffer (-Mg2+), 0.2mM dNTP (each), 1.5mM MgCl2, 0.2μM primer 
(each), 50ng template cDNA and 0.5 μl Taq. Cycling parameters used were: initial 94oC 
for 1 minute, followed by 30 cycles of 94oC for 30s and 72oC for 1.5 minutes, then an 
additional extension at 72oC for 7 minutes and finally holding at 4oC. The PCR products 
were analyzed by running at 90V on 1% (Ubb and Ubc products) or 1.5% (frizzled 
receptors PCR products) SeaKem agarose gel (Lonza; #50152) supplemented with 
ethidium bromide in 1X TAE buffer (40mM Tris, 20mM acetic acid, and 1mM EDTA). 
Rotor gene cyber green (Qiagen; #204074) based qRT-PCR was conducted on Rotor-
Gene RG-3000 cycler (Corbett Research), using 50ng total cDNA per reaction with the 
following settings: 95oC 5 minutes, followed by 95oC 5s and 60oC 10s for 40 cycles. The 
qRT-PCR results were analyzed using the cycle threshold method (CT, Applied 
Biosystems User Bulletin Number 2, P/N 4303859) and expressed as fold changes over 
controls. All the primers used here were designed through the PrimerQuest tool from 
Integrated DNA Technologies or IDT, and their sequences are summarized in Table III-1.      
Restriction enzyme (RE) digestion. Restriction digestions of PCR products were 
performed by incubating at 37oC water bath for at least 2 hours in a 20μl reaction system: 
final 1X buffer, 2μl of PCR DNA product, 0.1μg/μl BSA and 0.5μl of specific RE. Details 
of buffer types for all the REs: Buffer A (Promega) for ApaI (Promega; #R6361) and 
HpaII (Promega; #R6311); buffer C (Promega) for MboI (Promega; #R6711); buffer D 
(Promega) for BstEII (Promega; #R6641); buffer E (Promega) for HindIII (Promega; 
#R6041); buffer H (Promega) for PstI (Promega; #R6111); buffer J (Promega) for SmaI 
(Promega; #R6121). The digests were analyzed by running at 90V on 1.5% SeaKem 
agarose gel (Lonza; #50152) supplemented with ethidium bromide in 1X TAE buffer 
(40mM Tris, 20mM acetic acid, and 1mM EDTA).    
Protein assays and western blotting. Protein samples’ concentrations were 
determined using Pierce BCA protein assay kit (Thermo Scientific; #23227) unless 
otherwise mentioned. Immunoblotting was performed as reported previously (278). 
Specifically, 10μg proteins from each sample were prepared and diluted 4:5 with 
homemade 5X sample loading buffer (10% SDS, 50% glycerol, 25% β- mercaptoethanol, 
312.5mM Tris HCl and 0.01% bromophenol blue). Then they were subjected to SDS-
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PAGE electrophoresis at 160V on Criterion TGX precast gels (Bio-Rad; #5671033), and 
transferred to supported nitrocellulose membranes (Bio-Rad; #162-0070) at constant 
200mA for 90 minutes. The membranes were blocked at room temperature on an orbital 
shaker for 1 hour in SEA BLOCK (Thermo Scientific; #37527), followed by overnight 
incubation at 4oC with primary antibody diluted 1:5,000 for anti-MCT1, 1:5,000 for anti-
Actin (EMD Millipore; #MAB1501) and 1:20,000 for anti-β-catenin (EMD Millipore; 
#ABE208) in 1X TBST buffer (50 mM Tris base, pH 8.0, 0.9% NaCl, 0.1% Tween 20) 
supplemented with 1% SEA BLOCK. After washing in 1X TBST, the membranes were 
incubated at room temperature for 1 hour with rabbit anti-chicken IgY conjugated to 
horseradish peroxidase (Thermo Scientific; #31401) diluted 1:5,000 for MCT1, or goat 
anti-mouse IgG (Thermo Scientific; #31430) diluted 1:10,000 for Actin, or goat anti-rabbit 
IgG (Thermo Scientific; #31462) diluted 1:10,000 for β-catenin. Detection was 
accomplished after membranes being rinsed for 5 minutes in SuperSignal West Pico 
chemiluminescent Substrate (Thermo Scientific; #34080). The immunoblotting results 
were analyzed by densitometry, normalized to actin and then expressed as fold changes 
over control. 
Plasmid transfection. Transfection of mCherry-MCT1 vectors (a gift from Dr. Jeffrey P. 
Smith) into RBE4 cells was conducted using Transfectamine LTX with Plus (Invitrogen; 
#15338-100), according to the manual’s instruction. Briefly, the cells were exposed to 
the transfection complex, consisting of 1ng/μl DNA, 1μl/ml Plus Reagent and 4 μl/ml 
transfectamine LTX reagent in growth medium, for 4 hours and changed for fresh 
antibiotics-free medium. At least 18 hours later, transfected cells were trypsinized and 
reseeded at a density of 3x104 cells /well into µ-Slide 8 well plates (Ibidi; #80821) that 
were pre-coated with collagen. These re-plated cells were allowed for additional 24 
hours culture before they were treated with lithium chloride.  
Confocal microscopy. Confocal images were collected on a laser scanning confocal 
microscope (Zeiss LSM710). Transfected RBE4 cells growing in µ-Slide 8 well plates 
were directly subjected to the microscope, using the following configurations: 40X 
objective with H2O immersion; built-in settings for mCherry fluorescence (561nm laser); 
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scan mode as frame; frame size 512X512; averaging method as mean, number as 4 and 
mode as frame; 12 bit depth and 1 Airy Unit (AU). 
Cell surface protein isolation. Cell surface proteins were labeled with biotin and then 
captured through avidin beads, using the Pierce Cell Surface Protein Isolation Kit 
(Thermo Scientific; #89881). Specifically, RBE4 cells growing in 75-cm2 flasks (Corning 
Inc. #430725) were washed with ice-cold 1XPBS and incubated with 0.25mg/ml Sulfo-
NHS-SS-Biotin dissolved in 1X PBS at 4oC for 30 minutes on an orbital shaker. Then 
cells were scraped off, centrifuged to pellet and resuspended in 500μl provided lysis 
buffer for 60 minutes on ice with vortexing every 5 minutes. After that, the lysates were 
spun at 13,000rpm at 4oC for 2 minutes and the supernatant was incubated with 500μl 
NeutrAvidin agarose at room temperature for 60 minutes with end-over-end mixing. After 
washing three times, biotinylated proteins were eluted using 450μl SDS-PAGE sample 
buffer (Thermo Scientific; #39001) supplemented with 50mM DTT at room temperature 
for 60 minutes with end-over-end mixing. Pierce 660nm protein assay (Thermo Scientific; 
#22662) was used for determining the eluates concentration.  
Table III-1: (qRT-)PCR primers 
Gene Forward Primer Reverse Primer 
Mct1 GCTGCTTCTGTTGTTGCGAATGGA AAAGGCAAATCCAAAGACTCCCGC 
Lef1 TTCAGGCAAGCCTACCCATCTTCA TTCTCTGTTCGTGCTCAGGCTTCA 
CyclinD1 TGCTGCAAATGGAACTGCTTCTGG AAGGTCTGTGCATGTTTGCGGATG 
Pgp TCTCCTATGCTGCTTGTTTCCGGT TTCGCGTAGTCAGGAGCGAATGAA 
Gapdh ACAAGATGGTGAAGGTCGGTGTGA AGCTTCCCATTCTCAGCCTTGACT 
β-actin TTGCTGACAGGATGCAGAAGGAGA ACTCCTGCTTGCTGATCCACATCT 
Ubb GGCGGTTTGTTCCTTCATCGCATT ATCCTGGATCTTGGCCTTCACGTT 
Ubc AAAGATCCAGGACAAGGAGGGCAT TCTTGCCTGTCAGGGTCTTCACAA 
Fzd1 AAGTGCAGCAAGCTTTGTGGGT ACACACTGCCGTGAATCCAGACAA 
Fzd2 TGCTGTGCTGCGCTTCTACTTT TGTGCCGATGAACAGGTACACGAA 
Fzd3 TTGCTGTTTCATGCCAGTGCCT AGCTGGCCCATTCAAAGCATGT 
Fzd4 TTGGAATGGCCAGCTCCATTTGGT TTTCGTTGCCTTTCCCTGGCTT 
Fzd5 ATTCTTGGTGCGCCTGGTTGTA TGCCAATGCGGATCATGAGCTT 
Fzd6 ACATTAGCGGCGTTTGCTTCGT AGCCTGGTTTGCCATGCTTCTT 
Fzd7 TCATGAAGCACGATGGCACCAA AGCCAGCCCATGTCTTTCACAGTT 
Fzd8 TGGTTCTTGGCGGCTGGTATGAAA TTGGGCCTCCTTGTTGCTTGAT 
Fzd9 TGTGGTCCGCGTTGTGTTTCTT TGGTGCCGCCCGTCTTCATAATTT 
Fzd10 ATGTGGGCAGCATGGATGTCAA TGTTCTTGCAGTCAGCAGCCTT 
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Results: 
i. Expression profile of Wnt frizzled receptors in RBE4 cells.3 
In order to determine if Wnt signaling exists in RBE4 cells, the presence of its expressed 
frizzled (Fzd) receptors (Fzd1 to 10) was first examined via PCR using cDNA reverse 
transcribed from total RNA as template. The expected sizes of their PCR products are 
547bp, 527bp, 544bp, 669bp, 503bp, 588bp, 647bp, 301bp, 600bp and 614 bp for Fzd1, 
Fzd2, Fzd3, Fzd4, Fzd5, Fzd6, Fzd7, Fzd8, Fzd9 and Fzd10, respectively (summarized 
in Table III-2). Subsequent agarose gel analysis revealed that all of the receptors except 
Fzd10 are expressed in RBE4 cells, demonstrating that Wnt signaling could be activated 
readily (Figure III-4 A).  
The specificity of each PCR product for truly representing individual receptor gene was 
confirmed by restriction enzyme digestion. Namely, BstEII splits Fzd1 amplicon into 
403bp and 144bp, Fzd6 amplicon into 316bp and 272 bp; MboI splits Fzd2 amplicon into 
418bp and 109bp, Fzd4 amplicon into 373bp and 296bp; HindIII splits Fzd3 amplicon 
into 344bp and 200bp; ApaI splits Fzd5 amplicon into 368bp and 135bp; SmaI splits 
Fzd7 into 454bp and 193bp; HpaII splits Fzd8 amplicon into 165bp and 136bp; PstI splits 
Fzd9 amplicon into 317bp and 283bp. The enzymes used as well as the expected 
banding patterns after digestion for each PCR amplicon are summarized in Table III-2. 
Our results indicated that all of the digests gave expected bands for each gene being 
examined, confirming that the expression of frizzled receptors was truly represented by 
the presence of their PCR product bands (Figure III-4 B).     
                                                             
3
 We want to thank Thomas A. Haroldson for conducting the experiments of “Expression profile of 
Wnt frizzled receptors in RBE4 cells” and “commercial GSK-3β inhibitor SB216763” as shown in 
Figure III-4 and Figure III-6(B), respectively. 
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Figure III-4: Expression of Wnt frizzled (Fzd) receptors in brain endothelial cells. (A) Wnt 
Fzd receptor genes that are expressed in RBE4 cells were examined by PCR using cDNA as 
template, followed by 1.5% agarose gel analysis. Fzd1 to 9, from lane1 to 9 respectively, showed 
bands of the expected sizes as summarized in Table III-2. Fzd10 PCR didn’t give any visible 
bands (data not shown). (B) The specificity of each PCR product to that particular receptor gene 
was confirmed by using restriction enzyme digestion. All of the nine PCR digests showed 
expected banding patterns as indicated in Table III-2. Lane1: Fzd2 PCR; lane2: Fzd2 PCR+MboI 
digests; lane3: Fzd3 PCR; lane4: Fzd3 PCR+HindIII digests; Lane5: Fzd5 PCR; lane6: Fzd5 
PCR+ApaI digests; lane7: Fzd6 PCR; lane8: Fzd6 PCR+BstEII digests; Lane9: Fzd1 PCR; 
lane10: Fzd1 PCR+BstEII digests; lane11: Fzd4 PCR; lane12: Fzd4 PCR+MboI digests; lane13: 
Fzd7 PCR; lane14: Fzd7 PCR+SmaI digests; lane15: Fzd8 PCR; lane16: Fzd8 PCR+HpaII 
digests; lane17: Fzd9 PCR; lane18: Fzd9 PCR+PstI digests. All of the ladders used here were 
Low Molecular weight DNA ladders (New England; #N3233). 
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Table III-2.Expected sizes of PCR products and RE digests for Fzd receptors 
Receptor gene 
Expected size of 
PCR product (bp) 
RE for amplicon 
verification 
Banding pattern 
after digestion (bp) 
Fzd1 547 BstEII 403, 144 
Fzd2 527 MboI 418, 109 
Fzd3 544 HindIII 344, 200 
Fzd4 669 MboI 373, 296 
Fzd5 503 ApaI 368, 135 
Fzd6 588 BstEII 316, 272 
Fzd7 647 SmaI 454, 193 
Fzd8 301 HpaII 165, 136 
Fzd9 600 PstI 317, 283 
Fzd10 614 BstEII 497, 117 
   
ii. Canonical Wnt/β-catenin signaling pathway upregulates MCT1 protein 
expression in RBE4 cells.  
In order to determine the optimal working condition for LiCl to regulate MCT1 expression 
through activating Wnt/β-catenin pathway, both dosage response (control, 5mM, 10mM, 
20mM and 30mM) and time course (1h, 6h and 24h) studies were done in RBE4 cells at 
first, and their effects on MCT1’s expression were examined by western blotting. Our 
results indicated that within 24h treatment, 20mM LiCl started to show increased MCT1 
protein level compared with control, 5mM or 10mM group, whereas at 20mM LiCl 
concentration, 24h incubation time showed the maximal effect (Figure III-5 A). Then 
RBE4 cells were treated with vehicle control, or 20mM NaCl as osmotic control, or 
20mM LiCl in the presence or absence of 80μM quercetin for 24h. Compared with NaCl, 
LiCl significantly increased MCT1 protein level by 75% (One-way ANOVA followed by 
Scheffe’s post hoc test, p<0.05), which was negated by cotreatment with quercetin (One-
way ANOVA followed by Fisher’s LSD post hoc test, p<0.05), demonstrating the specific 
requirement of β-catenin mediated nuclear signaling transduction in the observed 
upregulation of MCT1 (Figure III-5 B).  
In accordance, nuclear accumulation of β-catenin was increased by 300% after 20mM 
LiCl treatment for 24h, which was brought down to normal by cotreatment with 80μM 
quercetin (Figure III-6 A; One-way ANOVA followed by Bonferroni post hoc test, n=3, 
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p<0.05), confirming the earlier observation that MCT1 is upregulated by LiCl in a β-
catenin signaling dependent manner. Similarly, treatment of RBE4 cells for 48h with 
 
 
Figure III-5: Regulation of brain endothelial MCT1 expression by Wnt/β-catenin pathway. (A) 
Dosage and time course studies of LiCl in RBE4 cells to regulate MCT1’s protein level. 20mM 
LiCl treatment for 24h gave the most significant increase. (B) RBE4 cells were treated with 
vehicle control, or 20mM NaCl osmotic control, or 20mM LiCl in the presence or absence of 80μM 
quercetin dihydrate, followed by western blotting analysis. Data are expressed as fold changes 
over control. MCT1 expression was found to be increased by Wnt pathway (75%, *P<0.05, one-
way ANOVA followed by Scheffe’s post hoc test; mean±SE), which was completely blocked by its 
antagonist (*P<0.05, one-way ANOVA followed by Fisher’s LSD post hoc test; mean±SE). 
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Figure III-6: Changes of nuclear β-catenin level by Wnt agonist and antagonist. (A) RBE4 
cells were treated with or without 20mM LiCl in the presence of absence of 80μM quercetin for 
24h. Then their nuclear portions were prepared and β-catenin level was examined by western 
blotting. Data are expressed as fold changes over control. LiCl increased nuclear β-catenin level 
(300%, *P<0.05, one-way ANOVA followed by Bonferroni post hoc test; mean±SE n=3), which 
was negated by Wnt blocker (150%, *P<0.05, one-way ANOVA followed by Bonferroni post hoc 
test; mean±SE n=3), indicating that our previous observation of MCT1’s regulation correlate with 
β-catenin’s functional localization. (B) RBE4 cells were treated for 48h with 5μM SB216763, a 
commercial GSK-3 β inhibitor. Western blotting showed that MCT1’s protein level was increased 
by 35% (*P<0.003, student t test, mean±SE n=5), confirming the regulation of brain endothelial 
MCT1 by canonical Wnt pathway.    
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5μM SB216763, another commercial GSK-3β inhibitor, also increased MCT1 protein 
expression significantly (Figure III-6 B). In sum, the canonical Wnt/β-catenin signaling 
pathway elevates brain endothelial MCT1’s protein level in a nuclear β-catenin-
dependent manner.     
iii. Mct1’s expression is not regulated transcriptionally by Wnt pathway. 
Using version 8.3 of TRANSFAC database, analysis of 5kb DNA sequences upstream of 
Mct1 transcription starting site revealed the presence of 7 putative TCF/LEF binding 
motifs (Figure III-7), raising the possibility that Wnt pathway might increase brain 
endothelial MCT1 protein expression by inducing its transcription. However, qRT-PCR 
results showed that compared with 20mM NaCl osmotic control, 20mM LiCl treatment in 
RBE4 cells for 24h didn’t elevate Mct1’s mRNA level significantly, although some of the 
well-known target genes of Wnt pathway were upregulated as expected, e.g. CyclinD1, 
Lef1 and P-glycoprotein (Pgp) (Figure III-8). In conclusion, the canonical Wnt/β-catenin 
signaling pathway upregulates brain endothelial MCT1 expression in a transcription 
independent manner.  
iv. Brain endothelial MCT1 is regulated by lysosomal, but not proteasomal, 
degradation. 
Because the observed upregulation of MCT1 by Wnt pathway is not due to increased 
transcription, its turnover rate might have been inhibited instead. Generally, cellular 
proteins can be degraded either in lysosome for membrane proteins, or in proteasome 
for intracellular proteins, or in both compartments. In order to determine how MCT1 is 
degraded in RBE4 cells, we first incubated cells with MG132, a commonly used 
proteasomal degradation inhibitor, at various concentrations for different time periods to 
test its toxicity on RBE4 cells. Our results indicated that the cells were viable in 0.2μM 
MG132 for up to 24h, whereas they are only healthy for up to 12h at 0.5μM, and 6h at 
1μM or 2μM (Figure III-9). As a result, RBE4 cells were treated with 0.2μM MG132 for 6h, 
12h or 24h, and 0.5μM for 6h or 12h, and 1μM or 2μM for 6h, followed by western 
blotting. We found no significant changes in MCT1’s protein level in any of the above 
treatments (Figure III-10 A). This result was confirmed by using another more selective 
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proteasome inhibitor, clasto-lactacystin beta-lactone (CLBL), to treat RBE4 cells at 1μM 
for 6h, 12h or 24h, with no significant changes of MCT1’s protein expression being 
observed (Figure III-10 B). The above results indicated that brain endothelial MCT1 is 
not regulated through proteasomal degradation. Next, we treated RBE4 cells for 24h 
with increasing concentrations of a lysosomal degradation inhibitor, chloroquine 
diphosphate (control, 50μM, 100μM and 200μM), and found a gradual elevation of 
MCT1’s protein level, compared with control (Figure III-11). Specifically, treatment of 
100μM chloroquine diphosphate for 24h significantly increased MCT1 protein expression 
by 100% in RBE4 cells (Figure III-11). In conclusion, brain endothelial MCT1 is regulated 
through lysosomal, but not proteasomal degradation route.     
 
Figure III-7: Promoter region of Mct1 contains putative TCF/LEF binding sites. Using a 
transcription factors binding prediction software (version 8.3 of TRANSFAC database), 5kb 
upstream of Mct1’s transcription starting site (+1) is found to contain seven TCF/LEF putative 
binding sites, the co-transcription factors critical for β-catenin signaling transduction, at around -
905bp, -1287bp, -2602bp, -3395bp, -3910bp, -4137bp and -4990bp positions, implying a possible 
transcriptional regulation of Mct1 by Wnt pathway.   
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Figure III-8: Regulation of Mct1 and Wnt target genes in brain endothelium by Wnt agonist. 
RBE4 cells were treated with vehicle control, 20mM NaCl or the agonist LiCl for 24h and 
subjected to qRT-PCR analysis. Results were first normalized to internal standard Gapdh, then 
expressed as fold changes over control as determined by ΔΔCT method. LiCl failed to induce 
Mct1’s transcription ( P>0.05, student t test, mean±SE, n=7), although it significantly increased 
Wnt target genes expression as expected (CyclinD1 *P<0.05, student t test, mean±SE, n=3; Lef1 
**P<0.003, student t test, mean±SE, n=6; Pgp *P<0.04, student t test, mean±SE, n=5).   
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Figure III-9: Effects of MG132 on RBE4 cells’ viability. RBE4 cells were cultured in 24-well 
plates with either DMSO control or different concentrations of MG132 (0.2μM, 0.5μM, 1μM and 
2μM; shown on the left) for various hours (6h, 12h and 24h; shown on the top). Treatments 
started when cells were ~90% confluence. Images were taken at indicated time points. Cells were 
in good condition at DMSO for up to 24h, at 0.2μM MG132 for up to 24h, at 0.5μM for up to 12h 
and at 1μM as well as 2μM for 6h.  
  66 
 
 
Figure III-10: Brain endothelial MCT1 is not regulated by proteasomal degradation route. (A) 
For the dosage response study, RBE4 cells were treated for 6h with DMSO, or MG132 at 
concentrations of 0.2μM, 0.5μM, 1μM or 2μM; for the time course study, RBE4 cells were treated 
with DMSO for 12h, or 0.2μM MG132 for 6h, 12h or 24h. Control groups had growth medium only 
and served as vehicle control. Immunoblotting on whole cellular protein was performed after each 
treatment against MCT1 and actin. No changes of MCT1 level was observed in any of these 
MG132 groups compared with DMSO. Statistical analysis (one-way ANOVA) did not find 
significant differences among groups of time course study, indicating that MCT1 in RBE4 cells is 
not regulated by proteasome. (B) RBE4 cells were treated with DMSO for 12h or 1μM clasto-
lactacystin beta-lactone (CLBL) for 6h, 12h or 24h. Immunoblotting on whole cellular protein was 
performed after each treatment against MCT1 and actin. No changes of MCT1 level was 
observed in any of these CLBL treatment groups compared with DMSO (One-way ANOVA, 
P=0.34). 
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Figure III-11: Brain endothelial MCT1 is regulated by lysosomal degradation route. A 
dosage response study was performed by treating RBE4 cells for 24h with vehicle control or 
increasing concentrations of chloroquine (50μM, 100μM and 200μM), followed by immunoblotting 
on whole cell protein against MCT1 and actin. Our results revealed that chloroquine elevated 
MCT1 protein level in a dosage dependent manner. 100μM chloroquine significantly increased 
MCT1 protein level compared with control group (student t test, *P<0.0004, n=3, mean±SEM).     
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v. Functional expression of brain endothelial MCT1 on cellular surface is 
increased by Wnt pathway. 
Our previous study has demonstrated an endosomal trafficking role of MCT1 in RBE4 
cells, which is regulated by cAMP signaling pathway (68). In addition, MCT1 protein 
contains several motifs that are well known for being involved in endosomal sorting 
process, such as dileucine, YXXφ and acidic clusters (Figure III-14). Combined with our 
earlier observation that MCT1 is regulated by lysosomal degradation, we hypothesized 
that the canonical Wnt/β-catenin pathway stabilizes MCT1 through regulation of its 
trafficking in the endosomal-lysosomal system, leading to an increased expression on 
the surface membrane. In order to test this hypothesis, we biotinylated and purified 
RBE4 cell surface proteins, which were then subjected to SDS-PAGE electrophoresis 
followed by immunoblotting against MCT1. We found that 20mM LiCl treatment for 24h 
in RBE4 cells significantly increased MCT1’s expression on surface membrane by ~200% 
(Figure III-12). This result was echoed by our confocal study, where mCherry-MCT1 
plasmid was transfected into RBE4 cells, and the localization of red fluorescence tagged 
MCT1 on plasma membrane was found to be increased by 20mM LiCl treatment for 24h 
(Figure III-13). These data suggested that the functional expression of brain endothelial 
MCT1 on surface membrane was increased by the canonical Wnt/β-catenin signaling 
pathway.  
 
vi. Ubiquitination is involved in brain endothelial MCT1’s expression.  
Ubiquitin has been known as a sorting signal not only for proteasomal degradation, but 
also implicated in the three major trafficking pathways: endocytosis, endosomal-
lysosomal trafficking and trans-Golgi network sorting into endosomes (279). In addition, 
the analysis of MCT1 protein structure reveals a PY motif (“PPTY”) on its N terminus that 
has been implicated in ubiquitin E3 ligase binding and late endosome/lysosome 
targeting (Figure III-14). In order to test the role of ubiquitination in brain endothelial 
MCT1’s regulation, we first did viability screening by treating RBE4 cells with increasing 
concentrations of a commonly used deubiquitinases (DUBs) inhibitor, N-Ethylmaleimide 
  69 
(NEM) at 2μM, 10μM or 20μM, for 2h, 6h or 12h time periods (Data not shown). After 
finding the optimal treatment condition, RBE4 cells were incubated with 10μM NEM for 
6h, followed by SDS-PAGE and immunoblotting against MCT1. Our results showed that 
MCT1’s protein level was upregulated by this DUBs inhibitor (Figure III-15 A). In order to 
confirm our results, we used another more specific commercial DUBs inhibitor, PR-619 
DUB V, to treat RBE4 cells at 10μM for 12h. A significant upregulation of MCT1’s protein 
level was observed again (Figure III-15 B). In sum, we conclude that brain endothelial 
MCT1 is modulated by ubiquitination. 
 
 
Figure III-12: Increased cellular surface expression of MCT1 by LiCl treatment in RBE4 
cells. RBE4 cells were treated with or without 20mM LiCl for 24h. Then cellular surface proteins 
were labeled with biotin, captured/purified by avidin beads and subjected to SDS-PAGE 
separation, followed by immunoblotting against MCT1 and actin. Densitometry measurements 
and statistical analysis were performed, showing that Wnt activation by LiCl increased MCT1’s 
expression on cellular surface membrane (Student t test, *P<0.002, n=3, mean±SEM).   
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Ubiquitin is encoded in mammals by 4 different genes. Uba52 and Rps27a genes code 
for a single copy of ubiquitin fused to the ribosomal proteins L40 and S27a, respectively. 
The Ubb and Ubc genes code for polyubiquitin precursor proteins with 4 and 10 ubiquitin 
repeats respectively (280). In order to identify the ubiquitin gene isoform (s) present in 
RBE4 cells that are involved in protein trafficking, we used PCR to screen for Ubb and 
Ubc genes first, followed by agarose gel analysis. We found that all the expected bands 
from Ubb gene were clearly visible on the gel, whereas Ubc didn’t give the expected 
banding pattern (Figure III-16). In conclusion, Ubb is the polyubiquitin gene isoform 
present in RBE4 cells.   
 
Figure III-13: LiCl caused brain endothelial MCT1 expression to be elevated on plasma 
membrane as revealed by confocal imaging. RBE4 cells were transfected with mCherry-MCT1 
fusion plasmid (red fluorescence attached to N terminus of MCT1 protein); then cells were 
reseeded and grown in µ-Slide 8 well plates. They were either untreated (A) or treated with 20mM 
LiCl (B) for 24h to activate Wnt pathway. Our results indicate that MCT1 expression on plasma 
membrane increased upon LiCl treatment. White bar: 5μm.    
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Figure III-14: Structure of rat MCT1 protein and the motifs implicated in intracellular 
trafficking. Rat MCT1 contains 494 amino acids, 12 transmembrane domains (TMDs) and one 
large intracellular loop. Both the C-terminal and N-terminal ends are inside the cell. Within the 
intracellular fragments, a “LL(I) motif (LI)” resides within the intracellular loop; a “YXXφ motif 
(YRLV)” and two “acidic clusters (EEE and DGKEDETSTDVDE)” are in the C-terminal end; one 
“PY motif (PPTY)” is found in the N-terminal end. “LL(I) motif”, “YXXφ motif” and “acidic clusters” 
have been involved in endosomal system sorting process (281, 282), whereas “PY motif” is 
implicated in ubiquitin E3 ligase binding and late endosome/lysosome targeting (283).   
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Figure III-15: Regulation of brain endothelial MCT1 by deubiquitinases (DUBs) inhibitors N-
Ethylmaleimide (NEM) and PR-619 (DUB inhibitor V). (A) RBE4 cells were treated with either 
DMSO vehicle control or 10μM NEM for 6h. Whole cellular proteins were prepared and separated 
on SDS-PAGE gel, followed by immunoblotting against MCT1 and actin. Densitometry 
measurements and subsequent statistical analysis revealed that NEM upregulated MCT1 
expression significantly (52%; student t test, *P<0.03, n=3, mean±SEM). (B) RBE4 cells were 
treated with either DMSO vehicle control or 10μM PR-619 for 12h. Whole cellular proteins were 
prepared and separated on SDS-PAGE gel, followed by immunoblotting against MCT1 and actin. 
Densitometry measurements and subsequent statistical analysis revealed that PR-619 also 
upregulated MCT1 expression significantly (73%; student t test, *P<0.05, n=4, mean±SEM). 
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Figure III-16: PCR screening for Ubb and Ubc expression in RBE4 cells. (A) Schematic 
representation of PCR strategy. Specific primers were made for Ubb and Ubc genes respectively. 
There are multiple annealing sites for each primer pair within the gene because of the presence 
of polyubiquitin repeats. Ubb forward primer is shown in red, reverse primer in green; Ubc forward 
primer is in orange, reverse primer in blue. cDNA templates were used. (B) PCR products for Ubb 
and Ubc genes analyzed on 1.5% agarose gel. Expected PCR bands are listed on the left and 
right side of the image for Ubb and Ubc, respectively. “Low M.W. ladders”: low molecular weight 
DNA ladders: (top 8 bands) 766bp, 500bp, 350bp, 300bp, 250bp, 200bp, 150bp and 100bp. “1kb 
ladders”: (the first 3 from bottom) 1kb, 2kb and 3kb. The presence of each band is indicated by 
either red arrow for Ubb or green arrow for Ubc. Our results indicated that all of the expected 
bands for Ubb could be identified, but not for Ubc. 
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Discussion: 
In this study, we report that brain endothelial MCT1 is upregulated by the canonical 
Wnt/β-catenin signaling pathway through enhanced plasma membrane expression and 
reduced degradation in the endosomal-lysosomal system, without an alteration of its 
mRNA level. We also found that MCT1 is regulated by the ubiquitin system, and the 
ubiquitination status of MCT1 may play a role in its observed regulation by Wnt pathway. 
This is the first report (to our knowledge) that examined the regulatory effect of Wnt 
pathway on MCT1, a key transporter for facilitated diffusion of critical metabolites, such 
as lactate, pyruvate and BHB. The role of canonical Wnt pathway in regulating MCT1 is 
not surprising given the fact that (1) Wnt signaling is necessary for normal blood-brain 
barrier development and maturation (275, 276), and (2) MCT1 is the major if not the only 
MCT isoform present at brain endothelial cells (67, 174). RBE4 cells are a cell line 
derived from immortalized rat brain endothelial cells, and thus served as a useful model 
for blood-brain barrier research, including transport and signaling studies (200, 201).   
Regulation of brain endothelial MCT1 by lysosomal degradation 
Our results on the β-catenin-dependent increase of MCT1 protein level but unaltered 
mRNA expression indicate that intracellular degradation routes are most likely the 
underlying mechanism of brain endothelial MCT1’s regulation by the canonical Wnt 
pathway. Cellular proteins are degraded by either proteasomes or lysosomes. The 
former route is more responsible for degrading intracellular proteins, whereas the latter 
one is majorly for extracellular and transmembrane proteins that are taken up by 
endocytosis (284), although some proteins, e.g. EGFR, have been shown to be 
regulated by both routes (285). Our additional observation that MCT1 in RBE4 cells is 
responsive to chloroquine but insensitive to MG132 or clasto-lactacystin beta-lactone 
suggests that lysosomal, but not proteasomal, degradation plays a role in its turnover 
rate control. Lysosomes are cytoplasmic, membrane bound vesicles that contain 
proteases and hydrolytic enzymes. After internalization, endocytosed integral membrane 
proteins pass through early and late endosomes before final delivery to lysosomes (286). 
Recent research has shown for the first time that brain endothelial MCT1 is rapidly 
internalized into early endosomes following cAMP-dependent PKA signaling activation. 
  75 
In addition, MCT1 is constitutively recycled through the clathrin vesicles into recycling 
endosomal system (68). MCT1 protein contains two acidic clusters and one YXXφ motif 
in its C-terminal end, as well as one dileucine (LL or LI) motif in the large intracellular 
loop (Figure III-14). Those motifs have been strongly associated with retention of 
transmembrane proteins into endosomal compartments (287), targeting of cellular 
surface proteins to lysosomes, endosomal compartments and trans-Golgi network (TGN) 
(281, 288, 289). For example, the intracellular sequestration of insulin-responsive 
glucose transporter GLUT4 in adipose tissue is found to be at least regulated by a LL 
domain (290) as well as an acidic-cluster-based motif in its C-terminus (291). Thus, our 
results are consistent with those previous findings that brain endothelial MCT1 is actively 
regulated through the endosomal-lysosomal sorting system. 
Our results do not exclude the possibility that enhanced translation of Mct1 mRNA 
contributes to the observed upregulation of MCT1 protein in the absence of 
transcriptional induction by the canonical Wnt pathway. Indeed, GSK-3 is able to 
phosphorylate and activate tuberous sclerosis complex 2 (TSC2), thus to inhibit 
mTORC1 activity (292). As a result, lithium can reverse GSK-3’s inhibitory effect and 
activate mTOR signaling pathway, leading to the phosphorylation of the p70 ribosomal 
protein S6 kinase 1 (S6K1) and eukaryotic translation initiation factor 4E (eIF4E)-binding 
protein 1 (4E-BP1). The phosphorylation of 4E-BP1 prevents its binding to eIF4E, 
enabling eIF4E to promote cap-dependent translation. In addition, the stimulation of 
S6K1 by mTORC1 leads to increased synthesis of ribosomal proteins. Together they 
positively control the capacity of protein translational machinery (293). Previous studies 
on MCT2, the neuronal MCT isoform, found that its elevated expression by 
noradrenaline is mediated by translational activation via stimulation of mTOR/S6K 
pathway (294). However, the much greater upregulation of MCT1 observed on cellular 
plasma membrane than that from the whole cellular lysates favors the notion that its 
intracellular trafficking is more likely affected by the canonical Wnt pathway.   
The role of post-translational modification in MCT1’s intracellular trafficking 
Our finding that both NEM and PR-619, two pharmaceutical inhibitors to DUBs, 
upregulated brain endothelial MCT1’s protein level, demonstrates that ubiquitination is 
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likely to be involved in regulating MCT1’s expression. As a major post-translational 
modification system, ubiquitin has been widely used as a sorting signal for targeting 
membrane proteins into endosomal-lysosomal system. It acts on many trafficking stages 
including initial clathrin-mediated internalization, sorting cargo proteins into 
multivesicular bodies (MVB) for subsequent infusion with lysosomes, directing damaged 
or functionally inappropriate proteins from TGN to endosomes and preventing their 
appearance on cell surface, and sequestering transmembrane proteins within recycling 
endosomes (279, 295-297). Although both monoubiquitination and K63-polyubiquitination 
have been experimentally supported in mediating effective internalization of their 
substrates and subsequent sorting between endosomes, recent studies seem to favor 
the latter modification as a stronger signal (279). In consistence, our identification of Ubb 
gene in RBE4 cells further supports a potent role of polyubiquitination in modulating 
MCT1’s endosomal-lysosomal trafficking. So it is likely that the enhanced localization of 
MCT1 onto plasma membrane after Wnt pathway activation is caused by at least one of 
the following: (1) reduced internalization of MCT1 from cellular membrane, or (2) 
suppressed cargo sorting into MVB intraluminal vesicles, which creates a “jam” along the 
trafficking path towards MVB-lysosome infusion and consequently slows down MCT1’s 
detachment from cell surface, or (3) enhanced recycling rate back onto plasma 
membrane. Further studies on MCT1’s ubiquitination status as well as its localization 
within endosomal system may shed lights on dissecting the molecular mechanisms 
underlying its regulation by Wnt pathway.   
Generally, polyubiquitination is associated with favored protein sorting into MVB-
lysosomes for degradation or sequestering within cytosolic vesicles (296, 298). DUBs 
remove ubiquitin moieties from targeted substrates and its inhibition helps retain an 
ubiquitination linkage state. Unexpectedly, our results showed that DUB inhibitors 
increase MCT1’s protein expression in RBE4 cells. This phenomenon is not surprising 
given the fact that over 100 DUBs have been identified, each with the potential to 
remove or remodel ubiquitin chains in response to unique biological cues (299). Besides, 
DUBs can associate with either specific membrane proteins, or certain components from 
sorting machinery, in order to regulate lysosomal allocation of cargo proteins (279). It is 
possible that an unknown negative regulator of MCT1 is lightly ubiquitinated and 
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maintained active under normal conditions due to the action of one or more DUBs. 
Inhibiting these DUBs helps to retain polyubiquitin chains on this negative regulator, 
leading to its proteasomal or lysosomal degradation and subsequent increase in MCT1’s 
level. For instance, some DUBs have been found to deubiquitinate and stabilize key 
ubiquitin-ligases that mediate cargo ubiquitination and degradation (300). In contrast, an 
intact ubiquitination status is required for some receptors to stay on cellular membrane. 
For example, PAR-1 is ubiquitinated in its basal state; receptor activation leads to the 
loss of ubiquitination and initiates its journey in ensosomal system. PAR-1 also 
undergoes constitutive internalization, a phenomenon that is enhanced in its mutant that 
lacks the major ubiquitinated lysine residues (301). The observed upregulation of brain 
endothelial MCT1 by DUBs inhibitors in our current study may belong to one of the 
above mentioned scenarios.  
Our results do not exclude other possible post-translational modifications activated by 
Wnt pathway in assisting MCT1’s intracellular trafficking onto or off plasma membrane, 
e.g. phosphorylation, association with ancillary proteins like CD147. Indeed, our previous 
research suggested that cAMP induces rapid dephosphorylation and subsequent 
caveolae-dependent internalization of brain endothelial MCT1 into early endosomes (68). 
This finding is supported by the same and other groups in that cAMP causes a reduction 
of Vmax without changes of Km in MCT1’s transport properties (67, 119). Thus, it is 
possible that Wnt signaling activates a kinase that phosphorylates MCT1, which then is 
retained on the cell surface. The successful targeting of MCT1 onto plasma membrane 
requires its tight association with CD147, an ancillary glycoprotein that belongs to the 
IgG superfamily (50). Enhanced association between MCT1 and CD147 has been 
reported to cause increased plasma membrane expression of this transporter protein (53, 
54), whereas silencing or knockout of CD147 in cultured cells or genetically modified 
animals results in decreased MCT1 plasma membrane localization, impaired 
MCT1:CD147 interaction, as well as altered tissue distribution of this transporter (55, 56). 
Future studies on MCT1’s phosphorylation status and association with CD147 upon Wnt 
signaling activation shall help better understand MCT1’s regulation by those post-
translational modifications.  
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Clinical relevance of MCT1 regulation by the canonical Wnt pathway  
A better understanding of MCT1’s function and regulation along brain endothelial cell 
wall has many clinical implications. In addition to the above mentioned pathological 
conditions including lactic acidosis during ischemic stroke and brain injury, anti-epilepsy 
drug transport across BBB, as well as ketone bodies delivery during fasting and in 
epileptic patients on ketogenic diet, brain endothelial MCT1 has also been suggested to 
help protect brain cognition through transporting some of its substrates. Specifically, 
provision of alternate fuels, e.g. lactate and BHB, in to brain was found to improve 
cognitive dysfunctions during acute hypoglycemia in both healthy and diabetic subjects 
(302, 303). This may imply a potential use of monocarboxylic acids as protective agents 
against hypoglycemia in diabetic patients. The presence of MCT1 at BBB ideally 
provides a therapeutic target for accomplishing the above mentioned clinical benefits.  
Beyond the BBB, both MCT1 and canonical Wnt pathway have been associated with the 
progression of many diseases, such as cancer, tissue self-renewal, and autoimmune 
disorders. For example, the canonical Wnt pathway has been long recognized as the 
single most dominant force in controlling cell fate along the crypt-villus axis within the 
intestinal system (304). Multiple mutations (e.g. APC, Axins and TCF) and aberrant 
modifications (e.g. hypermethylation) of players from this pathway have been well 
identified as causing reasons for the occurrence of colorectal cancer (305-308). Besides, 
other types of tumorigenesis, such as leukemia, hepatocelluar tumors, medulloblastoma 
and pediatric renal (Wilm’s) tumor, are also commonly associated with dysregulated 
Wnt/β-catenin signaling (274, 309, 310). The metabolic phenotype of solid tumors is well 
characterized by large consumption of glucose and aerobic glycolysis, a phenomenon 
referred to as the “Warburg effect” (311). The resulting excessive lactate needs to be 
exported out readily through MCTs including MCT1, in order to maintain an amenable 
intracellular pH environment and to optimize bioenergetic metabolism (312). A metabolic 
symbiosis model emphasizes that cancer cells in the hypoxic core of a tumor convert 
glucose to lactate through enhanced glycolysis, which then is extruded by MCT4 and 
taken up via MCT1 by aerobic cancer cells on the periphery for mitochondrial oxidation 
(185). In fact, MCT1’s expression level has been found to be upregulated, either mRNA 
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or protein or both, in various tumors, e.g. breast (75, 76), prostate (313), melanoma (79, 
80) and leukemia (49). As a result, given the importance of both MCT1 and the 
canonical Wnt pathway in cancer progression, a good appreciation of their 
interaction/regulation can provide valuable information for therapeutic benefits.   
Stem cells reside in renewing tissues (e.g. crypt-villus axis of the small intestine and hair 
follicle on epidermis) and possess the ability to differentiate into various cell types in 
response to external cues. Physiological signaling of the canonical Wnt pathway is 
tightly associated with maintaining cell fates within normal crypts or hair follicles, without 
promoting uncontrolled cell division leading to tumorigenesis (304, 314). Interestingly, 
immunostaining study in mouse showed a strong colocalization of MCT1 with both the 
crypts in gastrointestinal tract and the hair bulge, where stem cells are stored, 
respectively (315). In addition, Wnt signaling can affect the differentiation of naïve CD4+ 
T lymphocytes (316). In autoimmune diseases like rheumatoid arthritis and systemic 
lupus erythematosus, aberrant Wnt signaling has also been observed (317, 318). MCT1 
on T cells was identified as a target for immunosuppression and its normal activity of 
extruding glycolytic lactate is required for immune activation in response to antigen 
stimulation (184). The close coexistence of MCT1 and Wnt signaling in stem cell derived 
tissue renewal as well as in immune reaction implies a possible crosstalk between the 
two during these pathological conditions and merits future research.  
Our current study is the first one to examine a regulatory effect of Wnt signaling on 
MCT1 expression. This may lay down the first brick on the road to investigate regulation 
of this important metabolic transporter by a mighty signaling pathway that is essential for 
many biological processes. These results may have therapeutic implications in treating 
devastating diseases where the function of MCT1 is massively involved.  
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Chapter IV 
Regulation of brain endothelial MCT1 expression by Notch 
pathway and its interaction with the canonical Wnt/β-catenin 
pathway in RBE4 cells 
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Introduction 
Notch signaling pathway is highly conserved across the animal kingdom, from 
invertebrates like sea urchins and Caenorhabditis. elegans, to vertebrates such as 
Drosophila melanogaster, rodents and human (319). This pathway functions in 
determining cell fates during development through local cell-cell contact (320). In 
addition, Notch activity also contributes significantly to tissue self-renewal, proliferation, 
apoptosis and physiological disorders such as Alagille’s syndrome (321, 322) and 
various cancers, e.g. colon cancer (323) as well as T cell acute lymphoblastic leukemia 
(324). In mammalian Notch pathway, four receptors (Notch1-4), five ligands (Jagged1 
and 2, Dll1, 3 and 4) and two coligands (DLK-1 and -2) have been identified. Different 
receptors and ligands can have overlapping as well as distinct expression patterns 
during development and Notch receptors are found to have broad expression patterns in 
many tissues (320, 325). The Notch receptors are composed of a ligand-binding Notch 
extracelluar domain (NECD) that is noncovalently held together with a single-pass 
transmembrane signaling domain referred to as the Notch intracellular domain (NICD). 
The Notch pathway activation is mediated by a sequence of proteolytic events (Figure 
IV-1). Specifically, the binding of ligands on signal-sending cells to the receptors 
presented on the signal-receiving cells causes a cleavage of Notch at S2 site (~12 
amino acids before the transmembrane domain) by ADAM metalloprotease (ADAM10 or 
TACE), followed by γ-secretase cleavage of the tethered receptor near the inner leaflet 
of the membrane (S3 site), creating a transiently active NICD that translocates into 
nucleus, interacts with the DNA-binding protein CSL (CBF1/RBPjκ/Su(H)/Lag-1), recruits 
the coactivator Mastermind (Mam or MAML in mammals) and induces upregulation of 
downstream target genes (320, 326), e.g. Hes1, 5 and 7, Hey1, 2 and L (327, 328).     
The function of Notch signaling in the blood-brain barrier (BBB) mostly remains elusive. 
One study showed that activation of Notch pathway through Notch4 and Jagged1 in rat  
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Figure IV-1: Schematic representation of Notch pathway (Adapted and modified from (325)). 
Binding of Notch ligand (Delta in this example) on the signal-sending cell to the Notch receptor on 
the signal-receiving cell causes a proteolytic cleavage by metalloprotease ADAM10 or TACE at 
S2 site, generating the substrate for S3 cleavage by γ-secretase. The resulting Notch intracellular 
domain (NICD) fragment translocates into nucleus, where it binds CSL, releases co-repressors 
and recruits the co-activator Mastermind (Mam) to promote target genes expression.   
 
brain endothelial (RBE4) cells promotes endothelial cell differentiation and 
morphogenesis (329). Furthermore, Notch signaling appears to be one of the major 
forces involved in the stabilization growth of mature endothelium (330), and BBB 
endothelial dysfunction is correlated with an impaired expression of Notch4 after chronic 
exposure to nicotine (331). Other research in blood vessels revealed that during 
vascular development, the endothelial tip cells cap the migrating end of stalk cells, a 
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lumenized column of cells that form an angiogenic blood vessel (332). This precisely 
coordinated patterning of cells along the tubular structure is achieved through Notch-
mediated lateral inhibition that prevents extra cells from assuming the lead portion in 
Drosophila tracheal branching (333). In mammals, Dll4 appears to be the major Notch 
ligand to regulate vascular development in a dosage-dependent manner (334, 335). 
Rodent Dll4-Notch1 signaling was found to be a negative regulator in determining the 
number of tip cells during angiogenesis to control vessel sprouting and branching (336, 
337). The above observations are not surprising given the well-known role of Notch 
signaling as a determinant of cell fates.    
Morphogenesis, cell fates, cell proliferation and apoptosis during the developmental 
course are iteratively governed by a combinatorial use of a small number of conserved 
signaling pathways, including Notch, Wnt, Hedgehog, transforming growth factor-β 
(TGF-β) and a few others (320, 325, 326). In accordance, a strong interaction, either 
positive or negative, between Notch and Wnt signaling pathways has been 
demonstrated in a variety of biological conditions, such as colorectal cancer (338-341), 
breast cancer (342, 343), intestinal epithelia and osteoblast differentiation (344, 345), as 
well as stem cells and progenitor cells biology (346). Specifically, the oncogenic 
conversion of human breast epithelial cells by ectopically increased Wnt signaling 
requires the normal function of Notch pathway (342). In addition, a synergistic 
relationship exists between Wnt and Notch activities in the oncogenic progression of 
rodent intestinal tumorigenesis, as well as in the development of Drosophila eye (347). 
In contrast, antagonizing effects between these two signaling pathways have also been 
observed in many other studies. For instance, in colorectal cancer, Notch1 counteracts 
the canonical Wnt pathway by suppressing the expression of Wnt target genes through 
epigenetic modification (338). Notch antagonizes Wnt activity during Drosophila 
development through modulating the levels of active β-catenin (348). Particularly in 
vascular developmental process, canonical Wnt and Notch signaling have been found 
functionally connected and controlling each other. Specifically, endothelial stabilization of 
Wnt/β-catenin signaling during early embryonic development alters expression of Dll4 
ligand and causes vascular phenotype that is similar to what is observed by aberrant 
Notch pathway activation (349). The same functionality of Wnt/β-catenin-Dll4/Notch 
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signaling axis is also present in glioblastoma angiogenesis and responsible for the 
generation of a more normalized tumor vasculature phenotype (350).  
Given the critical role of Notch signaling in vasculature development and cell fates 
determination, and the lack of information on BBB modulation by Notch pathway, we 
decided to examine whether or not brain endothelial MCT1, one of the important nutrient 
transporters along BBB, is regulated by Notch signaling. In addition, a well-known keen 
interaction between canonical Wnt and Notch pathways inspired us to ask whether such 
a crosstalk exists in brain endothelial MCT1’s regulation.  
 
Materials and Methods: 
Cell Culture. Immortalized rat brain endothelial (RBE4) cells were cultured in equal 
parts minimum essential medium alpha (MEM-α) (Invitrogen; #12561-056) and F-10 
Nutrient (Ham’s) (Invitrogen; #12390-035), supplemented with 10% fetal bovine serum 
(Atlanta Biologicals; #S11150H), 0.3 mg/ml geneticin (Sigma-Aldrich, #A1720), and 1.0 
ng/ml basic fibroblast growth factor (Roche; #11363697001). 25-cm2 polystyrene tissue 
culture flasks (Corning Inc.; #CLS430372) were first coated with collagen by treating the 
surface area with 50ng/ml rat tail collagen type I (BD Biosciences; #354236) in 0.013% 
cyanamide solution (Sigma-Aldrich; C87908) for 2 hours, followed by water rinsing of the 
same volume twice. Cells were then cultured on these collagen coated flasks in a 
humidified incubator at 37oC with 5% CO2. All the experiments were conducted when the 
cells reached light (≥90%) confluence.  
Reagent Stocks. 1M lithium chloride (Sigma-Aldrich; #L-0505) stock was made in H2O 
and stored in 4oC. 50mM DAPT (Sigma-Aldrich; #5942) stock was made in DMSO 
(Sigma-Aldrich; #D2650) and stored in -80oC until use.  
Cellular proteins preparation. Cells were washed twice with 5ml ice-cold PBS 
(Mediatech, Inc.; #21-040-CV), supplemented with 1X protease inhibitor cocktail (Roche; 
#11697498001). Whole cellular protein samples were then prepared by direct in-flask 
scraping of cells within 100μl SDS boiling buffer (5% SDS, 10% v/v glycerol, 60mM Tris-
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Cl pH=6.8), transferred into 1.5ml eppendorf tubes (Sarstedt; #72690001), homogenized 
and centrifuged at 13,000 rpm for 10 minutes. 
RNA isolation, reverse transcription and quantitative real time PCR (qRT-PCR). 
Total cellular RNAs were isolated using RNeasy Mini Kit (Qiagen; #74104) according to 
the manufacturer’s instruction. After their concentrations being determined by ND-1000 
NanoDrop spectrophotometer, the RNA samples were converted to cDNAs using 
QuantiTect Reverse Transcription Kit (Qiagen; #205311). Rotor gene cyber green 
(Qiagen; #204074) based qRT-PCR was conducted on Rotor-Gene RG-3000 cycler 
(Corbett Research), using 50ng total cDNA per reaction with the following settings: 95oC 
5 minutes, followed by 95oC 5s and 60oC 10s for 40 cycles. The qRT-PCR results were 
analyzed using the cycle threshold method (CT, Applied Biosystems User Bulletin 
Number 2, P/N 4303859) and expressed as fold changes over controls. All the primers 
used here were designed through the PrimerQuest tool from IDT, and their sequences 
are summarized in Table IV-3.      
Protein assays and western blotting. Protein samples’ concentrations were 
determined using Pierce BCA protein assay kit (Thermo Scientific; #23227) unless 
otherwise mentioned. Immunoblotting was performed as reported previously (278). 
Specifically, 10μg proteins from each sample were prepared and diluted 4:5 with 
homemade 5X sample loading buffer (10% SDS, 50% glycerol, 25% β- mercaptoethanol, 
312.5mM Tris HCl and 0.01% bromphenol blue). Then they were subjected to SDS-
PAGE electrophoresis at 160V on Criterion TGX precast gels (Bio-Rad; #5671033), and 
transferred to supported nitrocellulose membranes (Bio-Rad; #162-0070) at constant 
200mA for 90 minutes. The membranes were blocked at room temperature on an orbital 
shaker for 1 hour in SEA BLOCK (Thermo Scientific; #37527), followed by overnight 
incubation at 4oC with primary antibody diluted 1:5,000 for anti-MCT1 and 1:5,000 for 
anti-Actin (EMD Millipore; #MAB1501) in 1X TBST buffer (50 mM Tris base, pH 8.0, 0.9% 
NaCl, 0.1% Tween 20) supplemented with 1% SEA BLOCK. After washing in 1X TBST, 
the membranes were incubated at room temperature for 1 hour with rabbit anti-chicken 
IgY conjugated to horseradish peroxidase (Thermo Scientific; #31401) diluted 1:5,000 
for MCT1, or goat anti-mouse IgG (Thermo Scientific; #31430) diluted 1:10,000 for Actin. 
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Detection was accomplished after membranes being rinsed for 5 minutes in SuperSignal 
West Pico chemiluminescent Substrate (Thermo Scientific; #34080). The immunoblotting 
results were analyzed by densitometry, normalized to actin and then expressed as fold 
changes over control. 
Table IV-1: qRT-PCR primers 
Gene Forward Primer Reverse Primer 
Notch1 CACCTGCACTGACTATCT TAGGCACTCGTTGATCTC 
Notch2 CTTTGAATGCCAGAGGAATAG CGTTGTTGCATCCCTTATC 
Notch3 CGGCTTGATTTCCCATAC GAAGATGACCAGCAGAAAG 
Notch4 GTGAACGCGACGTCAATGAATGCT ATTGAGACAGGTTCCAGGAAGGCA 
Jagged1 CAGAATGGCGCCCAATGCTACAAT AGTGGTCTTTCAGGTGTGAGCAGT 
Jagged2 ATCACCCAGAGAGGAAAC GGAAGAGCCACCCATAA 
Dll1 CTCTGTAGGAGAAGAGAAGAG CTTGGTGTCCTTTGAAGTAG 
Dll3 GGGACTCTCGATCTATTTATGT TCATTCAGGCTCCATCTC 
Dll4 GAACCACACACTGGACTA GGCACCTTCTCTCCTAAA 
Dlk1 CCAGGCCCTTCTACATTA GTTCACTAGATTCCACACAAG 
Dlk2 ATCAGGAGTGTCAGGTTAG AGGTGAAAGGAGGTAAGG 
Hes1 CAACACGACACCGGACAAACCAAA TGGAATGCCGGGAGCTATCTTTCT 
Hes5 CTACAGCGAGGGTTACT CGCTGGAAGTGGTAAAG 
Hes7 GCCTAGAAGAGCTGAGG GCGAACTCCAGTATCTCT 
Hey1 CTGAAGTTGCCCGTTATC GGATGCGTAGTTGTTGAG 
Hey2 CCATCCAGTAGTGCATTTATAC GTTCAGGCACTTAGGAAAC 
HeyL GGTCACTCAGAGGACAATA TCCTACCTAGCCAGAAATAC 
Gapdh ACAAGATGGTGAAGGTCGGTGTGA AGCTTCCCATTCTCAGCCTTGACT 
β-actin TTGCTGACAGGATGCAGAAGGAGA ACTCCTGCTTGCTGATCCACATCT 
 
 
Results: 
i. Notch receptors, ligands and target genes in RBE4 cells. 
The presence of Notch receptors (Notch1-4), ligands (Jagged1 and 2; Dll1,3 and 4; Dlk1 
and 2) and some of its known target genes (Hes1, 5 and 7; Hey1 and 2; HeyL) in RBE4 
cells were first investigated using quantitative real time PCR (qRT-PCR). Their 
abundances were shown as ratios to the expression level of internal standard gene 
Gapdh. Our results indicated that Notch2 is the most abundant receptor, followed by 
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Notch3, 1 and 4. Jagged 1 has the highest expression level compared with other ligands. 
Hes1 and Hey2 are the two most prominent target genes (Figure IV-2).      
 
Figure IV-2: Expression profiles of Notch receptors, ligands and selected target genes in 
RBE4 cells. Total RNA was prepared from RBE4 cells and converted to cDNA, which was then 
used as template in qRT-PCR. The relative amount of each gene’s expression level was roughly 
expressed as ratios to Gapdh gene, using ΔΔCT method with the formula of 2
(C
TX 
- C
TGapdh
)
. Data 
were summarized as mean±SEM. CTX: threshold cycle number of individual gene; CTGapdh: 
threshold cycle number of Gapdh internal standard. Our data suggested that Notch2 is the most 
abundant receptor, followed by Notch3 and Notch1, whereas Notch4 showed trace level. 
Jagged1 is the most abundant ligand, whereas all the rest showed residual expression. Hes1 is 
the predominant target gene, followed by Hey2 that is at significantly higher expression level than 
the others.  
 
ii. Inhibition of Notch pathway increased MCT1’s protein level in RBE4 cells.  
In order to see if brain endothelial MCT1 is regulated by Notch signaling, we used a 
common γ-secretase inhibitor DAPT to inhibit this pathway. Cell viability tests were first 
conducted with increasing concentrations of DAPT (control, 1μM, 5μM, 25μM and 
100μM) for different time periods (6h and 24h) to find the maximal concentrations that do 
not cause significant cell death. Our results showed that 25μM is the highest 
concentration still with good cell viability (Figure IV-3). So, we treated RBE4 cells with  
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Figure IV-3: Effects of DAPT on RBE4 cells’ viability. RBE4 cells were cultured in 24-well 
plates with either DMSO control or different concentrations of DAPT (5μM, 25μM and 100μM; 
shown on the left) for 6h or 24h shown on the top. Treatments started when cells were ~90% 
confluence. Images were taken at indicated time points. Cells were in good condition at DMSO, 
5μM and 25μM DAPT for up to 24h. Severe cell death was observed with 100μM DAPT treatment 
starting at 6h.  
 
  89 
5μM DAPT for 24h or 48h, or 25μM DAPT for 12h or 24h, followed by SDS-PAGE 
analysis of whole cellular proteins and subsequent immunoblotting against MCT1. We 
found that compared with DMSO vehicle control, 5μM DAPT treatment for 24h and 
25μM DAPT treatment for 12h significantly increased MCT1’s protein expression by 26% 
and 41%, respectively (Figure IV-4). qRT-PCR analysis of RNA samples from those two 
DAPT treatment groups showed significant downregulation of the two most abundant 
target genes in RBE4 cells, Hes1 and Hey2, demonstrating that the observed 
upregulation of MCT1 by DAPT was due to inhibition of Notch signaling (Figure IV-5). 
 
 
Figure IV-4: Effects of Notch inhibition by DAPT on brain endothelial MCT1 expression. 
Based on viability screening study with DAPT, RBE4 cells were treated with either 5μM DAPT for 
24h or 25μM DAPT for 12h, followed by SDS-PAGE separation and immunoblotting against 
MCT1 and actin. The results were expressed as fold-changes over DMSO control. Statistical 
analysis showed that MCT1 protein level was upregulated by both DAPT treatments (5μM DAPT 
24h: 26%; 25μM DAPT 12h: 41%; one-way ANOVA followed by Bonferroni post hoc test: *P<0.02, 
**P<0.01; mean±SEM).  
  90 
 
Figure IV-5: Notch target genes were downregulated by DAPT. RBE4 cells were treated with 
either 5μM DAPT for 24h (A), or 25μM DAPT for 12h (B) or 24h (C). After total RNA harvest and 
reverse transcription, qRT-PCR was performed to examine Hes1 and Hey2 expression. The data 
were first normalized to β-actin, and then expressed as fold-changes over control. ΔΔCT method 
was used for quantification. Mean±SEM. Our results indicated that Hes1 and Hey2 were 
downregulated by: (A) 53% (student t test, *P<3X10
-5
, n=4) and 54% (student t test, **P<4X10
-5
, 
n=4) respectively in 5μM DAPT treatment for 24h, (B) 43% (student t test, *P<0.02, n=3) and 65% 
(student t test, **P<0.007, n=3) respectively in 25μM DAPT treatment for 12h, and (C) 48% 
(student t test, *P<0.0007, n=3) and 41% (student t test, **P<0.002, n=3) respectively in 25μM 
DAPT treatment for 24h.  
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iii. Upregulation of MCT1 by the canonical Wnt/β-catenin signaling pathway 
requires Notch participation in RBE4 cells.  
Numerous studies have suggested a crosstalk between Wnt and Notch signaling 
pathways in a variety of biological conditions, either repressively or cooperatively. Here 
we wanted to ask if an interaction between the two pathways also exists in RBE4 cells in 
regulating MCT1’s protein expression. Cells were co-treated with 20mM LiCl and 5μM or 
25μM DAPT for 24h. Western blotting showed that the expected upregulation of MCT1’s 
protein level by 20mM LiCl was reduced by co-treatment with 5μM DAPT and negated 
by 25μM DAPT (Figure IV-6). These results indicated that although inhibition of Notch 
pathway by DAPT alone increased MCT1’s protein expression, intact Notch activity is 
required for MCT1’s upregulation by the Wnt pathway, implying a cooperative role 
between them.  
In order to confirm the observed interaction between Wnt and Notch pathways in RBE4 
cells, we treated cells with either 20mM NaCl or LiCl for 24h; then qRT-PCR was 
performed to examine any changes in the expression levels of players in Notch pathway, 
namely receptors, ligands and target genes. Our results showed that compared with 
NaCl control, LiCl upregulated Notch4, Dll3, Dll4 and Hes7 expression significantly, thus 
promoting Notch signaling transduction (Figure IV-7 A-D). Surprisingly, another Notch 
target gene, Hey2, was found to be downregulated by LiCl treatment (Figure IV-7 E). In 
conclusion, the interplay between Wnt and Notch pathways is complicated in RBE4 cells, 
with evidences supporting both a cooperative and a repressive role.  
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Figure IV-6: Interaction between Wnt and Notch pathways in regulating brain endothelial 
MCT1 expression. RBE4 cells were treated for 24h with or without 20mM LiCl, in the presence 
or absence of 5μM or 25μM DAPT. Whole cellular proteins were then prepared and separated on 
SDS-PAGE, followed by immunoblotting against MCT1 and actin. Densitometry was used for 
quantification and expression changes were manifested as fold-changes over DMSO control. 
Mean±SEM. Our results indicated that 20mM LiCl elevated MCT1 expression by 57%, which was 
reduced by cotreatment with 5μM (25%) or 25μM (-8%) DAPT. (One-way ANOVA followed by 
Scheffe’s post hoc test, *P<0.05) 
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Figure IV-7: Regulation of Notch pathway by the canonical Wnt/β-catenin signaling. RBE4 
cells were treated with either vehicle control, or 20mM NaCl (osmotic control) or 20mM LiCl for 
24h. Total RNA was prepared and reverse transcribed. qRT-PCR results were first normalized to 
the internal standard Gapdh and then expressed as fold-changes over control, followed by ΔΔCT 
method for quantifiaction. Mean±SEM. Our results showed that Wnt pathway significantly 
upregulated the expression of: (A) Notch4 to 10-fold (student t test, *P<0.03, n=6); (B) Hes7 to 
3.5-fold (student t test, *P<0.0002, n=6); (C) Dll3 to 4-fold (student t test, *P<0.004, n=5); and (D) 
Dll4 to 16-fold (student t test, *P<0.04, n=5). In contrary, Wnt was found to downregulate another 
targe gene (E) Hey2 to 0.42-fold (student t test, *P<0.02, n=5).     
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Discussion: 
In this report, we investigated the regulatory effects of Notch pathway on brain 
endothelial MCT1’s expression. Blockage of Notch signaling via the γ-secretase inhibitor 
DAPT increased MCT1’s protein level, while in the meantime it suppressed Notch target 
genes expression as expected. In addition, a cooperative interaction was observed 
between Wnt and Notch signaling pathways on modulating brain endothelial MCT1’s 
expression. Specifically, the observed upregulation of MCT1 by Wnt requires Notch 
activity, as inhibition of the latter by γ-secretase inhibitor (GSI) DAPT negates Wnt’s 
effect (Figure IV-8). Our findings of the modulatory effect of Notch activity on a nutrient 
transporter in brain endothelial cells are not surprising given the important role of this 
pathway in the normal development of vasculature (351). In addition, modulation of 
Notch activity in endothelial cells can control glycolytic switch via different signaling 
processes, one of which is downregulation of p53 signaling after Notch inhibition (352, 
353). In fact, MCT1 expression was found to be upregulated by hypoxia only in the 
absence of p53, mediated via NF-kB signaling pathway in cervix, breast and colon 
cancer cell lines (110). Lactate can accumulate intensively after glycolysis as well as 
within hypoxic conditions. In skeletal muscle L6 cells, addition of lactate increased MCT1 
expression at both mRNA and protein levels within 1h (126). Besides, lactate produced 
by tumor cells can be uptaken by human mesenchymal stem cells to increase their 
MCT1’s expression (127). Further research should shed lights on better understanding 
the molecular mechanisms of how Notch signaling modulates brain endothelial MCT1, 
e.g. transcriptionally, post-transcriptionally or post-translationally.  
The cooperative interaction between Wnt and Notch pathways on regulating brain 
endothelial MCT1 observed in our study is supported by the well established notion that 
these two signaling processes cross talk with each other in a variety of biological 
conditions, as covered in the Introduction session at the beginning. In accordance with 
our observation that the upregulation of brain endothelial MCT1 requires the participation 
of Notch signaling, previous research in mouse embryonic stem cells found that 
inhibition of Notch by DAPT caused a significant reduction of active β-catenin activity 
and its protein levels (346), thus quenching Wnt signaling transduction. Besides, Notch 
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is found downstream of Wnt in colorectal cancer cells through β-catenin-mediated 
transcriptional activation of Notch-ligand Jagged 1. The fully bloomed intestinal 
tumorigenesis by genetically activated Wnt/β-catenin signaling requires Notch activity 
(341). Further research showed that the effect of Wnt activation via LiCl on cell cycle 
progression in non-small-cell lung cancer cells was attenuated by siRNA knockdown of 
Notch3 signaling, confirming that a cooperative interaction exists between Wnt and 
Notch (354). Conversely, in the absence of DAPT, which guarantees an intact Notch 
signaling transduction, Wnt activation successfully increased MCT1’s expression, 
whereas in the presence of that γ-secretase inhibitor, this modulatory effect disappeared. 
As a consequence, another way of interpretating our results is that the canonical Wnt/β-
catenin pathway needs to act under the umbrella of an intact Notch signaling in order to 
regulate MCT1 in RBE4 cells. Indeed, Notch1 signaling was found to act upstream of 
Wnt pathway by stabilizing β-catenin during the progression of primary melanoma (355). 
Inhibition of γ-secretase causes the cellular equilibium between membrane bound Notch 
receptors and those undergoing proteolytic cleavage to be in favor of the former. Notch 
receptors within the plasma membrane were found to bind active β-catenin; together 
they go into lysosomal degradation system, thus reducing cytoplasmic β-catenin level 
(346). Further confirming a reciprocal reliance of Wnt and Notch pathways, previous 
research in colorectal tumorigenesis showed that intestinal proliferation phenotype 
induced by activation of Notch requires TCF4, the important Wnt effector, indicating that 
only cells in which the Wnt signaling remains “intact” are competent to respond to Notch 
stimulation (347). 
Our additional qRT-PCR data showing the upregulation of Notch4, Dll3, Dll4 and Hes7 
by Wnt activation (Figure IV-7 A-D), correlate well with: (1) the critical role of canonical 
Wnt signaling in normal blood-brain barrier development (275, 276) and the essential 
function of Notch signaling in vasculature formation, especially mediated through Notch4 
receptor (351, 356) and Dll4 ligand (334, 335); (2) the cooperative interaction between 
Wnt and Notch signaling activity. Surprisingly, Wnt activation didn’t change Hes1’s 
transcriptional level (data not shown), the classic Notch target gene that was actually 
found decreased by DAPT treatment in our current study (Figure IV-5). In addition, 
another Notch target Hey2 was found downregulated by Wnt pathway, suggesting an 
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antagonizing role of Wnt on Notch signaling (Figure IV-7 E). In fact, not all the Notch 
components are regulated by the Wnt/β-catenin signaling. For example, in adenomas 
from genetically modified APC+/- mice, only a subset of Notch receptors (Notch1, 2 and 4) 
and ligands (Jagged1 and 2, Dll4) were upregulated by loss of APC allele (340). 
Additionally, human Notch1, Jagged2, and Hey1 do not contain any putative LEF-1/TCF-
site. Semi-quantitative PCR results showed that suppression of Wnt activity by 
ectopically expressing wild type APC in HT29 cells failed to change most of Notch 
pathway genes transcriptional level, even though they contain putative LEF-1/TCF 
elements in their promoters (357). Even strikingly, Hes7, one of Notch targets and also 
upregulated in our data by Wnt signaling, was found to inhibit periodically selected Notch 
downstream target genes transcription e.g. Hes7 itself and Lfng, during the control of 
segamentation clock (358). This finding supports our observation that Hey2 was 
suppressed by Wnt pathway, possibly as a result of Notch feedback regulation. Another 
possible explanation for heterogeneous responses of Notch pathway genes to Wnt 
activation arises from the way it was manipulated. LiCl targets and inhibits GSK3-β, a 
convergent point of multiple signaling pathways in addition to β-catenin, such as PKA, 
PI3K-AKT, MAPK-MAPKPK1, mTORC1 and Myc transcription factor (359). Alteration of 
GSK3-β activity in our study may cause other associated signaling routes to respond 
accordingly in order to maintain the final expression levels of particular target genes. So 
it is very likely that inhibiting GSK3-β causes integration of other signaling branches to 
negate any effects caused by one of them. Indeed, Hes1 can be activated by other 
pathways besides Notch, like Sonic Hedgehog, IkBa and Ras/MAPK (340). Application 
of downstream activators more specific to Wnt pathway may help resolve this issue.    
The molecular mechanisms underlying the complicated cross-talk between Wnt and 
Notch pathways have received intensive investigations and generated a better 
understanding. For example, early insights on how Wnt signaling exerts an inhibitory 
effect on Notch signaling came from studies in Drosophila, where a physical binding of 
Dishevelled to NICD inhibits the latter-mediated Notch activity by disrupting the ability of 
NICD to act as a transcriptional regulatory factor in the nucleus (360). Besides, GSK3-β 
was found to bind and phosphorylate Notch1 intracellular domain, leading to the 
stabilization of NICD by preventing its entry into proteasomal degradation (361). One 
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mechanism of Wnt activating Notch was demonstrated as downregulating one of the 
latter’s negative target Atoh1 (340). Conversely, Notch1 signaling suppressed the 
expression of Wnt target genes in colorectal cancer via epigenetic modification through 
recruiting histone methyltransferase (338). In addition, these two pathways have been 
shown to share common cofactors in the nucleus, such as Mastermind (MAML) (362). 
Although a wealth of knowledge has been obtained on Wnt-Notch interaction, the 
detailed mechanism of how they precisely orchestrate each other in order to determine 
cell fates during development and tissue self-renewal still remains elusive and merits 
further research.  
Another contribution of our work here is to generate for the first time a complete gene 
expression profile of Notch ligands, receptors and some of the major downstream target 
genes in RBE4 cells, an in vitro model of BBB. These data shall be the basis for future 
studies on Notch signaling in brain endothelial cells.  
 
Figure IV-8: Summary of 
MCT1’s regluation within 
the endosomal-lysosomal 
system by the canonical 
Wnt/β-catenin and Notch 
signaling pathways. Left 
side: in resting cells, MCT1 
is first internalized into early 
endosomes (E.E). From here, 
MCT1 could be sorted into 
either recycling endosomes 
(R.E) for its redistribution on the plasma membrane, or into late endosomes and lysosomes 
(LE/LYS) for degradation. Right side: Activation of Wnt pathway through inhibiting GSK-3β by LiCl 
leads to nuclear β-catenin signaling and increased expression of MCT1 on the plasma membrane, 
presumably through either enhanced recycling rate via R.E or reduced degradation in LE/LYS or 
both. This regulation of MCT1 by Wnt pathway acts in a Notch signaling-dependent manner. FZD: 
Frizzled receptor; NICD: Notch intracellular domain; Mam: Mastermind.  
  98 
 
 
 
 
 
 
 
Chapter V 
Inhibition of MCT1 by small molecules: Metabolic blockage of 
MCT1 in human peripheral blood mononuclear cells (hPBMCs) 
 
 
 
 
 
 
 
 
  99 
Introduction: 
Metabolism is one of the most ancient functional features of cells to fulfill bioenergetic 
and biosynthetic demands, especially during active processes such as cellular growth 
and proliferation (363). As the primary source of nutrient under normal circumstances, 
intracellular glucose is usually broken down first by glycolysis to generate pyruvate 
through multiple intermediate metabolites that can be harnessed by different synthetic 
pathways as building blocks for bio-molecules, such as nucleotides via pentose 
phosphate pathway, amino acids using glycerate-3-phosphate and hexosamine from 
fructose-6-phosphate. In the presence of oxygen, pyruvate is fully consumed within 
mitochondria through tricarboxylic acid (TCA) cycle followed by oxidative 
phosphorylation to generate affluent ATP. In contrast, lack of oxygen diverts pyruvate 
into fermentative reaction and produces only 2 net ATP per glucose entry. Thus, 
glycolysis is generally considered as an inefficient way of generating cellular energy. 
As the central part of adaptive immune response, T lymphocytes (naïve and memory T 
cells) undergo rapid and extensive clonal expansion after receiving antigen stimulation, 
accompanied by a metabolic switch from β-oxidation of fatty acids to glycolysis and 
glutaminolysis in order to support their proliferation, growth as well as effector functions 
(364, 365). Increased glucose utilization through glycolysis in activated T cells, even in 
the presence of plenty oxygen, is believed to provide metabolic intermediates to elevate 
biosynthetic machineries for the production of proteins, nucleic acids, lipids and other 
building blocks for cellular growth as well as for generating new cells (363). The energy 
demand of T cells under reprogrammed metabolism that impairs normal energy 
production from oxidative phosphorylation, is partially rescued by ATP molecules 
generated during aerobic glycolysis as well as those from mitochondrial function fueled 
by α-ketoglutarate that is derived from glutamine (366). The enhanced aerobic glycolysis 
results in extensive intracellular accumulation of lactate, which must be removed quickly, 
presumably by MCTs, to prevent feedback inhibition on glycolytic pathway as well as a 
detrimental acidic environment. Indeed, both MCT1 and 4 were found to be present on T 
lymphocytes and their expression levels were elevated upon T cells activation (184). 
Strikingly, MCT1 on activated T cells was demonstrated to be a novel target for 
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suppressing their proliferation at the extremely rapid phase triggered by antigens (184). 
As a result, MCT1 possesses the potential to be a therapeutic target for 
immunosuppressant during acute immune reactions, such as organ transplantation.  
The most commonly used MCT inhibitor, alpha-cyano-4-hydroxycinnamate (α-CHC), 
was first identified as an inhibitor to mitochondrial pyruvate transport (367). Later kinetics 
studies demonstrated that the K0.5 of α-CHC on 5mM L-lactate transport through MCT1 
was 166μM (223). Besides, α-CHC is not specific to MCT1, but it also inhibits other 
MCTs, such as MCT2 and MCT4 (151, 160). In order to find more potent inhibitors that 
can block MCT1, more than 250 α-CHC analogues were synthesized and tested on 
RBE4 cells for their capacity to inhibit L-lactate transport. RBE4 cells predominantly 
express MCT1 than other MCT isoforms (67, 174), thus they are ideal model to screen 
for MCT1 inhibitors. Three potent lead compounds with high affinity and low EC50 values 
in the range of 3-8nM were discovered. Their structures have more than 20,000 times 
greater affinity than α-CHC for MCT1 and are designated MD1, MD2 and MD3. In this 
study, we examined MD1’s potency in suppressing human peripheral blood 
mononuclear cells (hPBMCs) proliferation upon antigen stimulation by phorbol myristate 
acetate (PMA) and ionomycin. hPBMCs are a group of blood cells, including 
lymphocytes, monocytes and macrophages, which are critical component in the immune 
system to fight infection and have been used as a model to study adaptive immune 
response to antigen challenging (184).     
 
Materials and Methods: 
Human Peripheral Blood Mononuclear Cells (hPBMCs) preparation and culture.  
hPBMCs were isolated from blood samples of a healthy male donor, using the 
LymphoprepTM Tube (Cosmo Bio USA; #AXS-1019818). Specifically, fresh blood 
samples were first mixed with 20% volume anticoagulant ACD-A (22g/L sodium citrate 
tribasic dihydrate; 7.3g/L Citric acid anhydrous; 24.5g/L dextrose); then they were diluted 
1:1 with equal volume of sterile 0.9% saline solution. After that, the diluted blood was 
applied to LymphoprepTM Tubes and centrifuged at room temperature for 15min at 800xg. 
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hPBMCs were thus collected from a distinct layer within the tube. They were frozen in 
growth medium plus 10% DMSO (Sigma-Aldrich; #D2650) and stored in liquid nitrogen 
until use.     
hPBMCs were cultured in their growth medium consisting of RPMI 1640 medium 
(Invitrogen; # 11835-030), supplemented with 10% FBS (Atlanta Biologicals; #S11150H), 
2mM L-glutamine (Invitrogen; # 25030081), 1X Non-Essential Amino Acids (Invitrogen; # 
11140-050), 1mM sodium pyruvate (Invitrogen; # 11360070) and 1X β-mercaptoethanol 
(Invitrogen; # 21985-023). Cells were kept in a humidified incubator at 37oC with 5% CO2.  
Reagent stocks. 1mg/ml phorbol myristate acetate (PMA) (Sigma-Aldrich; #P8139), 
1mg/ml ionomycin (Sigma-Aldrich; #I0634), 40mM cyclosporin A (Sigma-Aldrich; #30024) 
and 100mM MD1 (University of Minnesota Duluth; V.Mereddy’s lab) stocks were all 
dissolved in DMSO and stored in -80oC freezer until use, except for MD1 that was stored 
at room temperature.     
Proliferation assays. 2X 105 hPBMCs cells were plated into each well of 96-well plates 
(Corning; #3595). The next day, equal volume of growth medium containing 1ng/ml 
phorbol myristate acetate (PMA) and 1μg/ml ionomycin, with either DMSO vehicle 
control or 2X MD1 compound was added into each well, making the final growth medium 
with 0.5ng/ml PMA and 500ng/ml ionomycin, with either DMSO vehicle control or MD1 
compound at the desired concentration (2nM, 10nM, 50nM, 250nM, 1μM, 5μM, 25μM, 
50μM, 75μM or 100μM). Cyclosporin A was used instead of MD1 as a positive control at 
a final concentration of 2nM, 10nM, 50nM, 250nM, 1μM, 5μM or 25μM. Cells were 
incubated for 72 hours, after which they were aspirated off the old medium and frozen at 
-80oC overnight up to two weeks. Cyquant proliferation assay was conducted according 
to the manufacturer’s instruction (Invitrogen; #7026). Basically, the whole 96-well plates 
were thawed at room temperature and incubated with 200μl per well of the provided 1X 
lysis buffer supplemented with 1X green fluorescent GR dye that binds nucleic acids. 
The samples fluorescence then was measured directly at a Synergy 2 multi-mode 
microplate reader (Biotek) with filters for ~480nm excitation and ~520nm emission.   
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Results: 
In order to test our novel MCT1 inhibitor (MD1)’s potency in suppressing immune 
response, human peripheral blood mononuclear cells (hPBMCs) were isolated from a 
healthy donor, and stimulated by antigens of 0.5ng/ml PMA and 500ng/ml ionomycin for 
72 hours, in the presence or absence of MD1 at various concentrations (2nM, 10nM, 
50nM, 250nM, 1μM, 5μM, 25μM, 50μM, 75μM or 100μM). In the control group, hPBMCs 
remained in a quiescent state without any changes in the quantity of cells. Addition of 
antigens stimulated hPBMCs to proliferate and thus aggregate into small individual 
clusters (clonal expansion), as observed under light microscope (Figure V-1 A and B). 
However, cotreatment with MD1 inhibitors at various concentrations didn’t change the 
proliferation status of hPBMCs stimulated by antigens (Figure V-1 C-I), unless relatively 
high concentrations were applied (Figure V-1 J-L). Cyquant proliferation assay results 
corroborated our microscopic observation and showed that PMA/ionomycin successfully 
stimulated hPBMCs to proliferate by ~175%, which was only inhibited by cotreatment 
with MD1 at concentrations ≥50μM. Specifically, 50μM, 75μM, and 100μM MD1 caused 
63%, 62% and 95% inhibition on hPBMCs proliferation that was stimulated by antigens 
(Figure V-2). Cyclosporin A, a commonly used immunosuppressant drug, was able to 
inhibit hPBMCs proliferation by antigens at expected concentrations as low as 50nM, 
which was presented by both microscopy (Figure V-3) and Cyquant assay (Figure V-4), 
indicating that the novel MCT1 inhibitor, MD1, is less potent than cyclosporin A in 
suppressing immune response of hPBMCs.   
 
Discussion: 
Our results showed that a novel MCT1 inhibitor (MD1) suppressed proliferation of 
hPBMCs stimulated by PMA/ionomycin, only at high concentrations above 50μM, 
despite of the fact that it could inhibit L-lactate transport with an EC50 value of 6nM in 
RBE4 cells. Cyclosoprin A was included as a positive control in our current study, 
because it has been widely used as an immunosuppressant drug in clinic. The working 
concentration of cyclosporin A (≥50nM) in blocking PBMCs proliferation correlates well 
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with its role as a strong T-cell receptor signaling blocker and supported by previous 
similar research conducted by Astra Zeneca (184). In that same study, the authors used 
their newly designed immunosuppressive drugs to inhibit T lymphocytes proliferation by 
targeting MCT1 with an IC50 value being ~10nM. The EC50 value of that compound 
analogue was found to be 0.28-0.44nM for inhibiting lactate transport out of activated 
hPBMCs.   
The huge difference between EC50 of MD1 in inhibiting lactate transport in RBE4 cells 
(6nM) and its working concentration for suppressing activated hPBMCs proliferation 
(50μM) as observed in the current study, suggests that our compound may work 
differently from the ones developed by Astra Zeneca. In fact, α-CHC was first described 
as a potent mitochondrial pyruvate transport inhibitor (Ki=6μM); in addition, it inhibits 
pyruvate transport into human erythrocytes more strongly than lactate (367). It is thus 
likely that our MD1, an analog of α-CHC, may function similarly in activated T cells by 
preferentially binding with pyruvate transporters on mitochondria, sparing MCT1 on 
cellular surface intact. MCT2 has a much higher affinity for monocarboxylate substrates, 
such as lactate and pyruvate, than MCT1. The same difference has been observed for 
the MCT inhibitor α-CHC (IC50=425μM for rat MCT1 vs IC50=24μM for rat MCT2) (368). 
Amazingly, Murray et al (184) showed that MCT2 ectopic expression in INS1 cells didn’t 
contribute to L-lactate transport. Besides, their compounds were found to bind 
selectively with MCT1 over MCT2, partially explaining for the high sensitivity of activated 
T lymphocytes to their novel compounds. In contrast, our MD1 compound may be 
enriched at MCT2 binding sites on activated T lymphocytes and thus does not affect 
lactate transport via MCT1 when administrated at low concentrations. Additional kinetics 
studies of our MD compounds on different MCT isoforms (e.g. affinities, specificities et al) 
shall help shed lights on the mechanisms of their actions.     
Although MCTs are generally considered as bi-directional facilitators for 
monocarboxylates down their concentration gradient across cellular membrane, MCT1 is 
thought to be more prone for importing substrates, whereas MCT4 assumes more an 
exporting role. Initial insights came from studies where MCT1 was found more 
predominantly expressed on type I fibers in red skeletal muscle as well as in cardical 
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muscles (88-90), while MCT4 was correlated with type II fiber composition in glycolytic 
white muscles (141). Maybe the inhibition of MCT1 by MD1 in the context of glycolytic 
burst within activated T cells, where efflux of lactate predominates, is not so sensitive to 
the other direction in lactate uptake assay originally conducted in RBE4 cells. MCTs 
require ancillary proteins for assisted trafficking from intracellular compartments onto 
plasma membrane, such as CD147 or embigin for MCT1 and MCT4 (50), embigin or 
CD147 for MCT2 (52, 53). As a consequence, some inhibitors can target the ancillary 
proteins for suppressing MCTs transport function. For example, pCMBS inhibits MCT1 
and MCT4 activity through targeting CD147, causing dissociation of these proteins by 
modifying the disulfide bridge in the Ig-like C2 domain of CD147 (52). So it is possible 
that MD1 inhibits MCT1 though targeting its ancillary proteins with different capacities in 
RBE4 cells and activated T lymphocytes.  
Our results that coincubation of antigens with MD1 didn’t inhibit T lymphocytes activation 
in 72 hours, can be supported by the observation from Murray et al (184) that, incubation 
of T cells with their potent compounds from the time of activation showed no change in 
intracellular pH (pHi) compared with control cells over 72 hours. This puzzling 
phenomenon may indicate that inhibition of MCT1 by our MD1 stimulates other 
pathways within T cells to compensate for lactic acidosis-induced pH drop as well as 
proliferation arrest. In addition, our MD1 compound may act through modulating other 
signaling pathways, e.g. cytokine (interleukin-2) production or CD25 expression to shut 
down immune response, than simply blocking lactate efflux on cellular surface. Different 
mechanisms may require diverse thresholds of MD1 to be effective. Future research on 
lactate production, intracellular accumulation and MD1 binding assays during T cells 
activation are necessary to clarify the novel inhibitor’s working mechanism.   
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Figure V-1. Microscopic images of hPBMCs stimulated by antigens with or without MD1. 
2x10
5
 hPBMCs were cultured for 72 h in the growth medium supplemented with DMSO (A), or 
stimulated with 0.5ng/ml PMA and 500ng/ml ionomycin (B-L) in the presence of DMSO vehicle 
control (B), or MD1 at concentrations of 2nM (C), 10nM (D), 50nM (E), 250nM (F), 1μM (G), 5μM 
(H), 25μM (I), 50μM (J), 75μM (K) or 100μM (L). Our observations indicated that, compared with 
resting control (A), antigens stimulated hPBMCs proliferation and subsequent aggregation (B), 
which was only suppressed by cotreatment with MD1 starting from 50μM (J-L).  
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Figure V-2. Effects of MD1 on hPBMCs proliferation. hPBMCs proliferation was measured by 
DNA content using Cyquant assay. Data were expressed as fold-changes over control and 
presented as mean±SEM. (A) hPBMCs were cultured for 72h in the growth medium 
supplemented with DMSO, or stimulated with 0.5ng/ml PMA and 500ng/ml ionomycin (referred to 
as antigens). Antigens stimulated hPBMCs to proliferate up to 2.8-fold (Student t test, *P<0.0001, 
n=7). (B) Antigens were coincubated with DMSO or MD1 at concentrations indicated on the x-
axis. MD1 was able to suppress hPBMCs proliferation capacities only at 50μM or higher. 
Specifically, 50μM MD1 reduced the proliferation capacity of stimulated hPBMCs to 1.98-fold (63% 
inhibition); 75μM MD1 reduced that to 1.69-fold (62% inhibition) and 100μM reduced that to 1.42-
fold (95% inhibition) (one-way ANOVA, followed by Fisher’s LSD post hoc test, *P <0.05, n≥4). 
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Figure V-3. Microscopic images of hPBMCs stimulated by antigens with or without 
cyclosporin A. 2x10
5
 hPBMCs were cultured for 72 h in the growth medium supplemented with 
DMSO (A), or stimulated with 0.5ng/ml PMA and 500ng/ml ionomycin (B-I) in the presence of 
DMSO vehicle control (B), or cyclosporin A at concentrations of 2nM (C), 10nM (D), 50nM (E), 
250nM (F), 1μM (G), 5μM (H), 25μM (I). Our observations indicated that, compared with resting 
control (A), antigens stimulated hPBMCs proliferation and subsequent aggregation (B), which 
was suppressed by cotreatment with cyclosporin A starting from as low as 50nM (E), as expected.  
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Figure V-4. Effects of cyclosporin A (CsA) on hPBMCs proliferation. hPBMCs proliferation 
was measured by DNA content using Cyquant assay. Data were expressed as fold-changes over 
control and presented as mean±SEM. (A) hPBMCs were cultured for 72h in the growth medium 
supplemented with DMSO, or stimulated with 0.5ng/ml PMA and 500ng/ml ionomycin (referred to 
as antigens). Antigens stimulated hPBMCs to proliferate up to 2.4-fold (Student t test, *P<0.04, 
n=3). (B) Antigens were coincubated with DMSO or CsA at concentrations indicated on the x-axis. 
CsA was able to suppress hPBMCs proliferation capacities at expected concentrations as low as 
50nM. Specifically, 50nM CsA reduced the proliferation capacity of stimulated hPBMCs to 1.22-
fold; 250nM CsA reduced that to 1.22-fold; 1μM reduced that to 1.22-fold; 5μM reduced that to 
1.21-fold and 25μM reduced that to 1.47-fold (one-way ANOVA, followed by Tukey post hoc test, 
*P <0.05, n=3). 
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Chapter VI 
Inhibition of MCT1 by small molecules: Metabolic blockage of 
MCT1 on tumor cells proliferation in selected cancer cell lines 
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Introduction: 
Cancer cells rely on aerobic glycolysis, a reprogrammed metabolic phenotype adopted 
by fast dividing cells, to support their rapid proliferation rate and anabolic demands, a 
phenomenon known as “Warburg effect” (311). Although glucose consumed in this way 
rapidly generates ATP in a relatively inefficient manner, glycolytic intermediates along 
the pathway can be enriched and diverted into various precursors as “building blocks” for 
synthesizing big biomolecules that are necessary for cell dividing or growth, such as 
lipids, nucleic acids and proteins (369).  As a consequence of this metabolic switch, 
glucose is preferentially catabolized to lactate, rather than being fully oxidized in 
mitochondria. In addition, glutamine in cancer cells can be first converted to glutamate, 
then α-ketoglutarate and thus serves as an important carbon source to sustain 
mitochondrial TCA cycle as well as to maintain redox homeostasis (370). Malate 
generated from this α-ketoglutarate can exit the TCA cycle and be converted to pyruvate, 
which then can be converted to lactate by lactate dehydrogenase A (LDHA). Overall, 
lactate is excessively produced in cancer cells due to altered metabolism. The 
maintenance of a normal lactate homeostasis that is critical for an intracellular 
environment with physiological pH, requires its prompt transport together with a proton 
out of cells via MCTs (371).    
Conversely, the influx of lactate through MCTs has also been strongly implicated in 
tumorigenesis and cancer progression. Imported lactate can be used as an energy 
source for oxidation, promoting tumor inflammation, stimulating tumor angiogenesis as 
well as functioning as a signaling molecule that regulates multiple signaling pathways 
(74, 75, 87, 185). Three lactate shuttles have been proposed in cancerous condition. 
The first reverse Warburg effect model suggests that cancer cells secret hydrogen 
peroxide to create a pseudo-hypoxic environment to neighboring stromal cells, which are 
then adapted for aerobic glycolysis and export lactate back to cancer cells as oxidative 
fuel. The second metabolic symbiosis model indicates that cancer cells in hypoxic core 
of a tumor consume glucose through glycolysis to generate lactate, which is then 
excreted out into peripheral cancer cells with an oxidative metabolism. The third 
vascular-endothelial model implies that lactate generated from tumor cells through 
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glycolysis is delivered into endothelial cells, where it functions as a signaling molecule 
after being converted to pyruvate. The underlying mechanism is believed to be via the 
inhibitory effect of pyruvate on prolylhydroxylases (PHDs), the negative regulator of HIF-
1α pathway. MCT1 and 4 actively participate in the above mentioned models by 
facilitating lactate influx and efflux, respectively. As a result, they possess great 
therapeutic potentials as the targeting sites for cancer treatment (371).     
Previous research has investigated the effect of blocking MCTs and their ancillary 
chaperones on tumor cells, through both genetic knockdown and development of small-
molecule inhibitors. Specifically, application of α-CHC in glioblastoma (GLB) cells 
impaired their proliferation, migration and survival (372, 373). Furthermore, α-CHC 
inhibited lactic acid extrusion from GLB cells implanted into immunodeficient rats and 
reduced their invasion (374). In a mouse model of lung carcinoma and xenotransplanted 
human colorectal adenocarcinoma cells, administration of α-CHC retarded tumor growth, 
due to a forced metabolic switch from lactate-fueled respiration to glycolysis in 
oxygenated tumor cells (185). More strikingly, one of the highly potent MCT1/MCT2 
inhibitors (AZD3965) originally developed by Astra Zeneca is now under Phase I clinical 
trials for advanced solid tumors, prostate cancer, gastric cancer and diffuse-Large B cell 
lymphoma (375). Our novel MD inhibitors were analogs originally derived from α-CHC 
but exhibited substantially stronger potency in blocking L-lactate transport. Besides, 
based on T lymphocytes proliferation assay, our MD1 compound seems to work 
differently from the inhibitors developed by Astra Zeneca. As a consequence, we 
decided to study MD1’s role in suppressing proliferation of multiple cancer cell lines 
under both normoxic and hypoxic culturing conditions.         
 
Materials and Methods: 
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Normoxic and hypoxic cell culture.4 SW480 cells were cultured in DMEM (Invitrogen 
#12491-015), supplemented with 10% FBS and 2mM L-Glutamine. MDA231 and GL261 
cells were cultured in DMEM supplemented with 10% FBS. H4IIE cells were cultured in 
MEM-α, supplemented with 10% FBS. For normoxic culturing condition, cells were kept 
in a humidified incubator at 37oC with 5% CO2, whereas for hypoxic culturing, a 
humidified modular incubator chamber (Billups-rothenberg) was sealed with hypoxic air 
(Praxair; 1% oxygen, 5% CO2 and 94% nitrogen) and put inside a 37oC environment.    
Proliferation assay. 1X104 cells were seeded into each well of 96-well plates (Corning; 
#3595) and cultured under normoxic condition first. At least 18 hours later, cells were 
treated with either DMSO control or various concentrations of MD1 (2nM, 10nM, 50nM, 
250nM, 1μM, 5μM and 25μM) for 48 hours, at either normoxic or hypoxic culturing 
condition. Then the cells were derived of old medium and frozen in -80oC for at least 24 
hours up to a week. Cyquant proliferation assay was conducted according to the 
manufacturer’s instruction (Invitrogen; #7026). Basically, the whole 96-well plates were 
thawed at room temperature and incubated with 200μl per well of the provided 1X lysis 
buffer supplemented with 1X green fluorescent GR dye that binds nucleic acids. The 
samples fluorescence then was measured directly at a Synergy 2 multi-mode microplate 
reader (Biotek) with filters for ~480nm excitation and ~520nm emission.   
 
Results: 
To test our novel MCT1 inhibitor (MD1)’s ability to affect tumor cells proliferation capacity, 
we treated SW480 human colorectal cancer cells, MDA231 human breast cancer cells, 
GL261 mouse glioma cells and H4IIE rat hepatoma cells with either DMSO control or 
MD1 at various concentrations (1μM, 5μM or 25μM) and put them in either normoxia or 
hypoxic culturing conditions to proliferate for 48 hours. Both bright light microscopy 
                                                             
4 We deeply thank Dr. R. Cormier, Dr. T. Rose-Hellekant, Dr. A. Johnson and Dr. K. Wallace for 
providing SW480, MDA231, GL261 and H4IIE cell lines, respectively.   
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imaging and cyquant assay were then applied to evaluate those cells proliferation 
capacities. Our results indicated that MD1 inhibited SW480 cells proliferation only at 
25μM concentration under hypoxic conditions (Figure VI-2 A and D), although an 
obvious reduction of cell numbers was also observed in normoxic groups (Figure VI-1 A 
and D), as revealed by microscopy. These results were corroborated by Cyquant 
proliferation assay, where compared with DMSO control, 25μM MD1 inhibited SW480 
cells proliferation under hypoxic condition (Figure VI-3, *P<0.05). Interestingly, although 
no significant inhibition by MD1 was observed at lower concentrations under hypoxic 
culturing condition, hypoxia generally tends to sensitize SW480 cells to MCT1 inhibition 
(Figure VI-3, F(1,24)=3.1, P=0.08).   
H4IIE cells proliferation was not inhibited by MD1 at any of the concentrations used here 
under normoxic condition (Figure VI-4 A-D), whereas in hypoxic culturing, they were 
effectively inhibited at both 5μM and 25μM concentrations (Figure VI-5 A-D; Figure VI-6; 
*P<0.05). Strikingly, hypoxia significantly sensitized H4IIE cells to MCT1 inhibition 
(Figure VI-6, F(1,24)=16, φP=0.0005). However, no significant inhibition by MD1 was 
observed in MDA231 or GL261 cells under either culturing condition (Figure VI-7 and 8). 
Unexpectedly, 1μM MD1 was found to stimulate tumor cells proliferation in both SW480 
(Figure VI-3, *P<0.05) and H4IIE cells (Figure VI-6, *P<0.05) under normoxic condition. 
 
Discussion: 
In this study, we investigated the inhibitory effect of MD1, a more potent analog of α-
CHC, on the proliferation capacity of different tumor cell lines under either normoxic or 
hypoxic culturing condition, presumably through disrupting MCTs function. Our results 
showed that MD1 suppressed the proliferation capacity of SW480 colorectal cancer cells 
at 25μM under hypoxic condition, but not in normoxic condition. Similarly, it also inhibited 
H4IIE hepatoma cells at both 5μM and 25μM only under hypoxic condition. These 
findings are consistent with: (1) lactate homeostasis in tumor cells via its transport by 
MCTs plays a critical role in maintaining their reprogrammed metabolic phenotype that is 
required for fast proliferation (371); (2) hypoxia represents or emulates the in vivo tumor 
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environment and sensitizes tumor cells to therapeutic intervention aimed at targeting 
hypoxic metabolism. The latter is supported by the metabolic symbiosis model, where a 
tumor is composed of a hypoxic core and normoxic periphery. Hypoxic cells catabolize 
glucose molecules through glycolysis and export lactate for oxidation by peripheral cells 
(185). In fact, we found that compared with normoxic condition, hypoxia caused H4IIE 
cells and SW480 cells to be or tend to be sensitive to the same MD1 administrations.  
α-CHC has been tested as a therapeutic drug to arrest the proliferation, migration and 
invastion of glioblastoma cells in culture (372). Besides, after α-CHC treatment and 
subsequent exposure to low-dose irradiation, U87-MG gliomas became more 
susceptible to apoptosis (373). Temozolomide (TMZ) is widely used in clinic as an anti-
glioblastoma drug. A synergic interaction was observed between α-CHC and TMZ, 
where the former potentiates the latter, decreasing its IC50 value (372). Because of the 
low potency of α-CHC on inhibiting lactate transport, a relatively high working 
concentration range was used in the above studies, such as 5mM-25mM. Our MD1 
compound has a substantially stronger potency and was shown to inhibit tumor cells 
proliferation at concentrations as low as 25μM in the current study. Besides, according to 
our earlier findings from hPBMCs activation, MD1 at 25μM is not enough to inhibit T cells 
mediated immune response, which needs at least 50μM. Taken together, our novel MD1 
compound possesses great therapeutic potentials for treating aggressive tumors, while 
in the meantime, does not compromise immune system.   
Surprisingly, MDA231 breast cancer cells and GL261 mouse glioblastoma cells didn’t 
change their proliferation rates after MD1 treatment up to 25μM under normoxic or 
hypoxic culturing condition. This may be due to their low expression levels of MCT1 that 
is supposed to be the target of MD1. In fact, MDA231 cells have been shown to express 
predominantly MCT4 over MCT1 (376, 377), while MCTs expression profile in GL261 
cells is largely unknown. However, the affinity of MCT4 to α-CHC is known to be very 
low with IC50 being 350μM-1mM (154, 160), indicating that cells carrying abundant 
MCT4 may not be so sensitive to either α-CHC or its analogs. Although previous 
research has shown that glioblastoma cell lines could be inhibited by α-CHC to block 
their proliferation and invasion, they did not respond uniformly at all. For example, U251 
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cells were most sensitive to α-CHC with IC50 being 5.1mM, while another glioblastoma 
cell line SW1088 was the least sensitive cell line with an IC50 value of 10.8mM. The 
above mentioned difference is likely due to different levels of cellular surface MCT1 
expression (372). Similar difference was also observed in breast cancer cell lines. For 
instance, the metastatic MDA231 cells express limited amount of MCT1, while MCF-7 
breast cancer cells express abundant MCT1 (376). As a consequence, GL261 cell line 
may be among the glioblastoma cell lines that are least sensitive to MCT1 intervention. 
Our observation that H4IIE hepatoma cells responded most sensitively to MD1 
intervention under hypoxic condition correlates well with the previous finding that these 
cells contain significant amount of MCT1, as demonstrated in MCT:CD147 association 
study (50). Another explanation could be that MCT2 is much more sensitive to α-CHC 
inhibition than other MCTs, and MCT2 is readily expressed in liver cells (151, 378, 379). 
Another unexpected finding is that under normoxic condition, lower concentrations of 
MD1 treatment at 1μM caused increased proliferation in both SW480 and H4IIE cells. 
This may be explained by uncoupled glycolysis and mitochondrial oxidation through 
MD1 blocking pyruvate’s entry into mitochondria TCA cycle via mitochondrial pyruvate 
carriers (MPCs), which were originally demonstrated to have much higher affinity to α-
CHC than lactate (367). As a result, intracellular pyruvate generated from glycolysis is 
diverted to lactate, resembling aerobic glycolysis to support tumor cell growth and 
proliferation, like the role of pyruvate kinase 2 (380, 381). Further research on dissecting 
more possible targets of MD1 and its action sites in the cells would shed lights on and 
direct future studies to clarifying all the research questions mentioned above.    
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Figure VI-1: Microscopic images of SW480 cells with or without MD1 under normoxic 
culturing condition. 1x10
4
 cells per well were cultured in 96-well plate for 48h in the growth 
medium with DMSO (A), or in the presence of MD1 at concentrations of 1μM (B), 5μM (C), or 
25μM (D). Our observations indicated that, compared with control (A), the proliferation capacity of 
SW480 cells was not suppressed significantly by increasing concentrations of MD1.   
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Figure VI-2: Microscopic images of SW480 cells with or without MD1 under hypoxic 
culturing condition. 1x10
4
 cells per well were cultured in 96-well plate for 48h in the growth 
medium with DMSO (A), or in the presence of MD1 at concentrations of 1μM (B), 5μM (C), or 
25μM (D). Our observations indicated that, compared with control (A), the proliferation capacity of 
SW480 was suppressed by high concentrations of MD1.   
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Figure VI-3: Effects of MD1 on SW480 cells proliferation capacity. 1X10
4
 cells were seeded 
into each well of 96-well plate and cultured for 48h in the growth medium with DMSO, or in the 
presence of MD1 at concentrations of 1μM, 5μM, or 25μM, as shown on the x-axis. Results were 
presented as mean±SEM. Compared with baseline level, 25μM MD1 under hypoxic culturing 
condition (in darkred) reduced the proliferation of SW480 cells by 25% (Two-way ANOVA, 
followed by Fisher’s LSD post hoc test, *P<0.05). Compared with normoxic condition, hypoxia 
tend to sensitize SW480 cells response to MCT1 inhibition, thus to decrease their proliferation 
capacity (Two-way ANOVA, F(1,24)=3.1, P=0.08). Under normoxic condition (in blue), no reduction 
of cell numbers was abserved by any of the MD1 treatments. In contrast, 1μM MD1 was found to 
increase SW480 cells proliferation rate by 30% (Two-way ANOVA, followed by Fisher’s LSD post 
hoc test, *P<0.05).  
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Figure VI-4: Microscopic images of H4IIE cells with or without MD1 under normoxic 
culturing condition. 1x10
4
 cells per well were cultured in 96-well plate for 48h in the growth 
medium with DMSO (A), or in the presence of MD1 at concentrations of 1μM (B), 5μM (C), or 
25μM (D). Our observations indicated that, compared with control (A), the proliferation capacity of 
H4IIE, under normoxic condition, was not suppressed by MD1.  
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Figure VI-5: Microscopic images of H4IIE cells with or without MD1 under hypoxic 
culturing condition. 1x10
4
 cells per well were cultured in 96-well plate for 48h in the growth 
medium with DMSO (A), or in the presence of MD1 at concentrations of 1μM (B), 5μM (C), or 
25μM (D). Our observations indicated that, compared with control (A), the proliferation capacity of 
H4IIE, under hypoxic condition, was obviously suppressed by increasing concentrations of MD1.  
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Figure VI-6: Effects of MD1 on H4IIE cells proliferation capacity. 1X10
4
 cells were seeded 
into each well of 96-well plate and cultured for 48h in the growth medium with DMSO, or in the 
presence of MD1 at concentrations of 1μM, 5μM, or 25μM, as shown on the x-axis. Results were 
presented as mean±SEM. Compared with baseline level, 5μM and 25μM MD1 under hypoxic 
culturing condition (in darkred) reduced the proliferation of H4IIE cells by 17% and 21%, 
respectively (Two-way ANOVA, followed by Fisher’s LSD post hoc test, *P<0.05). Compared with 
normoxic condition, hypoxia sensitized H4IIE cells response to MCT1 inhibition, thus to decrease 
their proliferation capacity (Two-way ANOVA, F(1,24)=16, P=0.0005, followed by Fisher’s LSD post 
hoc test, *P<0.05). Under normoxic condition (in blue), no reduction of cell numbers was 
abserved by any of the MD1 treatments. In contrast, 1μM MD1 was also found to increase H4IIE 
cells proliferation rate by 19% (Two-way ANOVA, followed by Fisher’s LSD post hoc test, 
*P<0.05).  
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Figure VI-7. Effects of MD1 on MDA231 cells proliferation capacity. 1X10
4
 cells were seeded 
into each well of 96-well plate and cultured for 48h in the growth medium with DMSO, or in the 
presence of MD1 at concentrations of 1μM, 5μM, or 25μM, as shown on the x-axis. Results were 
presented as mean±SEM. Two-way ANOVA followed with Fisher’s LSD post hoc test showed 
that compared with DMSO baseline control, MD1 failed to affect MDA231 cells proliferation 
capacity at the given concentrations under either normoxic or hypoxic condition. In addition, 
hypoxia had no effect on MDA231 cells proliferation response to MCT1 inhibition (Two-way 
ANOVA, P=0.8>0.05).  
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Figure VI-8: Effects of MD1 on GL261 cells proliferation capacity. 1X10
4
 cells were seeded 
into each well of 96-well plate and cultured for 48h in the growth medium with DMSO, or in the 
presence of MD1 at concentrations of 1μM, 5μM, or 25μM, as shown on the x-axis. Results were 
presented as mean±SEM. Two-way ANOVA showed that compared with DMSO baseline control, 
MD1 failed to affect GL231 cells proliferation capacity at the given concentrations under either 
normoxic or hypoxic condition (P=0.56>0.05). In addition, hypoxia had no effect on GL261 cells 
proliferation response to MCT1 inhibition (Two-way ANOVA, P=0.6>0.05).  
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Summary 
The overall aim of this thesis was to elucidate multifunctional roles of monocarboxylate 
transporters (MCTs) and their diverse regulatory mechanisms. Within Chapter I, an 
updated review to all the known MCTs was presented, including solute carrier families 
SLC5, SLC16 as well as mitochondrial pyruvate carrier (MPC) family. We summarized 
their basic biological properties, various physiological functions, pharmaceutical drug 
transport potentials as well as numerous regulatory mechanisms. This chapter raises 
stimulation for novel research efforts to better understand and exploit these transporters 
functions.  
After that in Chapters II, III and IV, MCT1, the most ubiquitously expressed member was 
examined for its regulation by signaling pathways, such as cAMP-PKA, the canonical 
Wnt/β-catenin and Notch in immortalized rat brain endothelial cells. Specifically, we 
found that PKA activity led to a rapidly decreased phosphorylation and subsequent 
internalization of cellular surface MCT1 into early endosomes. This finding is consistent 
with and explanatory to our earlier observation that PKA caused a reduction of Vmax in 
MCT1-mediated lactate transporting kinetics in the same cell line. Additionally, as a 
potent modulator of blood-brain barrier development, Wnt/β-catenin signaling was 
hypothesized to regulate brain endothelial MCT1 expression. No changes in Mct1’s 
mRNA level were observed in this study. Instead, our findings indicated that this 
pathway increased MCT1’s protein level by decreasing its entry into endosomal-
lysosomal degradation system, thus retaining this transporter more on the cellular 
surface membrane. Ubiquitination may play an essential role during this process, 
because deubiquitinases (DUBs) inhibitors were also found able to positively modulate 
MCT1’s protein level. Accordingly, a polyubiquitin chain coding gene Ubb was identified 
by PCR analysis in RBE4 cells. To further our understanding of MCT1’s regulation by 
Wnt/β-catenin signaling, and given the well-known fact that a crosstalk has been 
demonstrated between the canonical Wnt/β-catenin and Notch pathways, we studied the 
regulatory effects of Notch on brain endothelial MCT1 expression. Our results showed 
that inhibition of Notch activity by a γ-secretase inhibitor DAPT enhanced MCT1’s 
protein expression. Interestingly, we also found that the previously observed regulatory 
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effect of Wnt/β-catenin on MCT1 requires an intact Notch activity, since MCT1’s 
upregulation by Wnt/β-catenin activation was negated in the presence of DAPT. This 
observed interaction was supported by our additional finding that activation of Wnt/β-
catenin modulated genes expression of Notch pathway in brain endothelium. 
In Chapter V and VI, we studied the role of MD1, an analog with substantially greater 
potency derived from the classic MCTs inhibitor α-CHC, in suppressing T cells mediated 
immune reaction and tumor cells proliferation, respectively. The biochemical basis 
underlying acquired immune response is that aerobic glycolysis and subsequent release 
of lactate through MCT1 is essential for T cells activation. Although MD1 could inhibit 
lactate uptake with an EC50 value being 6nM, it inhibited human peripheral blood 
mononuclear cells (hPBMCs) proliferation at concentrations no less than 50μM. The 
presence of a hypoxic core in solid tumors as well as the proposal of a “symbiosis 
metabolic model” where hypoxic tumor cells break glucose molecules via glycolysis and 
export produced lactate that is then imported into peripheral normoxic tumor cells for 
oxidation, promoted us to examine MD1’s inhibitory role in tumor cells proliferation under 
either normoxic or hypoxic culturing conditions. Our results indicated that under hypoxic 
culturing condition, MD1 inhibited SW480 colorectal cancer cells proliferation at no less 
than 25μM, whereas it started inhibiting H4IIE rat hepatoma cells proliferation at 5μM. 
Additionally, hypoxic condition sensitized H4IIE cell line to MCT1 inhibition. Interestingly, 
a transient increase in proliferation was observed in both tumor cell lines when treated 
with low concentration of MD1 at 1μM. No significant changes were observed for either 
MDA231 breast cancer cells or GL261 mouse glioblastoma cells under either culturing 
condition.  
 
Future directions 
cAMP-dependent PKA signaling regulation  
Our observation of reduced MCT1 phosphorylation upon PKA stimulation is consistent 
with an activated phosphotase that dephosphorylated MCT1 on cellular surface 
membrane. It would be important to identify such unknown phosphotase in future 
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research. Besides, MCT1 has 11 serine and threonine residues that can be 
phosphorylated, and dephosphorylation at one or more of these sites may mediate the 
observed internalization of MCT1 from plasma membrane. Future efforts to identify the 
critical residues through point mutation/amino acids substitution analysis may help 
dissect the molecular details of MCT1’s regulatory mechanism by PKA and broaden our 
understanding of this important transporter’s modification by one of the most widely 
existing post-translational mechanisms. Besides, CD147 has been known to facilitate 
MCT1’s trafficking onto plasma membrane as an ancillary protein and loss of its function 
jeopardized MCT1’s expression both on cellular surface and in intracellular pools. 
Whether or not CD147’s association capacity with MCT1 is altered upon PKA activation 
would be another interesting research area to pursue in the future.  
Wnt/β-catenin signaling regulation 
Enhanced MCT1 expression on plasma membrane by Wnt/β-catenin signaling pathway 
observed in our current study could be due to multiple mechanisms. First, because 
ubiquitination of substrate proteins has been well-known as a sorting signal within 
endosomal-lysosmal system, it would be interesting to examine MCT1’s ubiquitination 
status upon the activation of Wnt signaling. Secondly, thus far we don’t know whether 
the increased cell surface expression of MCT1 is caused by reduced internalization from 
the plasma membrane, or increased recycling rate from recycling endosomes, or 
disturbed trafficking into lysosomal compartments. Co-localization immunostaining 
studies in the future would shed lights on the underlying mechanisms of MCT1’s 
regulation by Wnt pathway.  
Notch signaling regulation and its crosstalk with Wnt pathway 
In addition, how Notch pathway modulates MCT1’s expression would be another 
important research topic to investigate, e.g. transcriptionally or post-translationally. 
Furthermore, how Notch and Wnt signaling corporate to upregulate MCT1 would be an 
inspiring project for future investigation as well. For example, as a critical determinant in 
Wnt pathway, whether or not β-catenin expression level or its nuclear activity upon 
Notch inhibition is altered would be a good starting point to gain a better understanding 
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of the integration between those two signaling pathways. Knowledge obtained from this 
study would also provide insights to understanding how blood-brain barrier (BBB) is 
dynamically maintained by different signaling inputs such as Wnt, Notch and Hedgehog, 
and how modulation of their interaction can help improve the functional output of BBB 
under pathological conditions.    
MCT1 inhibition by a novel MD1 compound  
Our novel MD1 analog showed stronger capacity to suppressing tumor cells proliferation, 
compared with its precedent compound α-CHC. It would be exciting to test whether the 
combinatorial use of MD1 with other chemotherapeutic drugs (e.g. Temozolomide) 
improves therapeutic benefits to the patients. One advantage of the MD1 compound 
may be that it inhibited tumor cells proliferation at concentrations that do not compromise 
T cells mediated immune response. Because different tumor cells tend to possess 
different profiles of MCTs expression, plus the fact that distinct MCTs can show different 
affinities to the same substrate, it would be good to test the specificity of MD1 compound 
to various MCT isoforms in the future, raising the possibility of combining different MCTs 
inhibitors as a customized therapeutic approach in accordance with MCT expression 
profiles in individual types of tumor. Additionally, our finding that MD1 inhibited hPBMCs 
proliferation at much higher concentration than its EC50 value observed in RBE4 cells, 
suggests that MD1 may inhibit lactate transport through different mechanisms in these 
two biological systems. As a consequence, it would be informative to figure out the 
principle of MD1 inhibiting MCT1 transport activity.   
 
Final conclusions 
In this report, we provided an updated summary of recent developments and insights on 
MCTs as well as their implications in physiological functions & diseases. In addition, we 
unraveled the mechanisms by which brain endothelial MCT1 can be regulated by 
diverse signaling pathways. Our studies are the first to investigate MCT1 intracellular 
trafficking within brain endothelium, which can be critically relevant for nutrients transport 
or pharmaceutical administration into CNS. A crosstalk between Wnt and Notch 
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signaling was also proposed, and provides an important piece of information for further 
studying signaling integration in brain endothelium. Furthermore, our promising findings 
of the novel MCT1 inhibitor in immune response and cancer biology through metabolic 
blockage, opens a new revenue for developing therapeutic intervention for treating many 
devastating disorders, such as autoimmune diseases, cancers and diabetes. Overall, 
our current study and, more importantly, continued future research, is necessary to 
achieve a more complete understanding of MCT1 as an important regulator in cellular 
metabolism and tissue homeostasis.    
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Introduction: 
MCT1’s multiple roles in cellular metabolism, drug transport and many pathological 
diseases make it an attractive target for intensive research. A better understanding of 
this monocarboxylate transporter’s function in different biological contexts not only 
expands our knowledge of alternative fuels such as lactate, acetate and β-
Hydroxybutyrate (BHB), but also facilitates the progression of deciphering the recent 
discovery of lactate’s complex but poorly understood functional roles in diseases 
including cancer, amyotrophic lateral sclerosis and diabetes (38, 371, 382). Based on 
these research findings, therapeutic methods can be developed for debilitating disorders. 
For example, reprogrammed metabolism research found in cancer cells leads to the 
finding of MCT1 as a critical factor in maintaining tumorigenesis by exporting or 
importing lactate (74, 75, 87, 185); thus multiple MCT1 inhibitors have been proposed 
and employed as potential therapeutic intervention in treating cancer, such as the highly 
potent AZD3965 that is now under Phase I clinical trials for advanced solid tumors, 
prostate cancer, gastric cancer and diffuse-large B cell lymphoma (375). As a 
consequence, continued bulky research on MCT1 is necessary and requires combined 
approaches as well as interdisciplinary efforts. 
Genetically modified mouse models have been studied for a variety of genes related to 
human diseases (383, 384). Approaches to study an in vivo gene’s function include but 
not limited to: (1) Transgenic expression (385), where exogenous coding DNA sequence 
is injected into pronuclei of zygote-stage embryos that are implanted back later into 
pseudopregnant recipient females to develop into newborns; (2) gene knockin (386), 
where an endogenous genomic locus of interest is replaced by exogenous targeting 
DNA vector carrying a modified version of the same gene; and (3) gene knockout (387-
389), which is similar to knockin approach, except that the genomic locus of interest is 
deleted or inactivated. Knockout mouse has become a valuable tool to discern the role 
of a gene during embryonic development, in normal physiological homeostasis as well 
as genetics diseases (390). More importantly, it allows researchers to delete and 
investigate genes in a tissue-dependent manner, where that particular gene is only 
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disrupted in certain types of cells. This can be achieved by Cre-LoxP conditional 
knockout system driven by the function of a cell type specific promoter (391).  
Gene knockout takes advantage of homologous recombination between the genomic 
locus of interest (target gene) and exogenous targeting vector in embryonic stem (ES) 
cells. The vector is engineered in a way that it now contains a modified version of the 
same gene. Specifically, the new sequence is identical to the original gene as well as its 
immediate neighboring DNA fragments (5’ and 3’ homologous arms), except that the 
protein coding sequence between the two homologous arms has been changed so 
substantially that the original gene’s function is inactivated (knocked-out). After 
introducing the targeting vector into ES cells, two homologous recombination events can 
happen at both the 5’ arm and 3’ arm sites, swapping DNA content between the 
endogenous locus on a chromosome and that residing on the vector. In this case, the 
original allele has been replaced with our modified/knocked-out version. These 
genetically engineered ES cells will be selected based on their resistance to neomycin, a 
capacity that is conferred by the Neo resistant gene originally present on and brought 
into genome by the targeting vector. Modified ES cells will then be injected into 
blastocysts derived from another mouse strain that exhibits a different coat color. As a 
result, any pups developed from those unique blastocysts will be chimeras, as 
demonstrated by their coats with mixed colors, and serve as founder strains. If their 
reproductive organs were developed from the genetically altered ES cells and they are 
crossbred with wild type animals, those chimeras can produce offspring that contain one 
copy of the knocked-out gene in their cells. When these heterozygous offspring are 
interbred, some of their progenies will inherit the knocked-out alleles from both parents 
and become homozygous knockout animals (Figure A-1). For conditional knockout, one 
or more exons of the target gene are flanked by two LoxP sites, 34bp palindromic DNA 
sequence. They can be recognized by Cre recombinase to initiate crossover between 
them. The ending result is the excision of exon(s) in between. As a consequence, mice 
carrying homozygous flanked exon(s) actually contain functional alleles of the target 
gene, unless they are challenged by the expression of Cre recombinase. Conditional 
knockout is conferred by mating those LoxP animals to others that only express Cre in 
certain tissues, like neurons, astrocytes or endothelial cells (Figuref A-2).          
  172 
Although MCT1 has recently received intensive research attention because of its critical 
roles in cellular metabolism and therapeutic drugs transport, animal models with 
modified MCT1 gene are a limiting factor for further understanding of this important 
transporter. Indeed, very recently, only Mct1+/- heterozygous mice have been reported, 
where the gene’s function in oligodentricytes during neurodegeneration was studied (38). 
Thus, we decided to generate homozygous Mct1 conditional knockout (Mct1-/-) mouse 
model that would greatly advance research progression on deciphering this critical 
monocarboxylate transporter’s function in vivo.  
 
 
Figure A-1: Generation of knockout mice. (A) Gene targeting in ES cells through homologous 
recombination. The presence of neomycin resistant gene (Neo
R
) in the vector replaces the 
original gene of interest (Goi)’s critical exon and inactivates its function. For detailed information, 
see text. (Panel B and its legends are shown on next page) 
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(B) Flow-chart of targeting ES cells in culture and subsequent breeding for homozygous null 
animals (Adapted and modified from © The Nobel Committee for Physiology Illustration: Annika 
Röhl). Briefly, identified positive ES cells from one strain (Red) with one modified allele are 
injected into blastocysts of another strain (Yellow). Those blastocysts with mixed ES cells are 
then transplanted into pseudopregnant females to generate chimeras in the next generation. 
Those male chimeras are crossbred with wild type females of yellow strain. Progenies (Goi
+/-
) 
derived from fertilization of red sperms that contain genetic modification and yellow oocytes that 
are wild type, are then identified and subject to interbred to generate homozygous offspring (Not 
shown in the illustration).   
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Figure A-2: Generation of conditional knockout mice (Adapted and modified from (383)). 
Homozygous mice with two LoxP sites flanking the critical exon in both alleles are generated from 
Figure A-1. In this case, the gene of interest can function normally because all the coding 
sequences are intact. In addition, a specialized transgenic mouse strain that express Cre 
recombinase (bright green) under the control of a tissue specific promoter (front paw specific in 
this example), is introduced to mate with the LoxP flanked animals. As a result, Cre recombinase 
is only expressed in front paw, thus the Goi is only deleted in a front paw-specific manner 
(indicated by green paw).   
 
Materials and Methods 
Mouse embryonic fibroblasts (MEFs) culture and inactivation. MEFs were cultured 
in 100mm x 20mm dishes (Corning #430167) within a humidified incubator at 37oC 
supplemented with 5% CO2.The growth medium was composed of DMEM (high glucose, 
Na Pyruvate and L-glutamine; Invitrogen #11960-044), 10% FBS (Atlanta Biologicals; 
#S10250), 1X Non-Essential Amino Acids (NEAA; Invitrogen #11140-50) and 1X L-
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Glutamine (Invitrogen #25030-081). For inactivation, confluent MEFs were washed with 
1X PBS (Invitrogen; #14190-144) once and then treated with 10μg/ml mitomycin-C 
(Sigma-Aldrich; #M4287) for 4h. After that, old medium was removed and cells were 
rinsed twice with 1X PBS before they were trypsinized (Invitrogen; #25200-056), 
quenched with growth medium and spun down to pellet. Inactivated MEFs were 
resuspended in ice-cold freezing medium (growth medium+10% DMSO (Sigma-Aldrich; 
#D2650)) to the concentration of 1x107 cells/ml, placed into -80oC freezer and then 
transferred to liquid nitrogen tank the next day for future use.    
Embryonic stem (ES) cells culture. CJ7 ES cells from mouse strain 129 were provided 
by University of Minnesota Mouse Genetics Laboratory Shared Resource facility. 
Inactivated MEFs were first plated into 100mm x 20mm dishes (Corning #430167) as 
feeder cells at a concentration of 200,000 cells/ml two days in advance of the day 
10,000 cells/ml ES cells were thawed and seeded. ES cells were cultured within a 
humidified incubator at 37oC supplemented with 5% CO2.The ES growth medium was 
composed of DMEM (high glucose, Na Pyruvate and L-glutamine; Invitrogen #11960-
044), 17% FBS (Atlanta Biologicals; #S10250), 1X Non-Essential Amino Acids (NEAA; 
Invitrogen #11140-50), 1X L-Glutamine (Invitrogen #25030-081), 22nM (1X) -
Mercaptoethanol (Invitrogen; #21985-023), 2mM HEPES (Sigma # H6147) and 1000 
units/ml LIF (Millipore # ESG007).  ES cells were passaged or frozen down at 1:6 when 
they became confluent (40-50%).  
Targeting vector transformation/preparation. Mct1 targeting construct was purchased 
from European Conditional Mouse Mutagenesis Program (EUCOMM) (#40919), after 
which the plasmid was transformed into the MAX Efficiency DH-10β competent E.coli 
cells (Invitrogen; #18297-010) according to the manufacturer’s instruction. Specifically, 
less than 20ng DNA was incubated with the thawed 50μl competent cells in each tube 
on ice for 30 minutes, heat-shocked for 30 seconds in a 42oC water bath, returned on ice 
for additional 5 minutes before they were mixed with 250μl S.O.C. medium (Invitrogen; 
#15544-034) in a Falcon Round-Bottom Polystyrene tube (Fisher Scientific; #14-959-1B) 
and shaken at 225rpm (at 37oC) for 1 hour. Then, 50μl transformants were pipetted onto 
a kanamycin (Fisher Scientific; #BP906-5) selective agar plate (15g/L agar, 10g/L 
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Tryptone, 10g/L NaCl, 5g/L Yeast Extract and 50μg/ml kanamycin) and spread out 
evenly across the surface using a sterile glass rod spreader. The whole plate was put 
into a 37oC oven for 24h.  
Candidate colonies that grew out on the plate were picked and inoculated into separate 
Falcon Round-Bottom Polystyrene tubes that had 2ml LB medium (10g/L Tryptone, 
10g/L NaCl and 5g/L Yeast Extract), supplemented with 50μg/ml kanamycin. They were 
shaken at 37oC, 225rpm for 16-18 hours. Plasmid DNA from each falcon tube was 
isolated by the MiniPrep Kit (Qiagen; #27104) according to its instruction. The integrity of 
each DNA preparation was verified using restriction enzymes digestion. The colony that 
passed the initial screen was subjected to 200ml LB culture supplemented with 
kanamycin at 37oC, 225rpm for 16-18 hours. Its DNA was prepared using the 
PureYield™ Plasmid Maxiprep System (Promega; #A2392). The quality of this final DNA 
preparation was further confirmed by sequencing (University of Minnesota Genomics 
Center).  
Restriction enzymes (REs) digestion. REs of EcoRI (Promega; #R6011), AvrII and 
SpeI (New England Biolabs; #R0174 and #R0133) were used separately to screen for 
Mct1 targeting vectors after plasmid DNA MiniPreps from candidate colonies as well as 
to verify the integrity of final DNA MaxiPrep. The expected band patterns (in bp) for each 
enzyme after complete digestion of Mct1 targeting vector are listed: AvrII (8134, 7014, 
2580, 1856, 831); EcoRI (12740, 2937, 2042, 1772, 882) and SpeI (8644, 4523, 4069, 
1864, 1315). The reaction conditions used were as followings: EcoRI in a 20μl volume 
with 1Xbuffer H, 1μg DNA, 10U RE and 0.1μg/ml BSA; SpeI in a 25μl volume with 
1Xbuffer 4, 1μg DNA, 10U RE and 0.1μg/ml BSA; AvrII in a 25μl volume with 1Xbuffer 4, 
1μg DNA and 10U RE. All the reactions were carried out in a 37oC water bath for at least 
4 hours. All the digests were analyzed on 1% agarose gels.  
Targeting plasmid DNA linearization and precipitation. SgrAI (New England Biolabs; 
#R0603) was used to linearize the Mct1 targeting vector by incubating 10μg DNA in a 
final 50μl reaction volume supplemented with 1Xbuffer 4 and 10U enzyme at 37oC for 1h. 
The same procedures were repeated for additional 30μg DNA in 3 separate tubes, 
making the final amount of linearized DNA to be 40μg. All the digests were pooled 
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together to make a total volume of 200μl, which was then mixed with a final 
concentration of 0.3M NaAc/70% ethanol and incubated for 30 minutes at -20oC. After 
that, the tube was centrifuged at 13,000rpm for 15 minutes at 4oC. The resulting 
supernatant was discarded and pellet was washed three times with ice-cold 70% ethanol 
followed by centrifugation at 13,000rpm for 5 minutes each time. After discarding the 70% 
ethanol supernatant, the DNA pellet was washed with ice-cold 100% ethanol, dried in a 
sterile hood and redissolved in 25μl 1X PBS at 4oC overnight. 0.2μg of the precipitated 
DNA was subjected to electrophoresis on a 0.5% agarose gel to check the successful 
linearization before being electroporated into ES cells.    
Agarose gel electrophoresis. DNA electrophoresis analysis was performed using 
SeaKem agarose gel (Lonza; #50152) supplemented with ethidium bromide in 1X TAE 
running buffer (40mM Tris, 20mM acetic acid, and 1mM EDTA), at various densities of 
1.5% for the PCR products of mycoplasma detection, 1% for restriction enzyme 
digestions, and 0.5% for linearized DNA vector confirmation as well as LA PCR products. 
All the experiments were run at 70V until the blue dye reached near the bottom of the gel, 
after which the whole gel was visualized under a UV imager.  
Electroporation. Six 100mm x 20mm dishes were first coated with 0.1% gelatin solution 
(Sigma-Aldrich; #G1393) for 2 hours, washed with H2O three times and dried in the hood 
for future use. Upon confluent (~50%), ES cells were trypsinized off the culture dish, 
spun to pellet and resuspended in 1X PBS (Ca2+-, Mg2+-; Invitrogen; #14190-144) to 
generate a single-cell solution of 1x107 cells/ml. Then 8 million ES cells were mixed well 
and incubated with either 20μg linearized Mct1 targeting vector DNA or equal amount of 
1X PBS control in a 0.4cm cuvette. After standing at room temperature for 5 minutes, 
electroporation was performed at 250V/500μF with exponential curve setting on the 
Gene Pulser Xcell system machine (Bio-Rad; #165-2660), according to the 
manufacturer’s instruction. The contents of the cuvette with DNA and half of the contents 
from the control cuvette were equally divided into four and two gelatin-coated dishes, 
respectively, which had inactivated MEFs plated already beforehand. 24 hours later, the 
plates started feeding with ES growth medium supplemented with 250μg/ml G418 
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(Sigma-Aldrich; #G8168) for selecting positive colonies. Change for fresh medium+G418 
daily until all the cells from the control plates died out. 
Picking candidate colonies. The picking process was performed on a cell culture light 
microscope sitting in a Laminar hood. Specifically, cells were deprived of old selective 
medium, washed once with and then kept in ES cell qualified 1X DPBS (Millipore; #BSS-
1005-B). A positive colony was first separated from the adherent MEFs layer by 
physically scratching and breaking the MEFs feeder cells surrounding it using a sterile 
10μl pipette tip. The subsequent floating loose colony was then pipetted up and 
transferred into a well of V-bottom 96 well plates (Sarstedt; #821583001) that contained 
25μl ice-cold 0.25% trypsin (Invitrogen; #25200-056). The same steps were repeated 
until all the colonies from that dish had been picked, or 24 wells of a V-bottom plate had 
been filled up. The ES cells dish was replaced with fresh medium and returned back into 
the incubator if needed. The V-bottom 96-well plate with colonies in trypsin was 
incubated at 37oC for 10 minutes; then the colonies were pipetted up and down until they 
disassociated into single cells. After that, these single cell suspensions were dispersed 
evenly into corresponding wells of a Corning Costar cell culture flat-bottom 96-well plate 
(Sigma-Aldrich; #CLS3585) that had already been gelatin-coated and seeded with 
1.2x104 inactivated MEF feeders in 150μl ES growth medium with G418. The growth 
medium was renewed daily until ES cells became confluent.  
Freezing colonies and establishing cultures for DNA isolation. ES cells growing in 
flat-bottom 96-well plates reaching confluence were rinsed once with 1X PBS and 
incubated with 40μl 0.25% trypsin at 37oC for 10 minutes, with pipetting up and down at 
the end to break up clumps into single cells. They were then quenched by 60μl 
additional growth medium. 33μl of the trypsinized ES cells was transferred to each of the 
duplicate flat-bottom 96-well plates that had 33μl ice-cold 2X freezing medium (ES 
growth medium with 20% DMSO) in the wells. Those duplicate plates were then stored 
in well sealed foam-box at -80oC undisturbed. The remaining 33μl ES cells were mixed 
with 100μl fresh growth medium and put back into 37oC incubator to grow to high 
densities for DNA isolation.  
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DNA preparation from 96-well plates. When ES cells grew confluent (100%), they 
were decanted of the old medium and washed twice with 1X PBS. Then they were 
incubated with 50μl lysis buffer (10mM Tris pH 7.5, 10mM EDTA pH 8.0, 10mM NaCl 
and 0.5% Sarcosyl (Sigma-Aldrich; #L7414)) supplemented with 1mg/ml proteinase K 
(Roche; #03115836001) within a humidified container at 55oC overnight. Then 100μl of 
NaCl/Ethanol mixture (100mM NaCl and 100% Ethanol) was added into each well and 
the whole plate was incubated at -20oC for 30 minutes or until precipitated DNA became 
visible. After washing three times with 70% ethanol and paper blotted by the end of the 
third wash, the plate was dried in hood for 15 minutes. 35μl TE buffer (10mM Tris, 1mM 
EDTA, pH 8.0) was then added to dissolve precipitated DNA in each well at 4oC 
overnight.    
Long range LA PCR screening. The correct targeting of Mct1 at its genomic locus was 
confirmed by long range PCR (LA PCR) from both 5’ and 3’ homologous ends. The 
expected PCR product sizes after homologous recombination are 10,914bp for 5’ end 
and 7,641bp for the 3’ end. The primers used here are listed as followings: 5’ forward 
primer: GGGAGTTACTTAGGACTCGTGGCATACCCGCCCAG, 5’ reverse primer: 
GGACGACGACAGTATCGGCCTCAGGAAGATCGCAC, 3’ forward primer: 
CGATGCCTGCTTGCCGAATATCATGGTGGA, 3’ reverse primer: 
GGCGACTGTGCAGCTTTCATCGTCTCCTTT. The reaction was carried out in a final 
50μl volume that comprised of 1X LA PCR buffer II, dNTP mixture (0.4mM each), 
forward primer (0.2μM), reverse primer (0.2μM), DNA template (<1μg) and 2.5U Takara 
LA Taq (Takara; #RR002). The cycling parameters used were: 94oC 1min, 30 cycles of 
94oC 30s, 68oC 10min and 72oC 15min, 72oC for 15min and 4oC hold.  
Expansion of positive ES colonies. 100μl pre-warmed ES medium was added into 
each well of the 96-well plates containing frozen ES cells from the -80oC freezer. Then 
the whole plate was put into a pre-warmed tupperware/H2O bath inside 37
oC incubator 
until the cells were completely thawed. All the contents were transferred into a 24-well 
MEF feeder plate filled with 2ml ES medium per well. Once those cells became confluent 
(50%), they were trypsinized and transferred into a 6-well MEF feeder plate filled with 
3ml ES medium per well, after which they were further transferred into 100mm dishes 
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with MEF feeders plated beforehand. When confluent, those ES cells were passaged at 
1:6 and stored in liquid nitrogen for future use. ES growth medium was renewed daily for 
all the cultures.  
Mycoplasma detection, karyotyping analysis and blastocysts injection. 
Mycoplasma detection was performed using the VenorGem PCR-based Mycoplasma 
Detection Kit (Sigma-Aldrich; #MP0025) according to its instruction. Specifically, positive 
ES colonies were cultured without antibiotics to full confluence (100%) without changing 
medium in between in order to enrich possible mycoplasma in the supernatant, which 
was heated for 5min at 95oC and served as DNA template. The PCR reaction volume 
was 25μl consisting of a Mastermix (provided by and prepared from the kit), 1 unit 
Jumpstart Taq polymerase (Sigma-Aldrich; #D9307) and a template being either H2O 
(negative control), or the provided positive control DNA, or our sample supernatant. The 
thermal cycling parameters were: 94oC for 2min, 39 cycles of 94oC 30s, 55oC 1min and 
72oC 30s, followed by 4oC hold.  
Karyotyping analysis of the positive ES colonies was conducted by University of 
Minnesota's Cytogenomics Laboratory. Blastocysts injection of ES cells was served by 
the Mouse Genetics Laboratory in the University of Minnesota.  
Western blotting. Protein samples were prepared by solubilizing cells in 1X lysis buffer 
(63mM Tris pH=6.8, 2% SDS, 10% glycerol, 5% beta-mercaptoethonal, 1X Roche 
protease inhibitor cocktail and 1mM PMSF) for 5 minutes, followed by centrifugation at 
13,000g for 8 minutes at 40C. The supernatant was collected and subjected to gel 
electrophoresis and subsequent MCT1 immunodetection as described in the Materials & 
Methods section of chapter III. 
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Results: 
i. Cloning of Mct1 targeting vector in competent E.coli. 
In order to prepare the Mct1 targeting vector after obtaining from EUCOMM, it was 
transformed into competent DH10β E.coli cells on kanamycin selective agar plates. The 
schematic diagram of the vector is shown in Figure A-3. The presence of a kanamycin 
resistant gene within the plasmid backbone allows its transformants to survive 
kanamycin stress. Four positive colonies were picked and their plasmid DNA was 
prepared for restriction enzymes (REs) digestions to analyze its integrity. Three REs 
were used for each clone: EcoRI, SpeI and AvrII. The expected banding pattern for each 
enzyme is summarized in Table A-1. Our results of all the REs digestions analyzed on 1% 
agarose gel indicated that colony #4 was the correct colony containing the expected 
Mct1 targeting vector (Figure A-4, A-C). Subsequently, this colony was cultured in a 
larger volume and its plasmid DNA was isolated by MaxiPrep, the quality of which was 
finally confirmed by the same enzymes (Figure A-4, D) as well as by sequencing. 
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Figure A-3: Schematic representation of Mct1 targeting vector (adapted and modified from 
EUCOMM). The total size of the vector is 20,415bp. SgrAI is the enzyme used to linearize the 
whole vector for electroporation into ES cells. 5’ arm and 3’ arm contain sequences identical to 
corresponding Mct1 genomic loci that allow homologous recombination. FRTs are short DNA 
fragments that, upon exposure to Flp recombinase, align with each other and recombine to delete 
sequences in between that are referred to as “promoterless cassette” within the vector. This 
cassette contains “neo” gene that gives cells resistance to the drug G418 and serves as the basis 
of positive selection for correctly targeted ES cells. LoxP sites, like FRTs, each contains two sets 
of short palindromic sequences and also recombines with each other to delete DNA fragment in 
between in the presence of Cre recombinase. The three yellow boxes represent exons of Mct1 
gene, with the critical first one being flanked by LoxP sites. KanR is the resistant gene that allows 
bacterial cells carrying the vector to survive kanamycin selection. PGK-DTA-pA cassette is the 
negative selecting fragment, which eliminates positive ES colonies that are not due to 
homologous recombination.      
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Figure A-4: Banding patterns of Mct1 targeting vector prepared from candidate colonies 
after restriction enzymes digestions. The vector was isolated from four individual colonies that 
survived kanamycin selection, and all the four DNA samples were then cut separately by EcoRI 
(A), AvrII (B) and SpeI (C). The digests were analyzed on 1% agarose gels. The expected bands 
after each digestion are summarized in Table A-1. Accordingly, only colony #4 (shown in green) 
showed correct bands after digestion by each of the three enzymes and was considered as the 
right one. The further MaxiPrep DNA from this colony #4 was verified by digestions using the 
same individual enzymes as indicated in panel (D). L1: 1kb DNA ladders (Promega; #G5711); L2: 
Mass DNA 1kb ladders (NEB; #N3237); N: Vector DNA not cut.   
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ii. MCT1 protein is expressed in both mouse embryonic fibroblasts (MEFs) cells 
and 129 embryonic stem (ES) cells.  
The promoterless selective cassette within Mct1 targeting vector (Figure A-3) enables 
correctly targeted ES cells resistant to G418 selection with the help of neo gene, whose 
successful expression after homologous recombination requires the functionality of 
endogenous promoter of the gene being targeted, in our case, Mct1. As a result, the 
protein expression status of MCT1 in 129 ES cells was first examined by western blot. 
MEFs were expanded and inactivated by mitomycin C before they were used as feeders 
for ES cells culture. Then each of two identical MEF dishes was either seeded with 129 
ES cells or left intact as control. When ES cells became 50% confluent, both dishes 
were incubated with 1X lysis buffer; then equal volumes of samples were subjected to 
SDS-PAGE electrophoresis, followed by immunoblotting against MCT1. As shown in 
Figure A-5, MCT1 protein (~45kD) has trace expression in MEF feeder cells and more 
abundant expression in MEFs seeded with ES cells, demonstrating that Mct1 gene is 
transcribed in 129 ES cells. This result indicates that targeting Mct1 gene in 129 ES cells 
using our vector is feasible.   
 
Figure A-5: MCT1 expression in MEFs and 129 ES cells. Two 100mm dishes were first plated 
with MEFs and then seeded with either 129 ES cells (A) or left intact (B). Cells from the two 
dishes were lysed in 1X lysis buffer and subjected to SDS-PAGE with equal sample volume 
loading, followed by immunoblotting against MCT1. MEFs showed baseline expression of MCT1 
(B), whereas the co-culture with ES cells robustly increased its expression level (A), 
demonstrating that Mct1 gene is transcribed in 129 ES cells.   
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iii. Gene targeting and identification of positive ES colonies  
Linearized plasmid DNA tends to run slower on agarose gel than uncut control, because 
the latter usually possesses supercoil conformation and migrates faster. In order to 
target the Mct1 genomic locus, the targeting vector was first linearized (Figure A-8), 
purified by NaAc/Ethanol precipitation and electroporated into cultured 129 ES cells. The 
presence of neo gene only allows ES cells that obtained the selective cassette from 
Mct1 targeting vector to grow under G418 selection, whereas the expression of 
diphtheria toxin A (or DTA) gene in the vector backbone serves as a negative selection 
and eliminates false positive colonies that were generated independent of homologous 
recombination. After a week, 32 candidate colonies were picked up and grown in 
separate wells of a 96-well plate. When they grew confluent, all the colonies were 
carefully stored in -80oC freezer for future use, while in the mean time, their individual 
genomic DNA was prepared and subjected to long range LA PCR for screening positive 
colonies. Correct targeting through homologous recombination replaces the portion of 
DNA fragment between the 5’ and 3’ homologous arms of genomic DNA with that in the 
targeting vector, creating new 5’ and 3’ genetic ends (Figure A-6). For LA PCR 
screening at 5’ end, the forward primer anneals upstream of the 5’ homologous arm, 
whereas reverse primer pairs with sequence from the selective cassette that is unique to 
the targeting vector but now present in the ES genome. The same thing is true for 3’ 
screening although its forward and reverse primers anneal to the opposite direction of 
that at 5’ end. In the wild type 129 ES DNA, neither of the two primer pairs is supposed 
to generate any PCR products (Figure A-7). Our LA PCR results indicated that two 
candidate colonies, named 3o 1-D and 3o 1-E (derived from their locations in the 96-well 
plate), showed correct genetic modification, generating a PCR band of ~10.9kb at 5’ end 
and another band of ~7.6kb at the 3’ end (Figure A-9). Those two colonies were thus 
thawed and expanded in culture from 24-well plates to 6-well plates and eventually to 
100mm X 20mm dishes.  
iv. Quality control tests of positive colonies 
The quality of our positive ES colonies for blastocysts injection was investigated on three 
levels: morphology, mycoplasma and karyotype. First, these two colonies were cultured 
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on MEF feeder cells and both of them exhibited standard morphological hallmarks of 
undifferentiated state: compact, multicelluar colonies of cells with cobblestone shape, a 
high nucleus-cytoplasm ratio and a distinct colony border (Figure A-10). Then, the 
absence of mycoplasma contamination, which significantly decreases the germline 
transmission potency of contaminated ES cells, was confirmed by PCR using primers 
that are specific to the conserved 16S rRNA coding region in the mycoplasma genome 
and sufficient for detecting all the 24 known species. Enriched cell culture supernatant 
was collected and used as DNA template. Our results indicated the absence of any 
mycoplasma contamination in either of the two positive colonies (Figure A-11). After that, 
karyotyping service of the two colonies was conducted by a cytogenomics lab (University 
of Minnesota-Minneapolis). 20 metaphases were completely analyzed by G-banding for 
each of the colonies. Although 3o 1-E cells showed no abnormalities on any of the 40 
chromosomes (19 pair + X + Y), a small deletion within the proximal long arm of 
chromosome 17 was observed in 3o 1-D colony (Figure A-12 A). Thus, 3o 1-E was the 
colony good for blastocysts injection.     
v. Blastocytes injection and breeding 
At least 75 blastocysts were injected with our genetically modified 3o 1-E ES cells and 
implanted into at least 5 pseudopregnant recipients.  A total of 8 chimeric mice (6 males 
and 2 females) were generated afterwards, however none of them showed signs of 
germline transmission after breeding with C57/B6 mice. 
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Figure A-6: Gene targeting scheme. The endogenous 129 ES cells genomic DNA is 
represented as solid grey lines, with polarity indicated at 5’ and 3’ ends, whereas DNA sequence 
from the targeting vector is represented in black lines. The homologous arms are enclosed by 
dashed grey lines, with 5’ arm on the left and 3’ arm on the right. Exons are represented by 
yellow boxes. The critical exon is flanked by LoxP sites. After homologous recombination, double 
crossovers (as indicated by crossing lines) happen between endogenous DNA and linearized 
targeting vector, one at the 5’ end and the other at 3’ end, which swaps the fragment between the 
two homologous arms in wild type DNA with that from the vector, generating the modified 
genomic Mct1 sequence.        
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Figure A-7: Long range LA PCR. Both the 5’ and 3’ ends are screened by LA PCR for positive 
homologous recombination. At 5’ end, its forward primer ( ) anneals upstream of 5’ 
homologous arm, whereas the reverse primer ( ) pairs with sequence from the targeting 
vector after correct homologous recombination, generating a PCR product of 10,914bp. For the 3’ 
end, its reverse primer ( ) anneals downstream of 3’ homologous arm, whereas the forward 
primer ( ) pairs with sequence from targeting vector after correct homologous 
recombination, generating a PCR product of 7,641bp. Neither of the two primer pairs amplifies 
any DNA fragments in the wild type genomic locus.  
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Figure A-8: Linearized Mct1 targeting vector by the restriction enzyme SgrAI. Our Mct1 
targeting vector was cut once and thus linearized by SgrAI, which was demonstrated by 
electrophoresis on a 0.5% agarose gel. The supercoil conformation, a key structural characteristic 
of native plasmids, caused a faster migration on the gel (Neg) than linearized DNA of the same 
size (lane #1 and lane #2). L: 1kb DNA ladders; #1 and #2: duplicate loadings of digested DNA by 
SgrAI; Neg: Mct1 targeting vector negative control without any restriction enzyme digestion.  
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Figure A-9: Identification of positive colonies that were correctly targeted as revealed by 
LA PCR. LA PCR using both 5’ and 3’ end screening primers was performed on either wild type 
control DNA (WT) or DNA prepared from positive colonies (3
o
1-D and 3
o
1-E). The products were 
then run on 0.5% agarose gel for analysis. (A) 3
o
1-D colony DNA showed correct targeting at 
both the 5’ and 3’ ends, generating the expected band of ~10.9kb and 7.6kb, respectively, 
whereas neither end gave any signals in WT control DNA. (B) Identical to colony 3
o
1-D, 3
o
1-E 
DNA generated a PCR product of ~7.6kb at the 3’ end, as well as a band of ~10.9kb at the 5’ end, 
demonstrating that 3
o
1-E was also correctly targeted. L: 1kb DNA ladders. 
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Figure A-10: Morphology of targeted colonies under light microscope. The positively 
targeted ES colonies of 3
o
1-D (A) and 3
o
1-E (B) were examined under microscope (at both 20X 
and 40X magnifications) to verify the characteristics of an undifferentiated state. The well 
established hallmarks include: compact and cobblestone shaped colonies with multiple cells, a 
high nucleus-cytoplasm ratio and a distinct colony border.  
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Figure A-11: Both targeted colonies 3
o
1-D and 3
o
1-E were mycoplasma negative. Enriched 
culture supernatant from each colony was collected and processed to serve as template DNA in 
subsequent PCR based detection of mycoplasma species. A successful PCR always generates a 
band of ~191bp due to the presence of internal control DNA in the reaction system. Negative 
control (N) only yields the internal control PCR band, whereas positive control (P) generates an 
additional band of ~270bp because of the presence of mycoplasma DNA. All the PCR products 
were analyzed on 1.5% agarose gel. Our results indicated that neither 3
o
1-D (A) nor 3
o
1-E (B) 
colony was contaminated by mycoplasma. L: 100bp DNA ladders 
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(A) 
 
Figure A-12: Karyotyping analysis of the targeted positive colonies. ES cells were first 
treated for 3 hours with colcemid, before being harvested according to standard cytogenetic 
protocol. (A) 20 metaphases from 3
o
1-D colony were completely analyzed by G-banding. All 20 of 
the metaphase cells analyzed had a male karyotype (38 total autosomes plus sex chromosomes 
of X and Y) including one normal chromosome 17 and one abnormal chromosome 17 with a 
small deletion within the proximal long arm (indicated by red arrow). (Panel B and its legends 
continued on the next page) 
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(B) 
 
(B) 20 metaphases from 3
o
1-E colony were completely analyzed by G-banding. 19 metaphases 
had a normal 40,XY male karyotype.  The remaining single metaphase had 42 chromosomes 
including one extra copy each of chromosomes Y and 8.   To rule out the presence of a cell line 
with +Y and +8, an additional 30 metaphases were screened.  All of them had only one Y and two 
#8 chromosomes present.  Thus, the single cell finding with +Y and +8 was considered nonclonal, 
and this study was interpreted as normal 40,XY. 
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Figure A-13: Chimeric mice generated from blastocysts injected with 3
o
1-E ES cells. 
Blastocysts of C57BL/6 strain (black coat color; panel A, adapted from the Jackson Laboratory) 
were injected with our genetically modified 3
o
1-E ES cells originally derived from 129S1/SvImJ 
strain (white-bellied agouti coat color; panel B, adapted from the Jackson Laboratory), and 
implanted into pseudopregnant C57BL/6 females. The resulting chimeras, generated from 
blastocysts containing both C57BL/6 and CJ129 ES cells, exhibited streaked black color across 
agouti (as indicated by green arrows in panel C). A total of 8 such chimeras were obtained, 2 of 
which were females and 6 were males.     
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Discussion: 
To study the multiple roles of MCT1 in various biological conditions, such as brain 
energy metabolism, long term memory, diabetes and cancers, we attempted to generate 
Mct1 conditional knockout mouse model. However, all the chimeras failed in producing 
desired offspring that inherited one copy of the knocked-out allele. Several possible 
reasons can account for the unsuccessful initiative, including: (1) one functional copy of 
MCT1 is not sufficient for normal germ cells (e.g. sperms) development and future 
fertilization; (2) the relatively long period of culture and high passage number of ES cells 
before injection may compromise their potency of inserting into germ line during 
embryonic development; (3) the presence of large foreign DNA sequence (e.g. NeoR, 
LacZ) in the animal’s genome may impose genetic perturbations that lead to reduced 
germ cells functionality; (4) injection of multiple positive colonies is recommended and 
has been shown to increase ES cells germline transmission.  
The design of our targeting vector ensures of generating a modified Mct1 allele that is 
inactivated and knocked-out upon correct homologous recombination, due to the 
presence of a polyadenylation signal pA right after NeoR gene. Therefore, transcription 
machinery stops immediately after the pA, leaving a truncated version of Mct1 mRNA. 
This is so called “Knockout-first” strategy (392). Although LoxP sites are still intact after 
homologous recombination in the modified allele, that Mct1 gene is already disrupted 
before embryonic injection. As a consequence, removal of the selective cassette before 
injection via Flp-FRT system will fix the knocked-out allele and restore two normal Mct1 
alleles, which may help improve the generation of desired offspring after chimeras. The 
necessity of maintaining a functional copy of Mct1 in germ cells comes from the 
observation that sperms, which usually contain half of a diploid genome and thus only 
one allele of a gene, expresses high quantity of MCT1 (53, 393). As a result, sperms 
carrying the allele copy derived from modified ES cells may not be functional as well as, 
if not lethal, than the wild type ones. Future efforts of removing selective cassette via 
Flp-FRT first before injecting blastocysts are likely beneficial to eliminate the adverse 
effect of knockout-first on sperm cells homeostasis.    
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As a golden rule of all cell culture, reduced incubation time in culturing dishes in vitro as 
well as maintaining a lower passage number of cells, can help preserve their functional 
performances and cellular characteristics. The long in vitro gene targeting process 
(about 4 weeks) and a relatively high passage number of ES cells before injection (P19) 
may compromise the inherent capacity of our cells to incorporate into germ line layers. 
Besides, the presence of large foreign DNA sequences (e.g. LacZ and NeoR gene) and 
their products, especially neomycin resistant protein, may exert unexpected stress on 
the recipient’s genome. In fact, insertion of NeoR gene into mouse genome for gene 
targeting purpose was found to interfere with neighboring off-target genes expression 
(394). So, removal of extra alien DNA sequences may help maintain ES cells normal 
health and improve reproductive efficiency. Finally, injecting multiple ES cell lines that 
have all gone homologous recombination and quality control tests, is believed to improve 
the chance for ES cells to translocate into inner cell mass where they will develop into 
reproductive system (395). Possible explanations include that: (1) multiple ES cells from 
different colonies injected into a host blastocyst provide some paracrine factors which 
support their initial survival; (2) not every single ES cell line is fully potent to support 
embryogenesis due to both genetic and epigenetic changes occurring during cultivation 
process (396). In this regard, the low efficiency of generating desired mice with single 
cell colony injection can be a likely reason to explain the absence of heterozygous mice 
in our current study.  
A recent study reported by Lee et al (38) shows the generation of Mct1 heterzygous 
knockout mice. In their study, the first exon of Mct1 was replaced by LacZ and neomycin 
resistance gene sequence, thus inactivating Mct1’s function in one of the two alleles. 
This observation supports the idea that sperms or oocytes without MCT1 may still able 
to survive and fertilize with normal oocytes or sperms respectively, to generate the 
heterozygous knockout animals. Another possibility that needs to keep in mind is that, 
their targeting strategy might generate a huge fusion protein (LacZ-NeoR-ΔMCT1), 
because all the other exons of Mct1 gene may be still transcribed and translated into 
peptides, thus providing some functionality of this transporter. Detailed information and 
clarifications from their targeting strategy would help resolve this question.  
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In summary, our study provided a valuable rationale for generating Mct1 conditional 
knockout model. Further efforts using modified targeting strategy, identifying more 
positive colonies, and starting with new ES cells with a low passage number, may 
greatly help to improve the outcome.      
 
